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 IV – ABSTRACT 
 
The three human Ras proto-oncogenes encode for four highly homologous protein 
isoforms, H-, K(A)-, K(B)- and N-Ras, that function as molecular switches and timers 
to transduce signals from activated cell surface receptors to modulate signalling 
pathways responsible for cell proliferation, growth, survival and apoptosis. 
Oncogenic mutations of Ras occur in ~16% of all human cancer cases and most 
often affect codons 12, 13 and 61, each resulting in constitutive activation of the 
protein. Currently, it is uncertain how many Ras molecules are present per cell and 
which isoform is most abundant, essential information for the emerging field of 
systems biology, which utilises mathematical modelling to understand the behaviour 
of complex signalling pathways in a holistic approach. In the first part of this thesis, 
a selected reaction monitoring (SRM)-based Ras quantification technique is 
established for the measurement of each major isoform, along with the generation of 
isotope-labelled Ras protein standards that support quantification using the protein 
standard absolute quantification (PSAQ) strategy. Combining targeted SRM-based 
proteomics with the PSAQ strategy enabled the most accurate measurement of 
cellular Ras isoform abundance to date, as detailed in the second part of this thesis. 
The target cell lines in the present thesis were a panel of isogenic SW48 colorectal 
cells, which express a variety of heterozygous Ras mutations following the 
exchange of a wild-type allele for a mutant Ras sequence through targeted 
homologous recombination. Over 250,000 Ras molecules per wild-type SW48 cell 
were quantified, with K(B)-Ras the major Ras isoform. ~114 Ras molecules are 
predicted to be bound per µm2 of plasma membrane, with the cellular molarity of 
Ras at 253 mM. Intriguingly, the presence of certain K-Ras mutations induced 
significant changes in cellular Ras abundance, which may be attributable to the 
specific transforming potential of each mutant protein. The presented data also 
suggests that, in addition to their structural and biochemical variations, Ras mutant 
proteins may exert their different biological effects through differential protein 
expression. 
 
Many cancer types demonstrate a preference for a single Ras isoform to be mutated 
and present a codon-specific mutation signature. In colorectal cancer, K-Ras is the 
most frequently mutated isoform, with over 75% of mutations accounted for by 
G12D, G12V and G13D in colon tumours with a K-Ras mutation. Clinical data 
 suggests that patients harbouring codon 12 or 13 K-Ras mutations have different 
overall survival rates and responsiveness to treatment. Isogenic SW48 cells 
harbouring the aforementioned K-Ras mutations were subject to mass 
spectrometry-based proteome and phosphoproteome quantitative analysis, to 
investigate the effects of different amino acid substitution (G12D vs. G12V) or codon 
mutation (G12D vs. G13D) on oncogenic Ras signalling. The presented data in the 
third part of this thesis provide the first quantitative proteomic and 
phosphoproteomic profile of signatures associated with specific K-Ras mutant 
proteins expressed at endogenous levels. Each K-Ras mutation induced a distinct 
signalling output, with the most variability observed between codon 12 mutants and 
G13D. This indicates that the position of a Ras point mutation may have more 
impact on signalling than an amino acid substitution. Several proteins relevant to 
colorectal carcinogenesis were found to specifically up-regulated by codon 12 or 13 
mutations, with one notable example being the recently described colon cancer 
stem cell marker double cortin-like kinase 1, which was sensitive only to codon 12 
K-Ras mutations. Together, the data presented in this thesis provides a novel 
insight into the behaviour of a range of Ras mutations in a colorectal cancer setting.  
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1 – INTRODUCTION 
 
1.1 RAS GENES, ISOFORMS, STRUCTURE AND SIGNALLING 
 
Ras small GTPases have become model proteins for signal transduction and 
molecular oncology research. Over the past 30 years, they have played a significant 
role in understanding the origins of cancer at the molecular level, establishing 
fundamental concepts in signal transduction and initiating the discovery of the large 
Ras protein superfamily (Cox and Der, 2010; Malumbres and Barbacid, 2003). 
Despite these research efforts, a comprehensive understanding of Ras function and 
dysfunction, particularly in human cancer, is yet to come. Here the work that led to 
the discovery of Ras and its characterisation as an oncogene is discussed, along 
with the current knowledge of Ras structure, isoforms, splice variants, expression 
levels and signalling. 
 
1.1.1 THE DISCOVERY OF RAS  
 
Ras was discovered as a result of extensive research of acutely transforming 
retroviruses isolated from mice, rats, cats and other animals; a field that dates back 
to the early 1900s with Vilhelm Ellerman, Olaf Bang and Peyton Rous’ discoveries of 
transmissible leukaemia and solid tumours in chickens (Ellermann and Bang, 1909; 
Rous, 1910). However, it was in 1964 and 1967 when we had our first glimpses of 
the genetic elements that we now recognise as HRAS and KRAS, respectively. In 
1964, Jennifer Harvey found that a preparation of Maloney’s leukaemogenic virus, 
taken from a leukaemic rat, induced sarcomas when injected into new-born mice 
(Harvey, 1964). Three years later, Kirsten and Mayer discovered that new-born rats 
developed multiple sarcomas following injection with spleen filtrates or plasma from 
rats infected with mouse erythroblastosis virus (Kirsten and Mayer, 1967). The Ras 
gene name was coined in the 1970s, after a new nomenclature for retroviral 
oncogenes was proposed, based on three-letter acronyms. Since Harvey and 
Kirsten oncoviruses cause rat sarcomas it became the basis of the ras gene name, 
with the discoverers’ names used to distinguish between them (Malumbres and 
Barbacid, 2003). During this time, Scolnick and colleagues suggested that 
incorporation of normal rat sequences into the viral genome was responsible for the 
transforming properties of the Harvey and Kirsten oncoviruses (Scolnick and Parks, 
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1974; Scolnick et al., 1973). However, molecular characterisation of these 
sequences was held back until restrictions on recombinant DNA technology, 
imposed during the Asilomar conference in 1975, expired. In the late 1970s and 
early 1980s, Ras research progressed at an astonishing pace, with Scolnick and 
colleagues delivering a series of fundamental discoveries that established the basic 
biochemical and cellular properties of Ras. They determined Harvey and Kirsten 
Ras genes encode 21 kDa proteins (Parks and Scolnick, 1977; Shih et al., 1979b), 
which bind GDP and GTP (Scolnick et al., 1979) and associate with the plasma 
membrane (Willingham et al., 1980). Moreover, they also detected Ras protein in 
human cells and those from various vertebrate species using a rat-derived anti-Ras 
antibody (Langbeheim et al., 1980) and identified Ras genes in rat, human and other 
vertebrate genomes (Chang et al., 1982b; DeFeo et al., 1981; Ellis et al., 1981). 
Also in the early 1980s, DNA transfection assays, using the transformation of mouse 
NIH-3T3 cells as readout, were heavily utilised to detect activated oncogenes in 
tumour-derived genomic DNA (Shih et al., 1981; Shih et al., 1979a). Several studies 
isolated oncogenes from the genomic DNA of various carcinomas, including human 
bladder, lung, colon and others; but the exact nature of the isolated genes was 
unknown (Goldfarb et al., 1982; Krontiris and Cooper, 1981; Murray et al., 1981; 
Perucho et al., 1981; Shih and Weinberg, 1982). The transforming genes were only 
exposed as cellular homologs of the viral Ras genes when transformed NIH-3T3 
genomic DNA was hybridised with retroviral probes (Der et al., 1982; Parada et al., 
1982; Santos et al., 1982). Soon after, it was demonstrated that overexpression of 
human H-Ras could transform NIH-3T3 cells (Chang et al., 1982a). Later in 1982, 
molecular cloning of normal and oncogenic H-Ras genes revealed the mechanism 
of Ras oncogene activation as a single point mutation at residue 12 or less 
commonly at 13 and 61 (Capon et al., 1983a; Reddy et al., 1982; Tabin et al., 1982; 
Taparowsky et al., 1982). This made H-Ras the first cell-derived oncogene whose 
mechanism of activation was elucidated at the molecular level. By 1983, Wigler and 
Weiss groups discovered the third member of the Ras gene family, designated N-
Ras, by identifying transforming sequences from neuroblastoma cell lines (Hall et 
al., 1983; Shimizu et al., 1983). In 1984, the discovery of mutated K-Ras oncogenes 
in tumour biopsies, but not in the normal tissue of the same patients (Nakano et al., 
1984; Santos et al., 1984), showed that Ras oncogene activation occurred in the 
wild and not only in the laboratory. The following section covers the biochemical and 
physiological properties of Ras, while section 2 describes the role of Ras in cancer.  
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1.1.2   RAS GTPases: PROTO-ONCOGENES, ISOFORMS AND SYNTHESIS 
 
Ras proteins are signal-transduction GTPases that sit near the top of signalling 
cascades and coordinate a wide variety of cellular functions, including cell 
proliferation and survival. They are also proto-oncogenes that are frequently 
mutated in human cancer. Mammalian cells ubiquitously express the three 
oncogenic members of the Ras family: H, K and N, which are encoded by separate 
genes and share a high degree of sequence homology, but are not functionally 
redundant (Fiorucci and Hall, 1988; Furth et al., 1987; Karnoub and Weinberg, 2008; 
Prior et al., 2012). Ras GTPases act as molecular switches and timers, alternating 
between GTP- and GDP-bound states, which differ by the conformation of their 
nucleotide-sensitive switch 1 and 2 regions. The GDP-bound state is generally 
considered inactive, while the GTP-bound state is a prolific signalling molecule that 
can bind to over twenty different effectors to activate a network of downstream 
signalling events (Goldfinger et al., 2007; Prior and Hancock, 2012). Since Ras 
proteins tightly bind GDP and hydrolyse GTP very slowly, they require the helping 
hand of guanine nucleotide exchange factors (GEFs), which facilitate dissociation of 
GDP, and GTPase activating proteins (GAPs) that stimulate GTP hydrolysis (Bos et 
al., 2007). Thus, the actual molecular switch is comprised of a Ras protein, a GAP 
and a GEF, rather than Ras alone.  
 
1.1.2A   RAS GENES AND SPLICE VARIANTS 
 
Human cells harbour 3 Ras proto-oncogenes that encode for H, K and N isoforms. 
The HRAS gene (11p15.5) is the smallest at 5,046 bases in size, then NRAS 
(1p13.2) at 12,431 bases, with the KRAS gene (12p12.1) the largest at 46,148 
bases. The HRAS gene comprises of 4 exons with an alternative exon, denoted 
‘intron D exon’ (IDX), located in the last intron (Cohen et al., 1989). A point mutation 
in the IDX sequence was shown to increase H-Ras levels ten-fold (Cohen and 
Levinson, 1988), suggesting this region was a negative-acting regulatory element. 
However, alternative splicing of H-Ras pre-mRNA was shown to render two mRNAs 
that encode for p21 H-Ras or p19 H-RasIDX that includes the IDX sequence (Cohen 
et al., 1989). The KRAS gene is composed of exons 1, 2, 3, 4A and 4B. Alternative 
splicing of the fourth exon renders two mRNAs that encode two different protein 
isoforms: K(A)- and K(B)-Ras (Capon et al., 1983b; McGrath et al., 1983). K(B)-Ras 
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is the predominant splice variant and ubiquitously expressed, whereas K(A)-Ras is 
not (Plowman et al., 2006). The functional differences between K(A)- and K(B)-Ras, 
and other Ras isoforms, are discussed in detail in section 1.3. Recently, alternative 
splicing of NRAS pre-mRNA has been reported to render 5 different mRNAs that 
encode 5 proteins of various lengths (20 to 208 amino acids) (Eisfeld et al., 2014).  
 
1.1.2B    RAS ISOFORMS AND THEIR STRUCTURE 
 
The three mammalian Ras proto-oncogenes encode for 4 major isoforms, H-, K(A)-, 
K(B)- and N-Ras, which are 21 kDa proteins, 188/9 amino acids in length and share 
almost complete sequence homology between residues 1-165, a region known as 
the G-domain that encompasses the nucleotide and effector binding motifs (Fig. 
1.1A). All major isoforms, bar K(A)-Ras, are ubiquitously expressed and are 
principally distinguished from each other by the C-terminal hypervariable region 
(HVR, final 23-24 amino acids) where there is < 15% sequence similarity (Fiorucci 
and Hall, 1988; Omerovic et al., 2007). Ras proteins, like all small GTPases, are 
comprised of a six-stranded β-sheet surrounded by five α-helices (de Vos et al., 
1988; Pai et al., 1989). On GDP-GTP exchange, a ‘conformational domino effect’ 
propagates throughout the Ras molecule and causes two nucleotide-sensitive 
regions to ‘switch’ their conformation. These surface-localised regions are named 
switch 1 and 2. Switch 1 spans residues 30 to 38 (corresponding to most of loop 2) 
and switch 2 comprises of residues 59 to 76 (loop 4 and α-helix 2) (Fig. 1.1 B) 
(Milburn et al., 1990). These subtle, disorder-to-order structural transitions reveal an 
effector-binding site on the Ras molecule (see section 1.3.1 for further details) and 
occur due to the presence of GTP’s ϒ-phosphate in the Ras nucleotide-binding 
pocket (Fig. 1.2). The binding pocket is primarily composed of loops L1, L2, L4, L8 
and L10; with guanine specificity conferred by DTAGQ-, SAK- and NKxDL-motifs. 
The aspartate side chains from the DTAGQ- and NKxDL-motifs (residues 57-61 and 
116-120, respectively) form a bifurcated hydrogen bond with the guanine base, 
while alanine from the SAK-motif (residues 145-147) would not tolerate an adenine 
amino group due to steric hindrance (Vetter and Wittinghofer, 2001). As a result, 
Ras has a nanomolar to picomolar affinity for GDP/ GTP and millimolar affinity for 
ADP/ ATP (Scolnick et al., 1979). 
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Fig. 1.1. The structure of Ras. (A) H-, K(A)-, K(B)- and N-Ras isoforms consist of a series 
of ten loops that interconnect six β-sheets and five α-helices, with the main sequence 
differences between isoforms located in the C-terminal hypervariable region (HVR). The 
HVR is post-translationally modified to enable membrane interaction and differential 
localisation. Key functional domains and motifs, common to all Ras family members, are 
indicated. Sequences and basic residues important for membrane affinity are highlighted in 
green; underlined CAAX-box cysteine residues are farnesylated following synthesis; 
remaining underlined cysteine residues are targeted for palmitoylation; linker domain has a 
role in nanoclustering. (B) Crystallographic structures of inactive H-Ras-GDP (residues 1-
171, 2.0 Å resolution) and active H-Ras-GppNHp (5'-Guanylyl imidodiphosphate) (residues 
1-166, 1.26 Å resolution) show the different conformations of the nucleotide-sensitive switch 
1 (residues 30-38) and switch 2 (residues 60-76) regions when GDP or GTP is bound to 
Ras. Structures are coloured according to A; areas of reduced transparency indicate switch 1 
and 2 regions; Mg2+ ion shown as a green ball; water molecules as red balls. H-Ras-GDP 
from (Milburn et al., 1990), Protein Data Bank (PDB) code 4q21; H-Ras-GppNHp from 
(Scheidig et al., 1999) , PDB code 1ctq. 
 
 
INTRODUCTION – RAS GENES, ISOFORMS, STRUCTURE AND SIGNALLING 
 6 
 
 
 
 
 
 
 
 
Fig. 1.2. The guanine nucleotide-binding pocket of Ras. (Left) Binding site of inactive H-
Ras-GDP and (right) of active H-Ras-GppNHp (5'-Guanylyl imidodiphosphate). Five G-motifs 
comprise the nucleotide-binding pocket; the P-loop (blue) responsible for binding with the β-
phosphate of GDP or GTP; T35 of switch 1 (turquoise) binds to the ϒ-phosphate of GTP and 
a Mg2+ ion (green ball) but makes no contact with GDP; DTAGQ-motif of switch 2 (green), 
D57 confers specificity for guanosine over adenosine, Q61 is critical for alignment of a water 
molecule (red balls) for GTP hydrolysis; NKxDL- (orange) and SAK-motifs (red) provide 
further selectivity for guanosine. The ϒ-phosphate of GTP induces structural rearrangements 
of nucleotide-sensitive switch 1 and 2 regions, through interactions with T35 and G60. 
Inactive Ras binding-site data from (Milburn et al., 1990), Protein Data Bank (PDB) code 
4q21; Active Ras from (Scheidig et al., 1999), PDB code 1ctq.  
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Fig. 1.3. Synthesis and processing of Ras. Ras proteins are synthesised in the cytosol by 
free ribosomes, where farnesyl transferase recognises their CAAX motif. Farnesylation 
confers some membrane binding ability to Ras, enabling it to associate with the ER 
membrane. At the ER, Ras encounters Ras converting enzyme, which removes the CAAX 
motif, before isoprenylcysteine carboxyl methyltransferase (Icmt) methyl esterifies the 
subsequent carboxyl group. K(B)-Ras, with its polybasic domain (red pluses), now has the 
necessary membrane-binding capability to associate with lipid membranes. H- and N-Ras 
require palmitoylation by Golgi-resident Ras palmitoyltransferase to enable plasma 
membrane binding. These isoforms then enter the exocytic pathway on their way to the 
plasma membrane. K(A)-Ras follows the trafficking route as of H- and N-Ras.  
 
The phosphate-binding loop (P-loop, residues 10-17) creates a polyanion hole that 
binds to and neutralises the negative charge of the nucleotide’s β-phosphate 
through residues 13-17 (Pai et al., 1989; Pai et al., 1990; Saraste et al., 1990; 
Valencia et al., 1991). Ras structural rearrangement is triggered when the γ-
phosphate of GTP hydrogen bonds with the main chain amino groups of switch 1’s 
T35 and switch 2’s G60 (part of the DTAQ-motif) (Milburn et al., 1990; Vetter and 
Wittinghofer, 2001). Upon GTP hydrolysis, the residues within switch 1 and 2 revert 
back to their inactive states. A helpful analogy for Ras conformational change is that 
of a loaded spring mechanism, where release of the γ-phosphate following GTP 
hydrolysis permits the two switch regions to relax back to their GDP-bound state.  
 
1.1.2C    RAS SYNTHESIS AND PROCESSING  
 
Ras proteins are synthesised in the cytosol as globular hydrophilic precursors by 
polysomes and need subsequent post-translational modification to enable them to 
stably associate with membranes, an essential requirement for biological activity 
(Willumsen et al., 1984). The initial triplet of modifications is directed against the C-
terminal CAAX-motif (in which A is any aliphatic amino acid and X any amino acid) 
that is common to all major Ras isoforms (Fig. 1.1A and 1.3). Firstly, the cysteine 
residue is farnesylated by farnesyl transferase (Reiss et al., 1990), which facilitates 
association to the cytosolic surface of the endoplasmic reticulum (ER). Secondly, an 
ER-localised endopeptidase, Ras and a-factor convering enzyme (Rce1), cleaves 
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the AAX tripeptide (Boyartchuk et al., 1997; Gutierrez et al., 1989; Kim et al., 1999). 
Thirdly, the C-terminal farnesyl-cysteine is methylated by isoprenylcysteine carboxyl 
methyltransferase (Icmt) (Dai et al., 1998; Hrycyna et al., 1991). Interestingly, K(B)-
Ras appears to be more efficiently methylated than H- or N-Ras, but it unclear why 
this is the case (Choy et al., 1999; Hancock, 2003). Following methylation, Ras 
proteins diverge on their path to the plasma membrane. H-, K(A)- and N-Ras are 
palmitoylated once or twice on cysteine residues in their HVRs by Ras 
palmitoyltransferase (DHHC9 in mammals), before entering the exocytic pathway 
and trafficking through the Golgi to their final cell membrane destinations (Apolloni et 
al., 2000; Casey et al., 1989; Choy et al., 1999; Swarthout et al., 2005) (Fig. 1.1A 
and 3). K(A)- and N-Ras, in addition to their mono-palmitoylation, also utilise 
hydrophobic/ basic residues in their linker domains for stable membrane localisation 
(Laude and Prior, 2008). The polybasic, lysine-rich region of K(B)-Ras enables it to 
electrostatically interact with negatively charged phospholipid head groups to 
support membrane association (Silvius et al., 2006). It also allows K(B)-Ras to forgo 
palmitoylation and bypass the Golgi on its way to the plasma membrane (Hancock 
et al., 1990), possibly through interactions with microtubules or with class C Vps 
proteins as observed in yeast (Chen et al., 2000; Thissen et al., 1997; Wang and 
Deschenes, 2006). Phosphodiesterase 6δ (PDEδ) may also have a role in 
chaperoning K(B)-Ras during intracellular trafficking, by shielding its hydrophobic 
farnesyl group from the aqueous environment of the cytosol (Chandra et al., 2012). 
However, the exact mechanisms underlying K(B)-Ras trafficking remain unclear.  
 
1.1.3 RAS SIGNALLING: EFFECTOR BINDING, REGULATION, ISOFORM- AND 
COMPARTMENTALISED-SIGNALLING 
 
Ras GTPases activate signalling pathways by binding to effectors and recruiting 
them to membranes. This can cause conformational change in the effectors and/ or 
facilitate interactions with activating proteins/ co-factors necessary for signal 
propagation (Prior and Hancock, 2012). Ras activation can occur following ligand 
binding with receptor tyrosine kinases, e.g. epidermal growth factor receptor 
(EGFR), that autophosphorylate before binding adapter proteins, e.g. GRB2, which 
recruit GEFs to the plasma membrane to facilitate Ras GDP-GTP exchange. Ras-
GTP then transduces the extracellular stimulus into a network of intracellular 
signalling events (Fig. 1.4). The plasma membrane is a critical platform for Ras 
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signalling, but endomembranes provide additional stages from which Ras can 
signal. Here various aspects of Ras signalling are discussed, including Ras effector 
binding, regulation of Ras activity with GEFs/ GAPs, isoform-specific and 
compartmentalised Ras signalling and nanoclustering.  
 
1.1.3A    RAS EFFECTOR REGION AND RAS INTERACTING DOMAINS 
 
Ras proteins primarily bind with effectors through residues 32-41, which overlap with 
the switch 1 region (Sigal et al., 1986). The Ser/Thr protein kinase c-Raf1 binds to 
switch 1 through a stable 81-residue domain, known as the Ras binding (RB) 
domain (Fig. 1.5) (Koide et al., 1993; Moodie et al., 1993; Nassar et al., 1995). The 
RB domain has an ubiquitin fold structure and interacts with Ras through 
complementary charge interactions and the formation of an inter-protein β-sheet 
(Fig. 1.5) (Emerson et al., 1995; Nassar et al., 1996). Other Ras effectors, e.g. 
RalGDS (Ral guanine dissociation stimulator), do not contain an RB domain but a 
Ras association (RA) domain (Ponting and Benjamin, 1996). Despite low sequence 
homology between RB and RA domains, they both have similar structures and bind 
to switch 1 of Ras in a similar manner (Geyer et al., 1997). Interestingly, RA 
domains can also interact with switch 2 of Ras (Huang et al., 1998). This 
involvement of switch 2 in protein-protein interactions is not an isolated case, as 
phosphoinositide 3-kinase (PI3K) gamma interacts with both Ras switch regions 
using its RB and catalytic domains (Fig. 1.5B) (Pacold et al., 2000). 
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Fig. 1.4. Overview of major Ras signalling pathways. Active (farnesylated, membrane- 
and GTP-bound) Ras stimulates a network of downstream signalling cascades, with the 
mitogen-activated protein kinase (MAPK, dark orange) and phosphoinositide 3-kinase 
(PI3K)-Akt (turquoise) pathways the two best characterised. The MAPK pathway is an 
essential element of mitogenic signalling involving receptor tyrosine kinases (RTKs) that 
trigger a variety of cellular processes crucial for cell growth, differentiation and apoptosis 
(Dhillon et al., 2007). Active Ras binds to the Raf family of Ser/ Thr kinases (Raf-1, A-Raf 
and B-Raf) to recruit them to membranes, where they are activated through phosphorylation 
by various kinases (Marais et al., 1998; Marais et al., 1995). Active Raf then phosphorylates 
MEK, which in turn activates extracellular signal regulated kinases 1 and 2 (ERK1/2). Active 
ERK1/2 then phosphorylates hundreds of cytoplasmic and nuclear substrates, including 
regulatory molecules and transcription factors (Roskoski, 2012). Scaffold proteins play an 
essential role in spatiotemporal regulation of MAPK signalling. Kinase suppressor of Ras 
(KSR) is one of several MAPK scaffolds and is constitutively associated with MEK1/2, only 
becoming associated with ERK1/2 following cellular stimulation (Brennan et al., 2011; 
Claperon and Therrien, 2007). The second best-characterised Ras effector family is the PI3K 
family, which have essential function on cell survival and growth (Castellano and Downward, 
2010). Active PI3K converts phosphatidylinositol (4,5)-bisphosphate (PIP2) into 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 binds to the plekstrin homology 
domain of AKT stimulating its kinase activity, leading to phosphorylation of a host of proteins 
that coordinate cell cycle entry, cell growth and survival. Another well-characterized Ras 
effector is Ral guanine nucleotide dissociation stimulator (RalGDS) (Ferro and Trabalzini, 
2010). These proteins link Ras signaling with activation of RalA and RalB small GTPases.  
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Fig. 1.5. Ras effector/ regulator complexes. (A) Active H-Ras-GppNHp (PDB code 1ctq). 
(B) Ras binding with its effectors. Left, Structure of H-Ras-GppNHp complexed with the Ras 
binding domain (RBD) of Raf-1 kinase (2.5 Å resolution, PDB code 4g0n). Right, H-RasG12V 
in complex with phosphoinositide 3-kinase (PI3K) gamma catalytic subunit (3.0 Å resolution, 
PDB code 1he8; (Pacold et al., 2000)). Effectors bind with Ras using an interface within the 
switch 1 region (residues 32-41), but Ras also uses its switch 2 region to bind PI3K. (C) Ras 
binding with its regulators. Left, H-Ras-GppNHp in complex with the plekstrin homology 
domain of Son of Sevenless (SOS) (2.8 Å resolution, PDB code 1bkd; (Boriack-Sjodin et al., 
1998) ). Right, H-Ras in complex with p120 Ras GTPase-activating protein (p120GAP) (2.5 
Å resolution, PDB code 1wq1; (Scheffzek et al., 1997)). (D) Left, Guanine nucleotide 
exchange (GEF) factor function. To eject GDP from the Ras binding pocket, SOS inserts its 
α-helical hairpin that reorientates A59 and disturbs K16 binding with GDP. Right, GAP 
function. p120GAP inserts a catalytic R789 finger into the Ras nucleotide binding site that 
reorientates Q61, which aligns a water molecule to enhance Ras GTPase activity whilst 
stabilising the protein.  
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1.1.3B   GUANINE EXCHANGE FACTORS AND GTPase ACTIVATING PROTEINS 
 
The GDP-GTP cycle of Ras is highly regulated by the coordinated action of GEFs 
and GAPs, of which there are 27 members of each in human cells. Interestingly, the 
Ras family, which has 36 members, outnumber their regulators (Cherfils and 
Zeghouf, 2013). As mentioned earlier, Ras is an incomplete enzyme that binds 
guanine nucleotides with high affinity and therefore must enlist the help of GEFs and 
GAPs to complete the molecular switch. The catalytic domains of many Ras GEFs 
are structurally unrelated and approach the G-proteins from different angles, yet 
they all utilise similar principles to deform the nucleotide-binding pocket, particularly 
the phosphate-binding region, to facilitate GDP ejection. For example, SOS makes 
extensive contacts with switch 2 and uses a α-helical hairpin to force open the 
binding site (Fig. 1.5C and D) (Boriack-Sjodin et al., 1998). GEFs sterically occlude 
the magnesium-binding site or reposition the alanine side-chain from the DTAG-
motif of switch 2, which in turn disturbs P-loop binding with the GDP’s β-phosphate 
(Bos et al., 2007).  
 
Ras GAPs can accelerate the intrinsic GTPase activity of Ras by five orders of 
magnitude (Gideon et al., 1992), through interactions that optimally align a water 
molecule for nucleophilic attack on GTP’s γ-phosphate (Fig. 1.5 C and D) (Scheffzek 
et al., 1997). For example, p120 GAP inserts a catalytic arginine finger into the 
nucleotide-binding pocket that alters the position of Q61, which in turn optimally 
aligns the attacking water molecule. The arginine finger also stabilises the transition 
state by neutralising the negative charge of the γ-phosphate (Bos et al., 2007). 
 
For some small GTPases, mainly Rab and Rho proteins, guanine-dissociation 
inhibitors (GDIs) provide an additional level of control. These proteins induce small 
GTPases to dissociate from membranes by sequestering prenyl groups on their 
lipidated tails and maintain them in the GDP-bound state (Bos et al., 2007; Cherfils 
and Zeghouf, 2013). So far, only PDEδ has been described as a GDI-like 
solubilising factor that interacts with farnesylated Ras proteins (Chandra et al., 
2012).  
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1.1.3C    ISOFORM-SPECIFIC RAS SIGNALLING 
 
Ras isoforms were originally considered to be functionally identical because they 
exhibit a high degree of sequence homology, appeared to be governed by a 
common cohort of regulators and activate the same group of effectors (Bos, 1989; 
Castellano and Santos, 2011; Chesa et al., 1987). However, the dramatic 
asymmetry of Ras isoform mutations in certain cancer types, e.g. the frequent 
mutation of K-Ras in colon, pancreatic and lung cancers (discussed further in 
section 2) (Bos, 1989; Bos et al., 1987), provided the first clues that H-, K- and N-
Ras had non-redundant roles.  
 
Although H-, K(A)-, K(B)- and N-Ras qualitatively activate the same effector 
pathways, they have quantitative differences in their ability to activate particular 
downstream effectors. It is apparent that Ras isoforms differ in their ability to 
activate Raf-1, Rac and phosphoinositide 3-kinase (PI3K), with K(B)-Ras the most 
potent activator of Raf-1 and Rac, while H-Ras is an efficient activator of PI3K 
(Voice et al., 1999; Walsh and Bar-Sagi, 2001; Yan et al., 1998). K(A)-Ras activates 
Raf-1 more strongly than H/ N-Ras, but not K(B)-Ras, and along with N-Ras enabled 
anchorage-independent growth of RIE-1 cells (Voice et al., 1999) H- and K(B)-Ras 
also induce higher activation of NFκB than N-Ras (Millan et al., 2003). Such 
differential activation of effectors has also been demonstrated for other members of 
the Ras protein superfamily, e.g. R-Ras, TC21, Rheb, Rin and Rap 1 and 2 
(Rodriguez-Viciana et al., 2004). In addition, H- and N-Ras may regulate the 
mitogen activated protein kinase (MAPK) pathway through different mechanisms, as 
treatment with a growth factor antagonist blocked proliferation of H-Ras transformed 
cells, but not those transformed with N-Ras (Hamilton and Wolfman, 1998). 
Furthermore, overexpression of Ras isoforms in isogenic colorectal cell lines 
revealed K-Ras is easily the most potent inducer of a transformed phenotype (Keller 
et al., 2007a).  
 
Ras isoforms also differ in their sensitivity to GAPs and GEFs. Regarding GEFs, 
Ras-GRF induces potent in vivo GDP-GTP exchange on H-Ras but to a lesser 
extent on K- and N-Ras (Jones and Jackson, 1998; Matallanas et al., 2003). 
RasGRP2 can activate K- and N-Ras but not H-Ras (Clyde-Smith et al., 2000), while 
RasGRP3 demonstrates the opposite behaviour (Lorenzo et al., 2001; Ohba et al., 
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2000). Furthermore, the ubiquitously expressed GEF Sons of Sevenless (SOS) can 
facilitate nucleotide exchange in all Ras isoforms, but demonstrates different 
degrees of potency: H > N > K (Jaumot et al., 2002). Considering GAPs, NF-1 and 
p120-GAP induce GTP hydrolysis at similar rates in H- and N-Ras, but N-Ras has 
slightly higher hydrolysis rates (Bollag and McCormick, 1991).  
 
Genetic studies in mice showed that the K-Ras gene is essential for embryo 
development (Johnson et al., 1997; Koera et al., 1997), while H- and N-Ras genes 
are dispensable (Esteban et al., 2001; Umanoff et al., 1995). K(A)-Ras is also 
unessential for correct development (Plowman et al., 2003). This indicates that the 
K-Ras gene has unique function during embryogenesis that H- and N-Ras genes 
cannot compensate for. However, if the K-Ras gene is replaced with H-Ras it 
supports normal mouse embryonic development, but when the mice reach 
adulthood they display cardiomyopathy and hypertension (Potenza et al., 2005). 
Thus, it could be that Ras expression levels is a critical survival factor during mouse 
development and that H-Ras, when expressed under the K-Ras promoter, can 
substitute for K-Ras in its essential functions. Yet, it also suggests that K-Ras has a 
role in cardiovascular homeostasis that H-Ras cannot replicate.  
 
1.1.3D    COMPARTMENTALISED RAS SIGNALLING  
 
Micro- and macro-localisation of Ras proteins at the plasma membrane and Golgi, 
ER, endosomal and mitochondrial endomembranes determine Ras signal output 
(Philips, 2005; Prior and Hancock, 2012). Although the cell surface represents the 
prime location for all isoforms, Ras proteins also signal from endomembranes. In 
most cell types, the relative contribution to the endomembranous Ras component is 
typically H ≥ N, K(A) > K(B) (Omerovic and Prior, 2009). Since Ras effectors, 
regulators and scaffolding proteins also display differential localisations throughout 
the cell, signalling from endomembranes is likely to engage different signalling 
pathways and therefore exert alternate biological outputs compared to the plasma 
membrane (Fig. 1.6A and B).  
 
The importance of Ras cellular localisation can be demonstrated in fission yeast, 
which have a single Ras protein: Ras1. By Restricting Ras1 to endomembranes 
morphogenesis was triggered, whereas plasma membrane-restricted Ras1 
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stimulated the mating response (Onken et al., 2006). The ER and Golgi have 
provided some of the best evidence in support of compartmentalised Ras signalling. 
Unlike the transient activation of Ras at the plasma membrane, Ras signalling at the 
ER/ Golgi is sustained and can be activated through a variety of growth factors 
(Chiu et al., 2002). Golgi/ ER-resident Ras activation can occur through in situ GEF 
activation, e.g. Golgi-RasGRP1 is activated following PLC-ϒ generation of second 
messengers (Bivona et al., 2003), or diffusion of active Ras from the plasma 
membrane (Fehrenbacher et al., 2009). Interestingly, tethering of oncogenic H-
RasG12V to different organelles showed that only Golgi-localised Ras was unable to 
induce cellular transformation (Matallanas et al., 2006). In contrast, Golgi-targeted 
Raf more potently activated ERK compared to ER-targeted Raf (Inder et al., 2008).  
 
K(B)-Ras demonstrates almost complete plasma membrane localisation, most likely 
because its polybasic domain is preferentially attracted to the plasma membrane’s 
net negative charge versus other intracellular locations, and exhibits membrane 
interactions with very short half lives (~ 7 mins) (Silvius et al., 2006; Yeung et al., 
2006). This short membrane residency means that K(B)-Ras cannot traffic between 
compartments via membrane carriers. Instead, K(B)-Ras is phosphorylated in its 
HVR at S181 by protein kinase C (PKC) that triggers translocation to the cytosol and 
accumulation on the outer mitochondrial, ER and Golgi membranes (Fig. 1.6A) 
(Ballester et al., 1987; Bivona et al., 2006; Prior and Hancock, 2012). The addition of 
a phosphate group acts as an electrostatic switch, as its strong negative charge 
partially neutralises the hexalysine sequence causing K(B)-Ras plasma membrane 
dissociation. K(B)-Ras may also dissociate from the plasma membrane due to 
interactions with calmodulin that binds with the HVR of K(B)-Ras. This triggers 
reversible localisation to the Golgi and early/ recycling endosomes, providing a 
mechanism for Ca2+ signalling to coordinate K(B)-Ras localisation (Fivaz and Meyer, 
2005; Villalonga et al., 2001). Intriguingly, there seems to be an interplay between 
PKC phosphorylation and calmodulin in K(B)-Ras regulation, as calmodulin can 
prevent S181 phosphorylation (Alvarez-Moya et al., 2011).  
 
The localisation of H- and N-Ras is mainly determined by the presence and 
positioning of palmitoyl groups. Palmitoylation, which occurs only at the Golgi, 
promotes stable tethering of otherwise cytosolic proteins to intracellular membranes 
and is the only reversible lipid modification (Smotrys and Linder, 2004). Mutagenesis 
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of H-Ras C181 and C184 revealed that mono-palmitoylation of C184 traps H-Ras on 
the Golgi, whereas mono-palmitoylated C181 H-Ras localises to the plasma 
membrane (Roy et al., 2005). Moreover, H- and N-Ras proteins undergo cycles of 
acylation and deacylation that enable rapid trafficking between the plasma 
membrane and Golgi via a non-vesicular pathway (Fig. 1.6A) (Goodwin et al., 2005; 
Rocks et al., 2005). Since Ras half-life is around 20 hours (Ulsh and Shih, 1984) 
and that of palmitoylation is estimated to between a few minutes and hours, H- and 
N-Ras proteins are likely to go through many depalmitoylation/ repalmitoylation 
cycles during their existence (Baker et al., 2003; Magee et al., 1987). H- and N-Ras 
can also localise to the early/ recycling endosomes following growth factor 
stimulation or by di-ubiquitylation (Roy et al., 2002). The 19 kDa variant of H-Ras, H-
RasIDX, exhibits a nuclear/ cytosolic localisation as it lacks the H-Ras HVR, due to 
an in-frame stop codon in the IDX sequence, meaning it cannot associate with 
membranes (Cohen et al., 1989; Guil et al., 2003). Interestingly, it does not interact 
with known Ras effectors Raf-1 or Rin-1, but interacts with RACK1 and p73β, which 
could indicate a role in organising scaffolding proteins and apoptosis/ cell cycle 
arrest (Guil et al., 2003; Jeong et al., 2006). Furthermore, cytosolic Ras has been 
shown to have a more pronounced effect on Drosophila eye development than 
membrane-bound Ras (Sung et al., 2010).  
 
1.1.3E    RAS PLASMA MEMBRANE NANOCLUSTERS 
 
The plasma membrane is a complex, dynamic, non-equilibrium mix of over 7,000 
different phospholipids, ~30-40 mol% cholesterol and 25% integral and peripheral 
membrane proteins; beneath which is an asymmetrical actin mesh that impedes 
lateral movement of transmembrane proteins (Prior and Hancock, 2012). This 
results in non-random distribution of lipids and proteins throughout the membrane.  
Upon plasma membrane binding, Ras isoforms rapidly diffuse and segregate into 
distinct, non-overlapping nanoclusters (Fig 1.6A) (Abankwa et al., 2007). Each 
cluster is estimated to be 12-24 nm in diameter, to comprise of 6-7 Ras proteins and 
have a half-life of 0.1-1 sec (Hancock and Parton, 2005; Plowman et al., 2005). Ras 
nanoclusters form due to the interplay between the C-terminal lipid anchor, adjacent 
hypervariable regions and the G-domain with certain phospholipids/ cholesterol.  
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Fig. 1.6. Differential cellular localisations of Ras isoforms and compartmentalised 
signalling. (A) Localisation of Ras isoforms throughout the cell. H- and N-Ras share some 
degree of overlap in their localisation, whereas K-Ras exhibits the most distinct localisation. 
Inset shows Ras isoform nanocluster preference for cholesterol, which alters dependent on 
activation status. (B) Compartmentalisation of Ras GEFs, GAPs and scaffolding proteins. 
Most of the listed proteins exhibit regulated recruitment from the cytosol. 
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Furthermore, there is further lateral segregation dependent upon activation state, 
such that GTP and GDP-bound Ras are spatially distinct for each isoform (Prior et 
al., 2001; Prior et al., 2003). They also exhibit switch-like behaviour over a wide 
input range, which in effect coverts an analogue signal into a digital one (Harding 
and Hancock, 2008). Interestingly, if Ras nanocluster formation is inhibited, 
signalling output is reduced to 3% of maximum (Tian et al., 2007). Such distinct 
nanocluster formation is believed to further underlie Ras isoform-specific signalling. 
 
1.1.4 RAS ABUNDANCE  
 
Modern biology is nearing the end of identifying/ characterising individual proteins 
and entering a phase where it aims to understand how proteins work together to 
form molecular networks and circuits (Bordbar et al., 2014; Janes and 
Lauffenburger, 2013). Since many signalling pathways contain large numbers of 
components and our minds can only make simple connections between them, the 
behaviour of complex networks is often difficult to understand. As a result, 
mathematical modelling of pathways is becoming a popular means to interpret and 
interrogate large signalling maps, as it can combine many aspects of signalling 
networks and provide platforms to generate and test new hypotheses (Klipp and 
Liebermeister, 2006). Although pathway models can be created with unknown 
variables or incomplete data, it is important to provide constraints to make the model 
more accurate. One key constraint is that of component concentration (Aldridge et 
al., 2006) and despite being studied for three decades, it is still unclear how many 
Ras molecules are present in a cell. Therefore, models of the MAPK and PI3K 
pathways currently lack a critical parameter. Here the current knowledge of cellular 
Ras abundance is discussed.   
 
The first data on Ras abundance was provided by RNA analysis of human and 
mouse samples (Fiorucci and Hall, 1988; Leon et al., 1987). These studies showed 
that, although H-, K- and N-Ras isoforms are ubiquitously expressed, RNA levels for 
each isoform vary considerably between tissue types and stages of development, 
e.g. K-Ras RNA was highly expressed in lung tumour samples, but was poorly 
expressed in mouse foetal liver samples, relative to H- and N-Ras. However, as 
RNA levels do not accurately predict protein expression (Gygi et al., 1999b), these 
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studies can only provide a provisional view on Ras protein abundance. 
Immunoblotting of commonly used cell lines, that utilised the change in signal of a 
pan-Ras antibody following isoform knock-down, demonstrated that K- and N-Ras 
are relatively the most abundant isoforms, while H-Ras is the minor isoform 
(Omerovic et al., 2008). In contrast, the identification of rare codons in the KRAS 
gene suggests that it is poorly translated due to the stalling of ribosomes (Lampson 
et al., 2013). Transfection of identically tagged H- and K-Ras cDNA, showed that H-
Ras was ~20-fold better expressed; plus converting the rare codons to common 
ones in the KRAS gene increased the abundance of K-Ras to levels comparable 
with H-Ras. These results indicate that K-Ras could be the least abundant isoform. 
Consequently, it is clear that the conclusions regarding Ras isoform abundance from 
the Lampson and Omerovic studies do not match. Moreover, neither study specifies 
an exact number of Ras proteins per cell. 
 
Presently, a popular approach to measure cellular protein abundances is by using 
mass spectrometry (MS)-based proteomics. Proteomics offers a variety of 
quantification strategies that can provide sensitive and accurate measurements of 
protein expression levels (see section 3.6 for a detailed discussion). Over the past 
few years, several targeted strategies have been applied to the question of cellular 
Ras abundance; see Table 1.1 for a summary. Vogelstein and colleagues extracted 
Ras isoforms from cell lysates using an immunoprecipitation strategy, before elution 
of bound Ras proteins and tryptic digestion into peptides. To achieve quantification, 
AQUA peptides (isotope-labelled peptide standards that act as surrogates for 
endogenous peptides) were then spiked into the digested sample followed by 
selected reaction monitoring (SRM) analysis on a triple quadrupole mass 
spectrometer (Wang et al., 2011). They found that on average there is over 1.3 
million Ras molecules per cell and that K-Ras is the major isoform, while H- and N-
Ras are expressed at similar levels. Although AQUA provides precise measurement, 
it does make assumptions regarding complete protein digestion and recovery that 
will impact upon its accuracy (Gallien et al., 2011; Lowenthal et al., 2014). Plus, in 
the Vogelstein study, a proportion of Ras protein remained attached to the beads 
after elution and that only ~25% of Ras from cell lysates was used for MS analysis, 
necessitating the use of a correction factor.  
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Table 1.1. Summary of Ras abundance measurements from previous targeted 
proteomics studies. Total wild-type and mutant (G12V, G12D or G13D) abundances 
detected in various cell lines, normal tissues (N), tumour samples (T) and xenograft samples 
(X). Cyst, pancreatic cyst; PANC and PT, pancreatic tumour; CRC and CT, colorectal 
tumour. Data from each study were converted into ng per 100 µg sample. Halvey et al. 
performed 3 biological replicates for the HCT 116 cell line but 3 technical replicates for the 
remaining cell lines. Data presented as mean ± SD. n = 3 for all samples where SD given. 
 
 
Ashman and co-workers employed the same approach to measure Ras abundance 
in tumour and xenograft samples (Ruppen-Canas et al., 2012). In one pancreatic 
tumour sample, wild-type and mutant G12D Ras were expressed at 37.2 ± 3.6 and 
13.4 ± 8.2 pg/ mg tissue, respectively. However, when these values and those from 
the Vogelstein study are converted into the same units, it is clear that there is a 
significant disagreement despite both studies employing the same technique (Table 
1.1). Liebler and co-workers employed SDS-PAGE to enrich for Ras proteins, then 
cut out the Ras-containing gel band and performed an in-gel digestion. Following 
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peptide extraction, AQUA peptides were added to enable quantification in SRM 
analyses (Halvey et al., 2012). They report that wild-type Ras is expressed at 0.7 ± 
0.01 fmol/ µg in LoVo cells, 2.4 ± 0.08 fmol/ µg in Caco2, while mutant Ras has 
concentrations of 0.6 ± 0.01 fmol/ µg in LS174T cells (G12D/G13D) and 3.2 ± 0.02 
fmol/ µg in SW480 cells (G12V). When these values are converted into ng per 100 
µg lysate, they are around 10-fold less than the results of the Vogelstein study. 
However, it is unclear how efficient the in-gel digest is and how many Ras peptides 
remain trapped in the gel.  Other proteomic studies, that adopt an entirely different 
approach as those mentioned above by employing a global, label-free quantification 
strategy, can provide a number of Ras molecules per cell. Selbach and colleagues 
employed intensity-based absolute quantification (iBAQ) to measure the abundance 
of over 6,000 proteins in mouse NIH-3T3 cells (Schwanhausser et al., 2011). The 
iBAQ algorithm normalises the summed intensities of observed peptides by the 
number of theoretically observable peptides from a protein to calculate protein copy 
numbers per cell (see section 3.6 for a more detailed explanation). In this study, 
Selbach reports that per NIH-3T3 cell the average protein copy number for H-Ras is 
22,089, for K-Ras 41,089 and N-Ras 378,351. Utilising the same technique, the 
Mann laboratory quantified over 10,000 different proteins from the HeLa cervical 
cancer cell line and calculated that 173,933 K-Ras molecules are present per cell 
(Nagaraj et al., 2011). However, the iBAQ technique can only provide approximate 
protein copy numbers per cell, since the utilised algorithm predicts the number of 
theoretically observable peptides, which could be inaccurate for many proteins. 
Nevertheless, these numbers are in stark contrast to those reported in the 
Vogelstein study, where it is reported that per SW480 cell there is 1.5 and 8.6 million 
molecules of wild-type and mutant Ras, respectively (Wang et al., 2011). In 
summary, the techniques employed to date to quantify cellular Ras abundance have 
several flaws, including the assumption that all endogenous protein is fully digested 
(as is the case in AQUA, employed by Halvey et al., Wang et al. and Ruppen-Canas 
et al.), that all peptides are recovered from the following in-gel digestion (as in 
Halvey et al.) and inability to compensate for differences in MS responses between 
detected peptides (as in Schwanhausser et al. and Nagaraj et al.). Many of these 
challenges are overcome using the PSAQ technique, which ensures standard and 
endogenous proteins are equally digested, the identical peptides are used for 
quantification and that standard and endogenous peptides undergo the same losses  
from the beginning of the experiment.
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1.2 RAS IN CANCER 
 
Cancer is characterised by the uncontrolled division of abnormal cells in the body. 
Following the multistep process of carcinogenesis, cancerous cells sustain 
proliferative signalling, evade growth suppressors, exhibit replicative immortality, 
induce angiogenesis, resist cell death and may also metastasise and invade other 
tissues (Hanahan and Weinberg, 2000, 2011). Ras proto-oncogenes are frequently 
mutated in human cancer, with an average mutation incidence of 16% (Prior et al., 
2012). However, analysis of isoform mutations reveals a clear bias in certain cancer 
types. Furthermore, each isoform mutation also has a distinct codon mutation 
signature and clinical data has demonstrated that specific codon mutations result in 
differential sensitivity to chemotherapeutic agents (De Roock et al., 2010; Mao et al., 
2013), suggesting that different codon mutations are unlikely to be equal in their 
signalling output. Discussed here is the spectrum and bias of Ras isoform and 
codon mutations observed in human cancer, the biochemical and structural 
properties of various Ras mutants and the biological effects and clinical relevance of 
Ras mutations.   
 
1.2.1 INCIDENCE AND SPECTRUM OF RAS MUTATIONS IN CANCER 
 
Out of the 3 Ras proto-oncogenes, K-Ras is the by far the most commonly mutated 
in human cancer. According to the Catalog of Somatic Mutations in Cancer 
(COSMIC), K-Ras was mutated in 22% of all tumours analysed, compared to 8% for 
N-Ras and 3% for H-Ras (Cox and Der, 2010; Prior et al., 2012). At a glance these 
numbers imply that Ras is mutated in ~30% of cancers, but, when all cancers with 
more than 20 tumours analysed were given equal weighting, the actual mutation 
rate drops to 16%. In most cancer types, there is a clear preference for mutation of a 
single isoform, e.g. pancreatic cancer has K-Ras mutated in 61% of cases, N-Ras in 
2% and H-Ras 0%; colorectal cancer (CRC), K-Ras 33%, N-Ras 3% and H-Ras 
<1%; skin cancer, N-Ras 18%, H-Ras 6% and K-Ras 3% (Prior et al., 2012). One 
exception is thyroid cancer, where the mutation rate is more equal: N-Ras 8%, H- 
and K-Ras both 3%. These mutation patterns are highly unlikely to occur by chance 
and suggest that certain Ras mutations happen for a reason in particular cancer 
types. In support of this notion, experiments using genetically engineered mice 
showed that oncogenic K-Ras, but not N-Ras, promoted colonic tumorigenesis 
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(Haigis et al., 2008). Such results demonstrate that there are clear phenotypic 
differences between Ras isoform mutants. 
 
Similar to the observed isoform bias in specific cancers, each Ras isoform has a 
preference for certain codon mutations. While Ras can be activated by single-base 
substitutions at codons 12, 13 or 61, 80% of K-Ras mutations occur at codon 12 and 
almost 60% of N-Ras mutations at codon 61 (Prior et al., 2012). H-Ras mutations 
are split 50% and 40% between codons 12 and 61, respectively. Such differences in 
codon specificity are unexpected, as these mutations fall in regions where Ras 
isoforms are identical and therefore assumed to have the same effects on protein 
activity; plus, K-Ras and N-Ras genes share identical sequences encoding G12 and 
Q61. Although codons 12, 13 and 61 can each be converted by base substitutions 
to encode 6 different amino acids, over 60% of Ras isoform mutations are 
accounted for by 3 of the possible 18 mutations (Cox and Der, 2010; Prior et al., 
2012). K-Ras mutations are dominated by G-to-A transitions at codons 12 or 13, 
which give rise to G12D and G13D, respectively, and G-to-T transversions at codon 
12 to produce G12V. N-Ras exhibits a similar pattern of codon 12 and 13 mutations, 
except at a much reduced rate, but also suffers from mutations in codon 61 giving 
rise, for example, to Q61K, Q61L and Q61R. Interestingly, K-Ras and N-Ras G13D 
mutations are only detected in significant numbers in colorectal and lymphoid 
cancers, respectively. In contrast, H-Ras favours G12V in cancers with codon 12 
mutations and shares a similar spectrum of codon 61 mutations as N-Ras. Together, 
these observations show that there is a link between Ras isoform and codon 
mutational status with specific cancer types.  
 
1.2.2 ONCOGENIC RAS MUTANTS 
 
Ras GTPases with mutations in positions 12, 13 or 61 are constitutively activated 
and signal uncontrollably. Each of these mutations interfere with the catalysis of 
GTP hydrolysis, causing Ras to remain locked in its active, GTP-bound form (Prive 
et al., 1992). Position 12/ 13 mutants are also resistant to GAP activity (Trahey and 
McCormick, 1987), as substitution of the glycine residues at either of these positions 
with any other amino acid, even alanine, will sterically clash with a GAP’s arginine 
finger and prevent it from entering the Ras nucleotide-binding pocket to accelerate 
GTPase activity (Fig. 1.7) (Scheffzek et al., 1997). Other than proline, any amino 
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acid will activate Ras if it is substituted at position 12 (Franken et al., 1993; Seeburg 
et al., 1984). Position 61 mutants lose the catalytic glutamine residue essential for 
GTP hydrolysis. In wild-type Ras, Q61 is orientated following GAP binding to 
optimally align a water molecule and enable the GTP hydrolysis reaction (Fig. 1.2) 
(Milburn et al., 1990). Any amino acid, bar proline, glutamic acid and glutamate, 
substituted at position 61 confers transforming activity (Der et al., 1986; Polakis and 
McCormick, 1993). In the following section the structural differences between 
various mutant Ras proteins are discussed, along with their biochemical and 
biological properties.  
 
1.2.2A    STRUCTURAL AND BIOCHEMICAL PROPERTIES OF RAS MUTANTS 
 
Wild-type and mutant Ras proteins as a whole are extremely similar, but have 
noticeable structural differences located around the nucleotide-binding pocket (Fig. 
1.7). G12D mutants exhibit a network of aberrant hydrogen bonding between the 
mutant aspartate residue, Y32 and G60, which causes P34 to become fully exposed 
at the molecule’s surface (Al-Mulla et al., 1999; Franken et al., 1993). In G12V and 
Q61L mutants, Y32 is orientated slightly differently (Buhrman et al., 2011; Buhrman 
et al., 2007). It has also been suggested that two pocket regions, located near the 
Ras binding site, are structurally different between wild-type and G12V Ras 
(Muraoka et al., 2012). Ras mutants also display differences in their conformational 
states. When GTP bound, Ras assumes two interconverting conformations, 
‘inactive’ state 1 and ‘active’ state 2, which are characterised by different positioning 
of Y32 relative to the nucleotide (Geyer et al., 1996; Shima et al., 2010). State 2 
closely resembles the Ras effector-bound state and has high affinity for effectors, as 
well as increased GTPase activity, while state 1 has reduced effector affinity and 
GTPase activity (Muraoka et al., 2012). Wild-type Ras can alternate between these 
states every few milliseconds, with state 1 population occupying 36 ± 2% for wild-
type H-Ras-GppNHp (Shima et al., 2010; Spoerner et al., 2004). However, 
mutations shift the equilibrium between the two states, as state 1 occupies 53% and 
58% for H-RasG12V-GppNHp and H-RasQ61L-GppNHp, respectively (Spoerner et 
al., 2004; Ye et al., 2005). The G12D mutation has also been shown to stabilise the 
state 1 conformation (Geyer et al., 1996). However, it is uncertain how the 
equilibrium is shifted in many of the other Ras mutants and the biological relevance 
of such shifts is unclear.  
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Fig. 1.7. The structure of oncogenic Ras. Whole molecules and nucleotide-binding 
pockets of wild-type and oncogenic H-Ras mutants: G12D, G12V and Q61L. All Ras 
structures are in their active conformation, bound to GppNHp. Mutation highlighted in red. 
WT H-Ras, PDB code 1ctq (Scheidig et al., 1999); G12D, PDB code 1agp (Franken et al., 
1993); G12V, PDB code 3oiw (Buhrman et al., 2011); Q61L, PDB code 2rgd (Buhrman et al., 
2007). 
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The above-mentioned structural differences may account for the discrete 
biochemical differences observed between mutant proteins, because specific 
mutations at position 12, 13 or 61 are likely to disturb residues within the binding 
pocket in their own unique way (Scheffzek et al., 1997). Oncogenic Ras mutants 
exhibit various dissociation rates for guanine nucleotides, e.g. GTP dissociation from 
G12D mutants is 8-fold faster than wild-type or G12V Ras (John et al., 1988; John et 
al., 1989). Ras mutants also display differentially impaired intrinsic GTPase activities 
compared to wild-type, e.g. Trahey et al. reported that H-Ras G12V and G12D retain 
12% and 43% of wild-type GTPase activity, respectively (Al-Mulla et al., 1999; Colby 
et al., 1986; Der et al., 1986; Franken et al., 1993; Gibbs et al., 1984; John et al., 
1988; Krengel et al., 1990; Trahey et al., 1987). However, the literature on mutant 
GTPase activity doesn’t entirely agree, possibly because different assay techniques 
were used. Recently, it has been reported that intrinsic Ras GTPase activity can be 
increased following Raf-1 binding via allosteric modulation (Buhrman et al., 2010). 
Ras mutants may not to be sensitive to this emerging mode of regulation, as their 
impaired GTPase activity may be non-enhanceable and mechanistically their 
mutated binding sites may not be unable to support it. Consequently, Ras mutations 
may provide a means to circumvent this effector-mediated regulation. 
 
1.2.2B DIFFERENT TRANSFORMING ACTIVITIES AND SIGNALLING OF RAS      
MUTANTS 
 
Focus formation assays have demonstrated that different H-Ras mutations exhibit a 
range of transforming abilities, e.g. G12V mutants exhibited strong transforming 
effects, while G12D, G12C, G12A and G13N transforming activities were slightly 
weaker (Der et al., 1986; Fasano et al., 1984; Seeburg et al., 1984; Smith et al., 
2010). These differences are very likely attributable to the subtle, but unique, 
biochemical and structural variations of each mutant Ras protein, as detailed above. 
Interestingly, G12P mutations, although insensitive to GAPs, could not transform 
cells, since it retains intrinsic GTPase activity (Schweins et al., 1995). Furthermore, 
K-Ras G12V transfectants have been shown to induce tumours in nude mice in 
shorter time and latency compared to G12D and G12C (Cespedes et al., 2006). 
Together, these studies show that different Ras mutations, even if they affect the 
same codon, cannot be considered the same, since they must signal differently in 
order to exert different biological effects.  
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The position of the Ras point mutation also seems to be associated with the degree 
of tumour cell aggressiveness. Codon 12 Ras mutations exhibit increased 
transforming capacity compared to those at codon 13 (Bos et al., 1985; Fasano et 
al., 1984; Sloan et al., 1990), offering a possible explanation why these codon 
mutations are more frequently observed in human cancers (Capella et al., 1991; 
Prior et al., 2012). Stable expression of K-RasG12D and K-RasG13D in NIH 3T3 
cells showed several functional differences, e.g. G12D mutant cell line formed 
colonies of increased density, spontaneously underwent anchorage-independent 
growth and had reduced ability to trigger apoptosis compared to G13D mutant cells 
(Guerrero et al., 2000). Guerrero et al. also show that G12D and G13D had similar 
abilities to activate ERK, but the former had greater capacity to activate AKT, 
suggesting that G12D signals more strongly through the PI3K pathway. This 
observation has, in part, been observed in nude mice xenografts, where K-
RasG12D demonstrated increased activation of AKT but very little activation of ERK 
(Cespedes et al., 2006). Structural analysis of the K-RasG12D protein predicts that 
it cannot interact with ERK, possibly explaining the reduced ERK activation (Al-Mulla 
et al., 1999). Injection of nude mice with NIH 3T3 transfectants showed that K-
RasG12D induced fibrosarcoma-like tumours, while K-RasG13D created tumours 
that resemble fibrous histocytomas (Guerrero et al., 2002). This study also showed 
that tumours derived from G13D transfectants grew at a slower rate and exhibited a 
higher level of apoptosis compared to the G12D transfectants. Plus, G13D tumour-
derived cells expressed more K-Ras and exhibited lower levels of AKT activation 
compared to those with G12D. Analysis of the metabolic flux of transfected NIH3T3 
cells using [1,2-13C2] glucose showed that K-Ras-G12D and -G13D mutations 
produce distinctive metabolic phenotypes (Vizan et al., 2005). Cells harbouring K-
RasG12D utilised more glucose for anaerobic glycolysis compared to G13D, which 
could explain how G12D cells have increased resistance to apoptosis, while G13D 
demonstrated increased use of anabolic pathways. 
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Fig. 1.8. Colorectal carcinogenesis. (Top) Anatomy of the colon and tissue layers that 
compose the colon wall. (Bottom) Vogelgram detailing the genetic alterations and mutations 
observed at different stages of colon cancer development. Based on (Fearon and 
Vogelstein, 1990; Saif and Chu, 2010). 
 
1.2.3 CLINICAL RELEVANCE OF RAS CODON MUTATIONS 
 
CRC is the third most common cancer worldwide with an overall 5-year survival rate 
of 11% for patients exhibiting metastatic disease (Siegel et al., 2012). In CRC, K-
Ras is most commonly activated at codon 12 (33% of cases), with aspartate (40% of 
codon 12) and valine (37%) amino acid substitutions the most frequent, followed by 
cysteine (11%) and serine (7.7%); codon 13 mutations are less prevalent (9.5% of 
cases) but aspartate substitutions dominate this position (95%) (Vaughn et al., 
2011). This mutation usually occurs at an early stage of colon carcinogenesis 
(Fearon, 2011; Fearon and Vogelstein, 1990; Vogelstein et al., 1988) (Fig. 1.8). The 
prognostic value of K-Ras mutations in CRC is uncertain, since many studies make 
conflicting conclusions (Anwar et al., 2004; Cerottini et al., 1998; Lievre et al., 2006; 
Locker et al., 2006; McLeod and Church, 2003; Ren et al., 2012). However, 
comparing survival statistics of patients who harbour specific Ras mutations reveal 
differences in clinical outcome. The Kirsten ras in-colorectal-cancer collaborative 
group (RASCAL) studies, which monitored over 3,000 patients from several 
countries, show that K-RasG12V mutations are associated with poorer prognosis 
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than other mutations, i.e. shorter disease-free survival and survival rate (Andreyev 
et al., 2001; Andreyev et al., 1998). However, other studies found that K-RasG13D 
mutations were associated with a worse clinical outcome. Bazan et al. monitored 
160 Italian CRC patients and found that those with codon 13 mutations had worse 
disease-free and overall survival compared to individuals with codon 12 mutations 
(Bazan et al., 2002). Similarly, Heinemann and co-workers, who studied 273 
German patients, found that those with a K-RasG13D mutation presented a more 
aggressive disease associated with local and distant metastasis at first diagnosis 
(Modest et al., 2011). Samowitz et al., who reviewed 1,413 American patients, found 
that K-RasG13D mutations were associated with a 40% increase in risk of short-
term mortality and Cerottini et al. showed that these mutations are linked with 
reduced disease free survival following surgery (Cerottini et al., 1998; Samowitz et 
al., 2000). Yet, Ogino and colleagues mined two pathological epidemiology 
databases of 1,261 rectal and colon tumours and found that G12D mutations, not 
G13D, were associated with inferior survival in BRAF wild-type CRC patients 
(Imamura et al., 2012). Overall, it is clear that some disagreement exists between 
studies, but the majority indicate that codon 13 mutations predict the worst patient 
outcome and out of the codon 12 mutations, valine substitutions may confer more 
aggressive tumour behaviour.   
 
Cetuximab (Erbitux®; ImClone systems/ Eli Lilly/ Bristol Myers Squibb), an 
immunoglobulin G1 monoclonal antibody against EGFR, has proven effective as a 
single agent or in combination with chemotherapy for the treatment of patients with 
metastatic CRC (De Roock et al., 2008; Jonker et al., 2007). This antibody binds the 
to the extracellular domain of EGFR to competitively inhibit EGF or other growth 
factors from binding, which prevents receptor phosphorylation and subsequent 
activation of downstream signalling events (Baselga, 2001; Graham et al., 2004). 
However, the European Medicines Agency and US Food and Drug Administration 
advise that patients harbouring codon 12 or 13 K-Ras mutations should be excluded 
from cetuximab treatment, since these mutations have been reported as resistance 
markers to anti-EGFR therapy (Karapetis et al., 2008; Lievre et al., 2008; Lievre et 
al., 2006). Yet, previous studies showed that a few patients with K-Ras mutant 
tumours did occasionally respond to anti-EGFR treatment (Frattini et al., 2007; 
Moroni et al., 2005). The majority of these patients suffered from K-RasG13D 
mutations, which suggests that codon 12 and 13 K-Ras mutations may have 
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different effects on cetuximab sensitivity. A retrospective analysis of 579 CRC 
patients treated with cetuximab, between 2001 and 2008, revealed patients 
harbouring a K-RasG13D mutation were associated with a longer overall survival 
(OS) and progression free survival (PFS), 7.6 months and 4.0 months, respectively, 
when treated with cetuximab monotherapy or any cetuximab-based therapy, 
compared to patients with other K-Ras mutations, OS 5.7 and PFS 1.9 months (De 
Roock et al., 2010). This study also demonstrated that isogenic colorectal cell lines 
containing wild-type or G13D K-Ras were sensitive to cetuximab treatment, while 
cells with K-RasG12V were resistant (Di Nicolantonio et al., 2008). Similarly, 
Messner et al. used a panel of cell lines harbouring various K-Ras mutations to 
show that those harbouring G13D mutations were more susceptible to cetuximab 
treatment compared to those with mutations at codons 12 or 61 (Messner et al., 
2013). Tejpar et al. analysed 533 CRC patients, of which 83 had G13D mutations 
and benefitted from first-line treatment with cetuximab (Tejpar et al., 2012). 
Cetuximab plus chemotherapy versus chemotherapy alone improved PFS (7.4 
versus 6 months) for G13D patients, but had little benefit for OS (15.4 versus 14.7 
months). Tejpar and colleagues also noticed that G13D patients receiving 
chemotherapy alone had a worse outcome compared to patients with other K-Ras 
mutations. Bando et al. retrospectively analysed 109 Japanese CRC patients, who 
were treated with irinotecan and cetuximab and found that the seven G13D patients 
in the analysis did not have significantly improved OS or PFS compared to other 
patients, despite showing a higher disease control rate (Bando et al., 2012). Gajate 
et al. reviewed 110 Spanish CRC patients and showed that G13D patients had no 
statistically different OS or PFS compared to other mutations (Gajate et al., 2012). 
However, neither the Gajate or Bando studies had G13D control groups, as all 
patients received cetuximab treatment in these retrospective analyses. 
 
Patients who initially respond to cetuximab treatment often develop secondary 
resistance following several months of treatment (Karapetis et al., 2008). Exposing 
cells to increasing concentrations of cetuximab in vitro causes them to develop 
acquired resistance, either through amplification of K-Ras alleles and increased 
protein expression or the appearance of K-Ras mutations (Diaz et al., 2012; Misale 
et al., 2012). Chronic treatment of cells with MET or MEK inhibitors also show that 
acquired resistance can occur through amplification of K-Ras (Cepero et al., 2010; 
Little et al., 2011). However, screening of 1,039 CRC samples revealed that K-Ras 
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amplification is a rare event occurring in 0.67% of samples; plus K-Ras amplification 
and K-Ras mutations seem to be mutually exclusive (Valtorta et al., 2013). Patients 
are likely to develop resistance because all tumours, even those characterised as K-
Ras wild type, are likely to have subpopulations of K-Ras mutant cells that DNA 
sequencing simply isn’t sensitive enough to detect (Parsons and Myers, 2013). 
Consequently, when patients are treated with cetuximab, the outgrowth of these 
mutant subpopulations occur leading to anti-EGFR resistance.  
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1.3 MASS SPECTROMETRY-BASED PROTEOMICS 
 
1.3.1 OVERVIEW OF MASS SPECTROMETRY 
 
Mass spectrometry (MS) is an analytical technique capable of measuring atoms and 
molecules, in their ionised form, to determine their molecular weight with great 
accuracy. It has a broad range of applications in such fields as food and water 
quality control, sports drug testing, forensic sciences, atomic physics and many 
others (de Hoffmann and Stroobant, 2013). Owing to technological advances over 
the past 15 years, in particular with ionisation, MS has most recently been applied to 
biological questions, such as the large-scale study of proteins, known as proteomics 
(Wilkins et al., 1997). Proteomics is one of many ‘–omics’ (e.g. metabolomics, 
genomics, transcriptomics) that collectively aim to characterise how biological 
molecules work in concert to understand the function and dysfunction of whole 
organisms. MS-based proteomics was the central technology employed in this 
thesis to address the questions of cellular Ras abundance and mutant Ras codon-
specific signalling. A mass spectrometer, the analytical instrument used in MS, 
manipulates and measures ionised species in the gas phase at low pressures by the 
application of electric and/or magnetic fields. A typical mass spectrometer consists 
of three basic components: an ion source, a mass analyser and a detector (Watson 
and Sparkman, 2007). Each of these components is further discussed with a 
particular focus on mass analysers. Also detailed are the two mass spectrometers 
employed in this thesis: the 4000 QTRAP and LTQ Orbitrap XL. 
 
1.3.2 TYPICAL MASS SPECTROMETRY-BASED PROTEOMICS WORKFLOW 
 
Accurately measuring the mass (or more precisely the mass-to-charge ratio, m/z) of 
biological molecules is a straightforward task for a modern mass spectrometer. In 
high-throughput proteomics, peptides rather than proteins are analysed and these 
are used to infer information regarding the proteins (a strategy known as surrogacy). 
This well-established ‘bottom up’ approach is favoured for numerous reasons, e.g. 
proteins are challenging to handle and might not be soluble in the same buffer, plus 
the sensitivity of the mass spectrometer is lower for proteins versus peptides (Steen 
and Mann, 2004). Crucially, sequence information is required if the experimental aim 
is to identify proteins. The mass spectrometer is most efficient at providing such 
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information using peptides ~20 residues long, not whole proteins. Yet, it must be 
noted that analysing intact proteins with MS (‘top down’ approach) is a growing field 
with potentially exciting applications, e.g. improved analysis of PTMs (Doerr, 2008); 
however, it is beyond the scope of this thesis. In a typical GeLC-MS ‘bottom up’ MS-
based workflow, proteins are isolated (released) from a biological source, e.g. cell 
culture or animal tissue (Fig. 1.9, step 1), fractionated using sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) (step 2) before in-gel 
proteolytic digestion (step 3) (Jeno et al., 1995; Shevchenko et al., 1996; Wilm et al., 
1996), typically with trypsin (Olsen et al., 2004). Despite protein digestion resulting 
in a considerable increase in sample complexity, most proteins yield at least some 
soluble and ionisable peptides, essential requirements for the subsequent MS 
analysis. A digested sample may contain thousands of peptides, spanning several 
orders of magnitude in abundance, which are impossible to effectively analyse 
simultaneously. Peptides are therefore commonly injected onto a high-performance 
liquid chromatography (HPLC) column directly coupled online to the mass 
spectrometer (LC-MS) (step 4) (Steen and Mann, 2004). C18 reversed-phase (RP) 
nanoflow HPLC provides high resolving power in the separation of peptide mixtures 
for MS (Makarov and Scigelova, 2010; Shen et al., 2002; Wolters et al., 2001). RP-
HPLC comprises of two phases: a stationary and a mobile phase, between which 
the analytes (peptide) are partitioned. The stationary phase is typically formed of 
C18-bonded silica particles resulting in a hydrophobic surface. The mobile phase is 
composed of a polar (e.g. water) and organic (e.g. acetonitrile) solvent mixture at 
low pH (pH < 3). Formic acid in the mobile phase causes low pH, which ensures 
peptides are positively charged and therefore improves peptide retention and aids in 
electrospray ionisation (discussed below), plus the low pH minimises ionised silica 
groups that may reduce resolving power. At the start of a typical gradient, the mobile 
phase is highly polar (> 95% aqueous) resulting in the binding of peptides through 
hydrophobic interactions with the C18 phase. As the proportion of organic solvent in 
the mobile phase increases, peptides elute in order of their hydrophobicity, 
delivering much simpler peptide mixtures for MS analysis (Biosciences, 1999; Shi et 
al., 2004).   
 
Peptides elute from the HPLC column at the ion source region of the mass 
spectrometer. Because MS measurements require gaseous ions, eluting peptides 
are electrostatically dispersed from a glass or metal capillary at the end of the 
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column (step 5). Known as electrospray ionisation (ESI), this technique was 
originally developed by Malcolm Dole (Dole et al., 1968) before John Fenn applied it 
to proteins (Fenn, 1993; Whitehouse et al., 1985). Fenn was awarded the 2002 
Nobel Prize in Chemistry, along with Koichi Tanaka who developed matrix-assisted 
laser desorption/ionisation (MALDI) (Liu et al., 1981; Tanaka et al., 1988). Both ESI 
and MALDI are ‘soft’ ionisation techniques as they overcome the propensity of 
macromolecules to dissociate when ionised. ESI is generated by applying a voltage 
(3-6 kV), under atmospheric pressure, to a liquid passing through a capillary at low 
flow rate. The electric field between the capillary tip and counter electrode, 
separated by 0.3-2cm, induces charge accumulation at the liquid surface. Conflicting 
forces between surface tension, which forms a droplet, and electrostatic attraction 
towards the counter electrode, causes the liquid to become cone shaped, known as 
the Taylor cone (Taylor, 1964). Positively charged droplets break from the Taylor 
cone to form a fine spray when a voltage threshold, the Rayleigh limit, is reached 
(Wilm and Mann, 1994). A curtain of heated inert gas (usually nitrogen) and/or a 
coaxial gas flow aids droplet desolvation. As droplets shrink their charge density 
increases because the liquid evaporates as a neutral species. These smaller, highly 
charged droplets undergo coulombic fission to form nanodroplets that lead to 
gaseous ions (de Hoffmann and Stroobant, 2013). Several ESI variations have been 
developed in recent years. One of note is nanoelectrospray ionisation (nESI) (Wilm 
and Mann, 1996), where nL/min HPLC flow rates are used instead of the µL/min of 
ESI. nESI generates smaller droplets that improves desolvation, enhances 
ionisation efficiency and therefore increases sensitivity. Typical flow rates of 200-
400 nL/min are employed in modern nanospray systems for proteomics. Following 
ionisation, gaseous peptide ions enter the mass spectrometer and are guided 
towards the mass analyser by electrostatic lenses (step 6). Peptide analysis in the 
mass spectrometer is detailed in the following section, but briefly the mass analyser 
first measures the m/z of intact peptide ions (precursor ions), before a peptide of 
interest is isolated and fragmented; a strategy termed tandem MS (MS/MS) (de 
Hoffmann and Stroobant, 2013; Watson and Sparkman, 2007). Utilising the 
precursor and fragment ion m/z values, the amino acid sequence can be deduced. 
Working alongside the mass analyser is the detector, which has an essential role in 
detecting ions and measuring their intensities. Most often, peptide quantification and 
peptide-to-spectrum mapping are performed computationally (step 7).  
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Fig. 1.9. Workflow of a typical MS-based proteomic experiment and examples of 
quantification strategies. Following sample preparation (1), fractionation is usually 
performed to reduce complexity (2) before digestion with trypsin or other protease (3). The 
subsequent peptide mixture is separated using reversed-phase high performance liquid 
chromatography (RP-HPLC) (4) then ionised using electrospray (ESI) (5). Alternatively, 
ionisation is achieved with matrix-assisted laser desorption/ionisation (MALDI). MS analysis, 
e.g. tandem MS, is performed in the mass spectrometer (6). Finally, peptide quantification 
and peptide-to-spectrum mapping are performed computationally (7). Arrows indicate the 
point reagents for a quantification method are added to the workflow.  
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1.3.3    MASS ANALYSERS 
 
Once gaseous ions enter the mass analyser they are separated according to their 
m/z. Several types of mass analyser have been developed that utilise different 
principles to separate ions, but they all employ static or dynamic electric fields, 
either in combination or alone, to achieve ion separation. The ways these fields are 
employed represent some of the most fundamental differences between analyser 
types. Examples of mass analysers include the quadrupole mass filter (Paul et al., 
1958), 3D ion trap (Steinwedel and Paul, 1960), linear ion trap (Hager, 2002; 
Schwartz et al., 2002), Time-of-Flight (TOF) (Wolff and Stephens, 1953), Fourier 
Transform Ion Cyclotron Resonance (FTICR) (Comisarow and Marshall, 1974) and 
Orbitrap (Makarov, 2000). What follows is a description of mass analysers employed 
in this thesis: the linear quadrupole, which forms the basis of the quadrupole mass 
filter (QMF) and linear ion trap (LIT), and the Orbitrap.  
 
1.3.3A    LINEAR QUADRUPOLES  
 
Linear quadrupoles are possibly the most extensively employed components of 
mass spectrometers today; having multiple applications as ion guides, mass filters, 
collision cells and LITs (Douglas, 2009). Wolfgang Paul and co-workers described 
the principles of using quadrupole electric fields to manipulate ion trajectories in 
1953 (Paul and Steinwedel, 1953), then developed the linear quadrupole for MS in 
1958 (Paul et al., 1958). The term quadrupole is derived from the use of four 
opposing electrical poles to create an electric field. As such, linear quadrupoles are 
constructed of four circular or, preferably, hyperbolic-shaped rods aligned perfectly 
parallel (Fig. 1.10A) (de Hoffmann and Stroobant, 2013). The specific electrical 
potentials applied to the rods determine the function of the quadrupole. Discussed 
below is how these are employed as QMFs and LITs. 
 
1.3.3B    QUADRUPOLE MASS FILTERS  
 
A QMF, also referred to as a transmission quadrupole, employs oscillating electric 
fields to selectively stabilise or destabilise ion trajectories according to their m/z 
value. Simply, these devices filter out a single m/z range from an unresolved ion 
beam (de Hoffmann and Stroobant, 2013). One pair of the QMF rods has an 
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oscillating radio frequency (RF) voltage superimposed on a positive DC voltage, 
while the other pair has a negative DC voltage and an RF voltage that is 180° out of 
phase with the first rod pair, which creates a quadrupole electric field in the centre of 
the rods (Fig. 1.10A). When the RF voltage reaches its peak opposite to the DC, it 
will overcome the DC and cause the rod to change polarity. The polarity is reversed 
when the RF voltage swings to its opposite peak. As typical RF voltages have 
constant frequencies of ~1.0 MHz, the rods oscillate their polarity hundreds of 
thousands of times every second (Douglas, 2009; Watson and Sparkman, 2007).  
 
The basic principles of ion motion in a quadrupole field can be described with the 
Mathieu equation:  
 !!!!!! + 𝑎! −   2𝑞!𝑐𝑜𝑠2𝜉 𝑢 = 0 
 
where 𝑢  represents x, y and z axes, au and qu are dimensionless trapping 
parameters, and 𝜉 is another trapping parameter equal to Ωt/2 (Ω is frequency and t 
time). 
 
The Mathieu equation was devised by Émile Léonard Mathieu (1835-1890), to 
calculate stability regions of drum skins when struck (March, 1997), and utilised by 
Paul to encompass quadrupoles (Douglas, 2009; Paul et al., 1958): 
 U  =  𝑎! !! !!!!!!!     V  =  𝑞! !! !!!!!!  
 
where U is DC voltage; V, RF amplitude; m/z, mass-to-charge ratio; e, elementary 
charge (1.602×10-19 C); r0, radius of the quadrupole; 𝜔, 2πv (v is RF frequency in 
Hz). This 6-dimensional problem of ion transmission can be mathematically reduced 
to 2-dimensional plots represented as au, qu space (Fig. 1.10B).  
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Fig. 1.10. Quadrupole mass filter (QMF) mass spectrometry. (A) Construction and 
operation of the QMF. Ions from the source pass through an RF only ion guide before 
reaching the QMF, which is constructed of four perfectly parallel rods with DC and RF 
potentials applied, that select for a single m/z value (resolution of 0.3 m/z units). Only ions 
with a stable trajectory (red) are transmitted to the detector, whereas unstable ions (black) 
strike a rod and are ejected from the quadrupole. (B) The first stability region. As RF and DC 
potentials are typically held at a fixed ratio, only values that lie along the operating line are 
available on the QMF. Grey area indicates stable region, occupied by theoretical ion m2. RF 
and DC potentials must be increased or decreased for other theoretical ions to experience a 
stable trajectory and be transmitted. DC and RF amplitudes are related to au and qu, 
respectively. Based on Douglas, 2009 and Watson and Sparkman, 2007. 
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When ions enter the QMF, they experience a total electrical quadrupolar field and 
must oscillate with a stable trajectory to be transmitted. An ion’s trajectory is 
considered stable if the amplitude of its oscillations remains constant. Conversely, 
an ion with unstable trajectory has oscillations that increase exponentially with time, 
consequently the oscillation amplitude will eventually reach r0 causing the ion to 
strike a rod, discharge and be ejected from the mass spectrometer (Fig. 1.10A) 
(Douglas, 2009). Transmission of ions with a single m/z value is achieved by 
scanning the amplitude of RF and DC voltages at a constant ratio (typically 6:1) to 
create an operating line; altering this ratio affects instrument resolution or sensitivity. 
At a certain RF/DC amplitude ratio, ions of a particular m/z will experience a stable 
trajectory and are transmitted, illustrated in Fig 1.10B. Overall, the QMF is a low-
resolution instrument (0.3 Th), operates at constant separation across the m/z 
range, has a dynamic range of 105 and mass accuracy of 100 ppm (Douglas, 2009; 
Watson and Sparkman, 2007). 
 
1.3.3C    LINEAR ION TRAPS 
 
Originally pioneered by Paul and Steinwedel, the quadrupole ion trap was originally 
designed as the 3D ion trap; a device (roughly the size of a tennis ball) constructed 
of two end cap electrodes and a ring electrode (Steinwedel and Paul, 1960). For his 
work in the development of the ion trap and QMF, Paul was awarded the 1989 
Nobel Prize in Physics. However, following the introduction of the LIT in 2002 
(Hager, 2002; Schwartz et al., 2002), with its 10-times improved ion trapping 
efficiency over the 3D trap (50% compared to 5%) and increased ion storage 
capacity, the 3D ion trap has effectively been replaced (Watson and Sparkman, 
2007). Yet, the principles of ion motion in both instruments are essentially the same. 
 
The LIT is based on the geometry of the QMF and confines ions radially by a 2D RF 
field and axially by DC stopping potentials applied to two end electrodes/ lenses 
(Fig. 1.11A). Like the QMF, the principles of ion motion in the LIT are explained by 
Mathieu equations, which can be mathematically reduced to 2D plots expressed as 
au, qu space (Fig. 1.11B). Ions are only stored in the trap if their trajectories are 
stable in r- and z-directions simultaneously (r, radial distance to a rod; z, axial 
distance to an end electrode). When experiencing a stable trajectory in a 3D ion 
trap, ions follow a figure-of-eight shape or Lissajous curve (Fig. 1.11C) (Nappi et al., 
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1997); this shape is elongated for a LIT. Ions can be ejected from quadrupole ion 
traps in a mass-selective manner. Ramping the RF voltage and/or applying an 
auxiliary RF voltage performs sequential mass-selective axial ejection (Hager, 2001; 
Londry and Hager, 2003). As the RF voltage is ramped, all ions experience an 
increase in axial velocity and when an ion’s qz reaches 0.908 (qeject) it becomes 
unstable and is ejected. qz is a dimensionless trapping parameter determining ion 
stability:  𝑞! =    8  𝑒𝑉𝑚(𝑟!! + 2𝑧!!)ω! 
 
where m is mass; z, charge; e, elementary charge (1.602×10-19 C); V, RF amplitude; 
r0, radius of the quadrupole ; 𝜔, 2πv (v is RF frequency in Hz). As ions with low m/z 
values have a higher initial qz they are ejected first. A useful analogy for this is an 
exotic drink arranged of several coloured liqueurs; if the drink is poured, the lightest 
liqueurs of the drink will be poured out first, followed by the second lightest and so 
on. In resonance excitation ejection, an additional RF voltage is applied to the end 
electrodes causes specific ions to obtain increased axial velocity, overcome the exit 
lens barrier potential, reach qeject and be ejected (March, 1997). Ejection of ions can 
be performed to transmit ions to detectors or to remove unwanted ions. Selected 
methods of ion trapping, isolation and ejection for Thermo’s LTQ and AB SCIEX’s 
LITs are illustrated in Fig 1.11D.  
 
A major limitation of the LIT is the so-called low-mass cut-off (LMCO). To fragment a 
peptide, the LIT first isolates it then, with resonant excitation, accelerates the ion 
through inert gas to cause fragmentation. However, due to this additional RF 
voltage, low-mass fragment ions (<28% of the precursor m/z) may have an initial qz 
greater than qeject and won’t be trapped (Douglas et al., 2005; March, 1997). Overall, 
LITs are low-resolution instruments, operate at a constant bandwidth, fast scan 
speeds, and have a mass accuracy around 100 ppm (Watson and Sparkman, 
2007).  
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Fig. 1.11. Ion trap mass spectrometry. (A) Schematic of a linear ion trap (LIT) and different 
modes of ion ejection. Based on Schwartz et al., 2002. (B) Mathieu stability diagram for a 
quadrupole ion trap. Regions of simultaneous overlap of r- and z-directions are highlighted in 
red. Zoom of stability region with qeject or low-mass cut-off indicated (qz = 0.908) indicated. 
Based on March, 1997 (C) Shape of a stable ion’s trajectory stored in a 3D ion trap. Based 
on Nappi et al., 1997. (D) Mechanisms of ion trapping, ion isolation and axial ion ejection.  
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1.3.3D    ION GUIDES AND COLLISION CELLS 
 
Quadrupoles can act as ion guides or collision cells when operated in RF-only 
mode. Without DC voltage, the quadrupole will transmit a broad range of m/z values, 
as ions will be confined radially within the centre of the quadrupole. Ion guides are 
often employed immediately after the ion source, in the relatively high-pressure of 
the first-pumped region, to collisional cool and radially confine incoming ions that 
reduces ion spread and enhances ion transmission (Douglas, 2009; Watson and 
Sparkman, 2007). When operated as a collision cell, the quadrupole accelerates 
ions through inert gas (usually argon or nitrogen) using a voltage between 20 and 
200 eV to fragment ions, in a process termed collision-induced dissociation (CID); 
discussed further in section 3.5. Following fragmentation, the collision gas 
collisionally cools the fragment ions enabling refocusing of the ion beam and 
effective transmission out of the cell. 
 
Other multipole configurations, e.g. hexapoles and octapoles, are also employed as 
ion guides and collision cells and transmit wider ion bandwidths than quadrupoles 
due to their steeper potential wells that lie closer to the rods. However, they cannot 
be employed as mass filters because their electric fields in x and y are coupled, 
meaning they cannot exploit stability regions (Douglas, 2009). 
 
1.3.3E    ORBITRAP MASS ANALYSER  
 
The Orbitrap is the latest development in ion trapping and mass analyser 
technology, transforming the field since its commercialisation in 2005. This device, 
not too much wider than a two-pence coin, is a derivation of the Kingdon trap 
(Kingdon, 1923), the first device capable of storing ions in an electrostatic field. The 
Kingdon trap comprised of a thin wire, acting as a cathode, surrounded by a 
cylindrical anode with two end-cap electrodes that have DC current applied. Knight 
further developed the Kingdon trap by changing the shape of the outer electrode 
and separated it into two sections (Knight, 1981). This added an axial electric field 
enabling ions to harmonically oscillate in the z-direction. Neither the Kingdon nor 
Knight trap was capable of generating a mass spectrum.  
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Fig. 1.12. Orbitrap mass spectrometry. The Orbitrap mass analyser consists of an outer 
electrode and spindle electrode that together generate an inhomogeneous, symmetrical 
electrostatic field (inset). When trapped, ions demonstrate harmonic oscillations along the z-
axis at frequencies dependent on their mass. These oscillations are detected in the barrel 
electrode as a time-domain signal using image current detection, which is converted into 
mass spectra using fast Fourier transformation. Red arrow indicates the trajectory of a stable 
ion in the Orbitrap. Based on Makarov, 2000 and Watson and Sparkman, 2007. 
 
The Orbitrap, developed by Makarov (Makarov, 2000), is a Knight-style Kingdon 
trap that orbitally confines ions in an electrostatic field and comprises of two coaxial 
axisymmetric electrodes: an outer barrel-like electrode and a central spindle-like 
electrode (Fig. 1.12). The outer barrel electrode is held at a near-ground potential 
whereas the spindle electrode has a constant DC potential of approximately -3400 
V. Unlike the quadrupole ion trap, no oscillating electric fields are typically used.  
 
When ions are injected directly into an electrostatic field they are not efficiently 
trapped, in fact they simply pass through. As a result, the ion injection process into 
the Orbitrap is complex: ions are first tightly focused in space and time in a curved 
linear trap (the C-trap), and injected into the Orbitrap, at a point offset from the 
centre, just as the Orbitrap’s electric field is briefly increased (> 300 nsec). Without 
this careful synchronisation, efficient trapping (~30%) would not be achieved 
(Watson and Sparkman, 2007). The Orbitrap can trap all ions, irrespective of m/z, as 
all ion orbits have the same amplitude in the r-direction (Makarov, 2000). Once 
injected into the Orbitrap, ions experience a constant electrostatic field that 
accelerates them towards the middle of the trap, and then decelerates them as they 
reach the opposite end, where they stop and are accelerated back towards the 
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middle of the trap (de Hoffmann and Stroobant, 2013; Makarov, 2000; Watson and 
Sparkman, 2007). Ions therefore display harmonic oscillation around the spindle 
electrode along the z-axis (Fig. 1.12), analogous to a swinging pendulum bob. This 
occurs because the electric field is inhomogeneous but symmetrical due to the 
opposing surfaces of the axisymmetric coaxial electrodes being non-parallel. The 
field is inhomogeneous in two ways; first, the electric field is a gradient, which is at 
its weakest in the middle of the trap and increases uniformly in opposing directions 
along the z-axis; second, the vectors of the electric field are non-parallel. It is this 
second aspect that causes ions to oscillate along the z-axis at a frequency 
dependent on their mass and enables the Orbitrap to function as a mass 
spectrometer. These oscillations are detected in the barrel-like electrode, by two 
electrically isolated components, as a time-domain signal using image current 
detection. The image currents are then transformed into mass spectra using fast 
Fourier transform, similar to the method used in FTICR MS (de Hoffmann and 
Stroobant, 2013; Makarov, 2000).  
 
Overall, the Orbitrap is a high-resolution device (100,000+), capable of sub ppm 
mass accuracy, a dynamic range of > 4,000, a mass range of 200-4000 m/z and 
simultaneous measurement of thousands of m/z values (Makarov et al., 2006a; 
Thermo, 2008; Watson and Sparkman, 2007). 
 
1.3.4 HYBRID INSTRUMENTS 
 
Most modern mass spectrometers rarely comprise of a single mass analyser but are 
constructed of multiple analysers of different types. These hybrid instruments can 
take advantage of each analyser’s characteristics and therefore provide unique and/ 
or improved capabilities compared to the individual mass analysers alone. Examples 
of hybrid instruments are the AB SCIEX 5800 (TOF-TOF), AB SCIEX 5600+ (Q-
TOF), Thermo Q Exactive (Q-collision cell-Orbitrap) and Waters Xevo TQ MS (QMF-
collision cell-QMF). These are just a small selection of the types of mass 
spectrometer available today; however, each employs different analysers in different 
configurations meaning they have specific capabilities that will be suited for certain 
tasks and possibly not others. Below, the hybrid mass spectrometers employed in 
this thesis are discussed: the 4000 QTRAP and LTQ Orbitrap XL.  
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1.3.4A    4000 QTRAP 
 
The 4000 QTRAP® is a triple quadrupole (QqQ) mass spectrometer, introduced by 
Applied Biosystems/ MDS Sciex (now AB SCIEX) in 2003 and is very similar in 
design to the original QqQ developed in 1979 (Yost and Enke, 1979). The 4000 
QTRAP comprises of three quadrupoles: a QMF (Q1), a collision cell (q2) and an 
LIT (Q3) that has dual function as either a LIT or a QMF (Fig. 1.13A) (ABSCIEX, 
2010; Hager, 2002). In this thesis the 4000 QTRAP was used predominately in two 
modes: selective-reaction monitoring (SRM) (Anderson and Hunter, 2006) and 
multiple reaction monitoring-initiated detection and sequencing (MIDAS) (Unwin et 
al., 2005).  
 
In SRM, also referred to as multiple-reaction monitoring (MRM), a precursor ion is 
isolated, fragmented and the intensity of several selected fragment ions measured 
consecutively (Fig. 1.13B). The QTRAP system performs SRM scans by collimating 
and collisionally cooling an unresolved peptide ion beam in the Q0 ion guide, before 
it is transmitted into Q1 QMF that allows ions of a single m/z value to experience a 
stable trajectory and be transmitted into q2, the collision cell. Here selected 
precursor ions are rapidly accelerated through inert nitrogen gas, causing them to 
fragment, before continuing into Q3. Operating in QMF mode, Q3 transmits a 
specific fragment ion to the EM detector where signal intensity is recorded. The 
selected precursor and fragment (product) ion masses can be altered every few 
msec, allowing multiple precursor/ fragment ion pairs, known as transitions, to be 
monitored in rapid succession. This results in a highly selective and sensitive 
approach for peptide quantification; further discussed in section 3.6.2. In MIDAS, 
SRM scans are performed for user-defined transitions similarly to that described 
above. However, when the signal intensity for a transition reaches a user-defined 
threshold, Q3 switches from QMF to LIT mode. Since fragmentation occurs in the 
collision cell, all fragment ions are trapped without LMCO and accumulated in the 
LIT, before axial ejection to the detector to acquire an MS/MS spectrum. MIDAS is 
particularly useful for identification of PTM sites and for validation of SRM transitions 
amongst other applications (Lange et al., 2008; Unwin et al., 2009). Other scan 
modes available on the 4000 QTRAP include neutral loss scan, precursor ion scan 
and information dependent acquisition (IDA). 
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Fig. 1.13. The 4000 QTRAP® triple quadrupole mass spectrometer (AB SCIEX) and 
operating principles of Selected Reaction Monitoring (SRM). (A) Schematic of the 4000 
QTRAP. It comprises of an ion guide, for collimating the ion beam and enhancing ion 
transmission; a quadrupole mass filter (QMF), which filters sample ions according to m/z 
value; a linear accelerator (LINACTM) collision cell, for fragmentation of selected sample ions 
(cut out shows how its rods are angled); and a linear ion trap that can also function as a 
QMF. Based on ABSCIEX, 2010 and Hager, 2002. (B) Overview of SRM for peptide 
quantification. Q1 QMF alternates transmission of light (endogenous) and heavy (standard) 
versions of the same peptide into the q2 collision cell for fragmentation, before being sent 
into Q3. Operating as a QMF, Q3 alternates transmission of predetermined fragment ions to 
the detector where signal intensity is measured. Multiple precursor and fragment ion pairs 
(transitions) are monitored for both heavy and light forms of the peptide, using identical dwell 
times, to measure a proportion of the peptide’s ion current. When the transition signals are 
integrated, absolute quantification of the light (endogenous) peptide can be performed, as 
the abundance of heavy (standard) peptide is known. 
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1.3.4B    LTQ ORBITRAP XL 
 
Introduced in 2007, the LTQ Orbitrap XL is the second major release of Thermo’s 
Orbitrap family. This instrument comprises of: quadrupole and octapole ion guides, a 
linear ion trap, C-trap, HCD collision cell and an Orbitrap mass analyser (Fig. 1.14A) 
(Makarov et al., 2006a; Makarov et al., 2006b; Thermo, 2008).  
 
In the present thesis, the LTQ Orbitrap XL was used exclusively in data-dependent 
acquisition (DDA) mode, which enables the instrument to combine the Orbitrap’s 
high-resolution scanning capabilities with the LTQ’s rapid fragmentation and scan 
speeds. In DDA, three multipole ion guides transmit peptide ions through stages of 
differential pumping towards the LTQ. In the LTQ, a pre-determined number of ions 
are trapped before they are axially ejected into a region of higher vacuum through 
an octapole and into the C-trap. Here the ion packet is focused and injected into the 
Orbitrap that performs a high-resolution MS1 scan, providing precursor ion m/z 
values with high mass accuracy. A user-defined number of the most abundant ions 
(six was employed in this thesis) are then reported to the LTQ, which sequentially 
isolates, fragments and radially ejects the subsequent fragment ions to EM 
detectors (Fig. 1.14B and C). To fragment ions, the LTQ uses resonance excitation 
to increase the precursor ion velocity and therefore the energy of collisions between 
precursor ions and inert helium buffer gas (discussed further in section 3.5.1); as a 
result the LTQ exhibits LMCO. The LTQ and Orbitrap function in parallel, so that as 
the Orbitrap is acquiring an MS1 spectrum, the LTQ is isolating and fragmenting 
ions reported from the previous MS1 scan. Overall, this process of measuring the 
m/z of precursor then subsequent fragment ions is termed tandem MS or MS/MS 
and summarised in Fig 1.14B.  
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Fig. 1.14. The LTQ Orbitrap XLTM (Thermo Scientific). (A) Schematic of the mass 
spectrometer. Red line indicates the ion beam. Based on Thermo, 2008. (B) Data-
dependent, parallel acquisition of the Orbitrap and linear trap quadrupole (LTQ). Following 
ionisation, peptide ions are trapped by the LTQ before being guided into the C-trap, which 
tightly focuses and efficiently transfers them into the Orbitrap where a high-resolution (≥ 
30,000) scan is performed, generating an MS1 spectrum. m/z values of the top 6 precursor 
ions from the MS1 are reported to the LTQ where they are sequentially isolated, fragmented 
and product ions scanned out to generate MS/MS spectra. (C) Peptide fragmentation 
techniques in the LTQ. Collision-induced dissociation (CID) commonly provides structurally 
informative product ions (top). However, when a post-translational modification is present 
(e.g. phosphorylation), fragmentation can be poor making peptide identification difficult 
(middle). Multistage activation (MSA) employs additional activation at the m/z(s) where, in 
theory, the neutral loss ion(s) should reside (bottom) (Schroeder et al., 2004). 
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1.3.5    PEPTIDE FRAGMENTATION 
 
MS-based proteomics relies on peptide fragmentation to generate information on 
peptide sequences and sites of post-translational modifications. There are different 
fragmentation techniques available in MS; those most commonly used are collision-
induced dissociation (CID) (Haddon and McLafferty, 1968; Jennings, 1968; 
McLafferty and Bryce, 1967), electron capture dissociation (ECD) (Zubarev et al., 
1998) and electron transfer dissociation (ETD) (Syka et al., 2004). In CID, precursor 
ions are accelerated to higher kinetic energy and allowed to collide with inert gas 
molecules to cause fragmentation. In ECD, peptide ions are irradiated with low-
energy electrons to cause random backbone fragmentation through radical-driven 
pathways. Because ECD has essentially been limited to FTICR instruments, ETD, 
an ion-ion analogue of ECD compatible with ion traps and multipoles, was 
developed. In ETD, electrons are transferred to peptide ions from a radical anion, 
e.g. anthracene and fluoranthene, to fragment the peptide backbone. CID, the sole 
dissociation technique employed in this thesis, is currently the most popular and 
established means of gas phase fragmentation of peptides in proteomics and is 
discussed further below. 
 
1.3.5A    COLLISION-INDUCED DISSOCIATION OF PROTONATED PEPTIDES 
 
In CID, peptide ions are accelerated by electric potentials and allowed to collide with 
inert neutral gas, e.g. nitrogen or helium. These collisions partially convert an ion’s 
kinetic energy into internal vibrational energy that is distributed throughout the 
molecule. According to the ‘mobile proton’ model, first introduced by the groups of 
Wysocki (Dongre et al., 1996) and Gaskell (Burlet et al., 1992), this causes 
additional proton(s) to mobilise and populate energetically less favourable 
protonation sites. Being multifunctional compounds, peptides have multiple 
protonation sites, e.g. terminal amino groups, amide oxygens and nitrogens, and 
side chain groups. Protonation of amide nitrogens is favourable for peptide 
decomposition, as this weakens the amide bond and renders the neighbouring 
carbonyl group susceptible to nucleophilic attack by next neighbouring carbonyl 
groups or nearby electron-rich groups (Paizs and Suhai, 2004). Because different 
protonated species of the same peptide can coexist, fragmentation occurs at various 
sites along the peptide backbone, usually at amide bonds, thus generating 
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sequence-informative b- and y-ions, as well as other ions, e.g. a-ions, internal ions, 
immonium ions and non-sequence ions related to water/ ammonia loss (Fig. 1.15A). 
As the mobile proton model only provides a qualitative understanding of peptide 
fragmentation, efforts have been made to explain fragmentation in a semi-
quantitative manner by predicting ion intensity relationships in MS/MS spectra. The 
emerging ‘pathways in competition’ (PIC) model considers all known fragmentation 
pathways, including pre-dissociation, dissociation and post-dissociation events  
(Paizs and Suhai, 2005). 
 
Low-energy CID, the technique used in this thesis, employs a collision energy range 
of 1-100 eV, pressures of ~10 mTorr and activation times 10-30 msec (Wells and 
McLuckey, 2005). It fragments peptides by breaking their weakest bonds, 
predominantly through charge-directed rearrangement reactions, e.g. the bx-yz and 
‘diketopiperazine’ fragmentation pathways. In the bx-yz pathway (Paizs and Suhai, 
2001) (Fig. 1.15B), an additional proton mobilises to the nitrogen of the amide bond 
to be cleaved, before nucleophilic attack on the neighbouring carbonyl group from 
oxygen of the next neighbouring carbonyl group, thus forming b-ions with cyclic 
oxazolone structure and linear y-ions. A proton dimer (a short-lived, loose complex) 
may form between the fragment ions, which will dissociate following transfer of the 
additional proton to the ion with greatest proton affinity (Harrison, 1998; Paizs and 
Suhai, 2005). Diketopiperazine fragmentation pathways are also initiated by 
mobilisation of additional proton(s) to amide nitrogens (Cordero et al., 1993) (Fig. 
1.15B), before nucleophilic attack by the terminal amino group on the neighbouring 
carbonyl group. Following amide bond cleavage, b-ions often dissociate as a neutral 
species, because they are unable to compete for the additional proton as large 
cyclic b-ions have much lower proton affinities than linear y-ions (Nold et al., 1999). 
As the mechanism of bond cleavage in the ‘diketopiperazine’ pathways differs 
depending upon which amide bond is targeted, it is referred to as diketopiperazine-
yN-n, where N is the total number of residues in the peptide and n the amide bond 
(aa(n)-aa(n+1)) to be cleaved. For example, the diketopiperazine-yN-2 pathway 
requires trans-cis isomerisation of the N-terminal amide bond to enable 
fragmentation, whereas this isn’t required in the diketopiperazine-yN-n (n>2) pathway 
(Paizs and Suhai, 2004). The above-mentioned fragmentation pathways are by no 
means an exhaustive list, as peptides may fragment through various other 
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mechanisms, e.g. the a1-yx pathway, the aziridinone pathway and nucleophilic attack 
by amino acid side chains (Paizs and Suhai, 2005). 
 
Peptide fragmentation under low-energy CID conditions is not random and the 
eventual fragmentation pattern observed in MS/MS spectra depends on several 
factors, e.g. amino acid composition, instrument type and fragmentation technique. 
Peptide ions can be placed into two broad categories, the first category contains 
ions that have one or more highly favoured protonation sites, e.g. a singularly 
charged peptide with an arginine/lysine residue or a multiple charged peptide with 
many basic residues. This category is characterised by the large amount of energy 
required to mobilise the additional proton(s) to other protonation sites and will 
demonstrate limited fragmentation or resist fragmentation altogether. The second 
category contains peptides that have many protonation sites accessible within a 
narrow energy range and therefore suited for MS/MS analysis with CID. This 
category is best represented by doubly charged tryptic peptide (Paizs and Suhai, 
2005). Numerous studies have shown residue-specific cleavage, especially at 
proline, aspartic acid and glutamic acid residues. Proline-containing peptides exhibit 
a distinct, highly abundant y-ion N-terminal of proline (Schwartz and Bursey, 1992). 
This has been attributed to proline’s high proton affinity and also that b-ion formation 
is not favoured C-terminal to this residue (Vaisar and Urban, 1996). Glutamic acid- 
and aspartic acid-containing peptides generate abundant b-ions C-terminal to these 
residues. Peptides preferentially fragment at these points possibly because the bond 
is more labile than others (Qin and Chait, 1995; Yu et al., 1993).  
 
The instrument type used for fragmentation can also affect which product ions are 
detected. LITs and collision cells are unlikely to generate identical MS/MS spectra, 
despite both utilising low-energy CID. Because LITs use resonant excitation CID, 
fragment ions aren’t exposed to collision energy once produced, allowing labile 
fragment ions (e.g. large b ions) to remain stable and be detected when scanned 
out. Whereas collision cells expose all ions to collision energy, causing labile 
product ions to further fragment and not be detected. Additionally, collision cells 
have no LMCO enabling detection of low mass fragment ions, while LITs suffer from 
LMCO and are unable to trap such ions during fragmentation. 
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Fig. 1.15. Fragmentation of protonated peptides. (A) Nomenclature developed by 
(Roepstorff and Fohlman, 1984) and adapted by (Biemann, 1988). (B) Charge-directed 
fragmentation pathways common in low-energy collision-induced dissociation. Following 
collisions between peptide ions and inert molecules in a collision cell/ ion trap, the internal 
energy of the ions increases causing their extra proton(s) to mobilise and populate 
energetically less favourable sites. Protonation of amide nitrogens considerably weakens 
amide bonds and permits nucleophilic attack by functional groups: the N-terminal adjacent 
amide oxygen (bx – yz pathway, left) or the nitrogen from the N-terminal amino group 
(diketopiperazine pathways, right). Based on (Paizs and Suhai, 2005).  
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1.3.6 QUANTIFICATION STRATEGIES IN MASS SPECTROMETRY-BASED 
PROTEOMICS 
 
Quantitative proteomics’ ability to measure the abundance of thousands of proteins 
in many biological systems has seen it become a widely applied approach. 
Especially since mRNA levels cannot accurately predict protein expression levels 
(Gygi et al., 1999b) and that these protein levels reflect the cell’s ultimate decision 
on its physiological needs. Quantifying the differences in a biological system 
between two or more physiological states is not only one the most important tasks in 
proteomics, but it is also one of the most challenging. Many MS-based quantification 
methods utilise differential stable isotope labelling to create specific mass tags, 
which are recognised by the mass spectrometer and enable quantification by 
comparing their respective signal intensities. These mass tags can be introduced 
metabolically, chemically, enzymatically or through spiked synthetic peptides/ 
proteins (Bantscheff et al., 2007). As a result of constantly improving LC-MS 
equipment, label-free quantification strategies, which forgo an isotope label, have 
grown in popularity and perform quantification by comparing samples after 
independent analyses. The labelling techniques employed in this thesis, stable 
isotope labelling by amino acids in cell culture (SILAC) (Ong et al., 2002) and 
protein standard absolute quantification (PSAQ) (Dupuis et al., 2008), are discussed 
below, along with alternatives. A summary of various MS-based quantification 
techniques is provided in Fig 1.9. 
 
1.3.6A    SHOTGUN PROTEOMICS AND RELATIVE QUANTIFICATION 
 
Shotgun proteomics refers to the use of bottom-up proteomic techniques, described 
in section 3.2, in identifying peptides in complex mixtures. Named after shotgun 
DNA sequencing, where long DNA sequences are reconstructed computationally 
from many short reads, shotgun proteomics identifies peptides by matching MS/MS 
spectra of proteotypic peptides with those in a database (discussed in section 3.7) 
enabling identification of the protein (Washburn et al., 2001). Heavily used in 
discovery proteomics today, this approach has become a powerful tool in the 
unbiased analysis of protein abundance, modifications and interactions. However, 
coupling accurate peptide quantification with shotgun proteomics has been 
challenging, because peptides have unique physicochemical properties, e.g. 
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hydrophobicity, charge, size, amino acid composition, they will be unequal in their 
mass spectrometric response, even if they are from the same protein (Bantscheff et 
al., 2007). Nevertheless, by comparing each individual peptide between 
experiments, accurate quantification can be achieved. This was realised following 
the introduction of stable-isotope labelling of peptides in 1999 (Gygi et al., 1999a; 
Oda et al., 1999; Paša-Tolić et al., 1999). Since an isotope-labelled peptide is 
chemically identical to its non-labelled counterpart, they are expected to behave 
identically during MS analysis, yet the mass spectrometer can differentiate between 
the two peptide forms and quantification is achieved through comparison of their 
signal intensities.  
 
Metabolic labelling provides the earliest possible point to introduce a stable isotope 
signature into proteins, thus minimising systematic errors, and was pioneered using 
15N-labelling of bacteria (Oda et al., 1999). Presently, SILAC is one of most popular 
forms of metabolic labelling (Ong et al., 2002), which in its original configuration 
utilised leucine isotopes but now more commonly uses isotopes of arginine and 
lysine, such that tryptic peptides will carry at least one label (Fig. 1.16A). In a triplex 
SILAC experiment, cells representing different conditions are grown in ‘light’, 
‘medium’ or ‘heavy’ media. All amino acids in ‘light’ media contain 12C and 14N (i.e. 
no labelling), whereas ‘medium’ and ‘heavy’ are depleted of unlabelled arginine and 
lysine. Instead, ‘medium’ contains 4,4,5,5-D4 L-lysine (+4 Da) and 13C6 L-arginine 
(+6 Da), and ‘heavy’ 13C6 15N2 L-lysine (+8 Da) and 13C6 15N4 L-arginine (+10 Da) 
isotopes. Before MS analysis, the cells are lysed, lysates mixed at a 1:1:1 protein 
ratio, then, depending on the aim of the experiment, subject to selected sample 
preparation techniques. Due to the differential labelling, lysine-containing peptides 
from the ‘medium’ and ‘heavy’ conditions can be recognised by their +4 and +8 Da 
shift in the MS1 spectrum, respectively. Similarly, arginine-containing peptides will 
exhibit a +6 or +10 Da shift. Comparing the extracted ion chromatograms (XICs) 
integrated from the MS1 signal intensities of the SILAC triplet enables relative 
quantification, whilst MS2 spectra provide information for peptide identification. This 
approach enables the simultaneous identification and quantification of thousands of 
peptides in various biological systems, provided that the system can be 
appropriately labelled with stable isotopes. It is reported to have a linear dynamic 
range of between 1 and 2 orders of magnitude (Bantscheff et al., 2007).  
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Isotope signatures can also be introduced following protein isolation, as is the case 
for the isotope-coded affinity tags (ICAT) technique. Here proteins are chemically 
labelled by targeting cysteine thiol groups through covalent attachment of ‘light’ 
(containing no deuterium) or ‘heavy’ (containing 8 deuteriums) reagents prior to 
digestion (Gygi et al., 1999a). ‘Light’ and ‘heavy’ peptides are then distinguished by 
a +8 Da shift in MS1 spectra. However, deuterium causes a chromatographic shift 
that produces ‘doublet’ peaks, which correspond to the deuterium-labelled and 
unlabelled peptide. Other quantification techniques target digested peptides for 
labelling. In dimethyl labelling, formaldehyde with cyanoborohydride is covalently 
bound to digested peptides (Hsu et al., 2003), which contain either no label (‘light’, 
+28 Da) deuterium and/or 13C (‘medium’, +32 Da; ‘heavy’, +36 Da). In isobaric tags 
for relative and absolute quantitation (iTRAQ, Fig. 1.16B), isobaric mass labels are 
covalently attached to peptide N-termini or lysine residues (Ross et al., 2004). The 
chromatographically indistinguishable isobaric tags generate low-mass reporter ions 
and therefore a MS/MS signature that supports quantification. Tandem mass 
tagging (Thompson et al., 2003), as well as the non-isobaric variant of iTRAQ, 
mTRAQ (DeSouza et al., 2008), adopt a somewhat similar approach. An additional 
approach to label peptides is to introduce a heavy oxygen isotope during digestion 
(Yao et al., 2001). Here two 18O atoms are incorporated into the C-termini of 
peptides, resulting in a +4 Da shift in the MS1 spectra for labelled peptides. Label-
free quantification, as the name implies, attempts to quantify proteins without the 
use of isotope labels, instead using spectrum counting- or MS1-intensity-based 
approaches. Reviewing the different label-free methodologies in-depth is beyond the 
scope of this thesis (for a recent excellent review refer to (Bantscheff et al., 2012)). 
To briefly mention a few examples, the number of peptide-to-spectrum matches or 
total ion currents (TICs) from MS/MS spectra have been used as a readout of 
protein abundance (Asara et al., 2008; Liu et al., 2004); plus integrating MS1 ion 
intensities of any given peptides over its chromatographic peak between 
experiments has shown to provide excellent linear responses (Bondarenko et al., 
2002). One methodology of note is intensity-based absolute quantification (iBAQ) 
(Schwanhausser et al., 2011), where the intensities of observed peptides from any 
given protein are integrated and divided by the number of theoretically observable 
peptides to give an ‘iBAQ intensity’. iBAQ intensities are then compared to those of 
a standard of 48 unlabelled proteins, spiked in at known concentrations, using linear 
regression, to provide an approximate abundance for thousands of proteins. 
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Fig. 1.16. Common strategies in quantitative proteomics using stable-isotope 
labelling. (A) Stable isotope labelling by amino acids in cell culture (SILAC) (Ong et al., 
2002). Cells are metabolically labelled after being grown in media containing different 
isotopes of lysine and arginine. Cells are lysed, lysates mixed then subject to a chosen 
sample preparation technique, before LC-MS/MS. A characteristic shift in the MS1 spectra 
enables the peptides origin to be determined and relative quantification occurs through 
comparison of the integrated SILAC triplet extracted ion chromatograms (XICs) (B) Isobaric 
tags for relative and absolute quantitation (iTRAQ) (Ross et al., 2004). Isotope-coded tags 
are covalently bound to the digested peptides’ N-termini or lysine residues. The tags are 
indistinguishable chromatographically but generate a reporter ion series in MS2 to enable 
quantification.  
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1.3.6B   TARGETED PROTEOMICS AND ABSOLUTE QUANTIFICATION 
 
Although shotgun proteomics is a powerful tool, it is not optimal for the systematic 
quantification of proteins in biological samples due to the usual high complexity of 
such samples, the limited sensitivity and stochastic nature of the approach and that, 
most often, relative quantification of the sample’s most abundant proteins is 
performed. Consequently, to complement discovery-based strategies, techniques 
have been devised that target known peptides for accurate absolute quantification 
from complex matrices at low abundances. 
 
SRM has been the reference quantitative technique for small molecules for several 
decades (Baty and Robinson, 1977; Zakett et al., 1978), but over the past few years 
it has emerged as an ideal tool for targeted proteomics because of its very high 
sensitivity (femtomole to attomole range), wide linear dynamic range (4 to 5 orders 
of magnitude) and high selectivity (Gallien et al., 2011; Stahl-Zeng et al., 2007). 
Targeted SRM approaches measure the signal intensity (peak area) of precursor/ 
fragment ion pairs (transitions) for a set of predefined peptides, over their 
chromatographic peaks, to achieve quantification (Anderson and Hunter, 2006). 
Such transitions are generally acquired using a QqQ, where precursor ions are 
selected in Q1, fragmented using CID in q2 and predefined fragment ions 
transmitted to detectors by Q3 (described in section 3.4.1, Fig. 1.13). Q1 is typically 
set to alternate transmission of precursor ions corresponding to unlabelled and 
stable-isotope-labelled versions of the same peptide for fragmentation in the 
collision cell. Coinciding with Q1, Q3 alternates transmission of (multiple) selected 
fragment ions to the detector, such that a large proportion of a peptide’s total ion 
current (TIC) is measured (depending on amino acid composition, the top 5 
transitions usually accounts for  >70% of a peptide’s TIC) (Lange et al., 2008). 
Signal-to-noise is low, as only the precursor of ion of interest is selected in Q1, and 
selectivity is high because of the requirement for both precursor and fragment ions 
being present. Consequently, when an unlabelled biological sample has an isotope-
labelled standard spiked in (spike-in strategies discussed later), comparison 
between the relative intensities of the unlabelled and labelled transitions enables 
accurate and precise quantification. Furthermore, SRM assays can be segmented, 
such that peptides are monitored only when they are eluting from the LC column, 
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enabling a large number of peptides to be quantified in a single LC run (Stahl-Zeng 
et al., 2007).  
 
Unlike unbiased shotgun proteomics, a minimum amount of prior information is 
required before an SRM assay can begin. This information is gathered during assay 
development, a slow and iterative process, that comprises of the following steps: (1) 
selection of target protein(s), (2) identification of proteotypic peptides, (3) selection 
of suitable transitions for each peptide, (4) optimisation of instrument parameters for 
each transition/peptide (e.g. collision energy, dwell times, retention times etc.), (5) 
determination of detection and quantification limit, (6) determination of peptide signal 
response across different concentrations, (7) validation of each transition (Gallien et 
al., 2011; Lange et al., 2008). Only once these steps have been performed, can an 
SRM assay begin. 
 
Similar to relative-quantification strategies, there are various ways to introduce an 
isotope label into a targeted proteomics workflow. But a key difference here is that 
by knowing the amount of an isotope-labelled standard, it is possible to measure the 
absolute amount of a peptide and, by inference, the protein of interest in a sample. 
AQUA peptides (AQUA an acronym for absolute quantification) are synthetic 
isotope-labelled peptides that may be spiked into peptide digests to act as surrogate 
standards for endogenous peptides (Barr et al., 1996; Gerber et al., 2003). 
QconCAT involves the generation of a concatemer of isotope-labelled peptides that 
is spiked into a sample immediately before digestion (Beynon et al., 2005). The 
concatemer can contain peptides from multiple proteins and is synthesised such that 
proteolytic digestion releases the isotope-labelled peptide standards. Yet, these 
techniques do have some drawbacks, chiefly they assume either complete protein 
digestion (as is the case for AQUA) or equal digestion between the concatemer and 
endogenous protein (as for QconCAT), as well as equivalent losses and recoveries 
of endogenous and isotope-labelled peptides, assumptions that are very likely not 
true (Gallien et al., 2011; Lowenthal et al., 2014). Nevertheless, these methods will 
undoubtedly provide reasonable data, but for truly accurate measurements they are 
likely to fall short. PSAQ however is recognised as the most accurate method 
currently available to quantify a protein, as this involves spike in of full-length, 
isotope-labelled protein into an unlabelled sample (Dupuis et al., 2008). 
Consequently, digestion conditions for the endogenous and labelled proteins are 
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identical, the effects of protein structure and amino acid sequence on digestion are 
equalised and systematic errors are avoided as the protein standard is added at the 
beginning of the workflow. Other methodologies similar to PSAQ have been 
described, e.g. full-length expressed stable isotope-labeled proteins for 
quantification (FLEXIQuant) (Singh et al., 2009) and absolute SILAC (Hanke et al., 
2008). Interestingly, Hanke et al. did not utilise SRM or a QqQ, but selected ion 
monitoring (SIM) on an LTQ-Orbitrap to perform peptide quantification.  
 
Accurate and consistent quantification of proteins is an essential requirement for 
systems biology to precisely construct metabolic networks and cellular signalling 
pathways. The development of SRM-targeted quantification, coupled with the above-
mentioned spike-in strategies, has great potential to provide this required 
information. Yet, the field of proteomics is still very much in development, emerging 
techniques, e.g. sequential window acquisition of all theoretical fragment-ion spectra 
(SWATH) (Gillet et al., 2012), potentially have the power to deliver SRM-like quality 
data, while reducing assay develop time and significantly increasing the number of 
quantified proteins in a single run. It is no longer in the realms of science fiction to 
suggest that quantitative proteomics may retire the Western blot for protein 
quantification.  
1.3.7    SOFTWARE TOOLS 
 
A major challenge in MS-based proteomics today is that of data handling and/or 
interpretation. Because a single shotgun proteomics experiment generates a 
quantity of data that makes manual interpretation unfeasible, software packages 
designed to computationally interpret tandem MS data have become invaluable. A 
variety of software suites are currently available, from both academic and 
commercial sources, which are used for quantification, peptide-to-spectrum mapping 
and the identification and localisation of post-translational modifications. This section 
briefly describes a number of such software suites that are commonly used by the 
proteomics community. 
 
1.3.7A    QUANTIFICATION TOOLS 
 
Over the past few years the number of software packages available to analyse 
proteomics data has risen dramatically. Researchers now have a variety of software 
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tools to choose from to computationally process, interpret and quantify their 
discovery- and targeted-based proteomic data. In shotgun proteomics, a popular 
and freely available software tool is MaxQuant (Cox and Mann, 2008), which has 
been used in hundreds of studies since its initial release in 2008 (judging by 
citations). Following its integration with the Andromeda database search engine 
(discussed in next section), the MaxQuant suite of algorithms incorporates all steps 
needed in a computational proteomics platform. Once data is input into MaxQuant, it 
is processed with the ‘quant’ module, before MS/MS spectra are matched with 
database-derived peptide sequences with Andromeda, and the subsequent data 
from each is combined and subject to statistical analysis using the ‘identify’ module. 
The ‘quant’ module searches MS1 for isotope clusters and SILAC peptide pairs, and 
performs quantification by integrating XICs. The ‘identify’ module compiles the final 
output files and calculates various statistics, e.g. peptide posterior error probability 
(PEP) score. Recent releases of MaxQuant are compatible with a variety of stable-
isotope relative quantification techniques, e.g. SILAC, TMT and iTRAQ, as well as 
label-free methods, e.g. iBAQ. Freely available software alternatives for 
quantification of proteomic data include: OpenMS (Kohlbacher et al., 2007), Viper 
(Monroe et al., 2007) and Census (Park et al., 2008). Commercial alternatives 
include: Proteome Discoverer (Thermo), Progenesis LC-MS (nonlinear dynamics, a 
Waters company) and Mascot distiller (Matrix Science Ltd). 
 
In targeted proteomics, Skyline is a popular, open-source software package for SRM 
assay setup and quantitative analysis, designed by the MacCoss group (MacLean et 
al., 2010). It is compatible with all spike-in quantification techniques discussed 
earlier and quantifies peptides by integrating the XICs of multiple transitions. As 
SRM assay setup is a slow and iterative process, functionality to import public 
spectral libraries, e.g. PeptideAtlas (Desiere et al., 2006), predict peptide retention 
times (Escher et al., 2012) and streamline collision energy optimisation was added 
to Skyline to aid with this process.  
 
1.3.7B    SEARCH ENGINES  
 
Database search algorithms (search engines), which match MS/MS spectra to 
peptide sequences from curated databases, are critical components of modern 
discovery-based proteomic workflows (Marcotte, 2007; Nesvizhskii et al., 2007). The 
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first major attempt to correlate fragment ion spectra with database-derived peptide 
sequences was performed by the group of John Yates III, who described the 
Sequest strategy (Eng et al., 1994). The algorithms of this strategy search a protein 
database for peptides that match the molecular weight of the experimentally 
observed peptide, before a cross-correlation function is used to match m/z values of 
predicted fragment ions to those observed experimentally. A score is then assigned 
to describe the nearness of the match. Currently, Mascot (Matrix Science Ltd) 
(Perkins et al., 1999) and Andromeda (Cox et al., 2011) are two commonly used 
search engines. Mascot compares experiment-derived MS/MS spectra to in silico-
generated data in a similar way to Sequest, but incorporates a probabilistic-scoring 
model by calculating the probability that an observed match is a chance event. This 
provides a simple rule to judge whether a match is significant and guards against 
false positives. Similarly, Andromeda uses probability-based scoring. It has now 
replaced Mascot as the search engine integrated into the MaxQuant environment 
(Cox and Mann, 2008) and utilises a scoring function derived from the p-score, 
introduced for the interpretation of MS3 spectra (Olsen and Mann, 2004). 
Andromeda separates the spectra into 100 Th bins, before dynamically match 
testing the peaks within each bin, in an intensity-prioritised manner. When 
compared, Mascot and Andromeda demonstrated a high level of correlation in terms 
of peptide identifications, with few peptides identified exclusively with either 
approach (Cox et al., 2011). The techniques employed by these search engines to 
identify and localise post-translational modifications are discussed in section 3.8.2.  
 
1.3.7C    DATABASES 
 
A variety of publically available databases have been developed to provide the 
proteomics community with complete human, mouse, rat and E.coli protein 
sequences, amongst others. These databases play a crucial role in enabling the 
identification of peptides and proteins using MS/MS spectral searching. The 
International Protein Index (IPI) (Kersey et al., 2004), retired in 2011 due to 
advances in data organisation, offered non-redundant data sets on human, mouse, 
and rat proteomes by combining Swiss-Prot, TrEMBL, Ensembl and RefSeq 
databases. IPI users are now directed to use the Universal Protein Resource 
Knowledge Base (UniProtKB) (Apweiler et al., 2004; UniProt, 2011), which expertly 
curates, manually annotates and reviews the Swiss-Prot database.  Other 
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databases, e.g. NCBI and EMBL EST divisions, are available for peptide-to-
spectrum mapping, but discussing these is beyond the scope of this thesis. 
 
1.3.8 PHOSPHOPROTEOMICS 
 
Out of the > 200 different PTMs that can occur on proteins (Wold, 1981), none are 
as universally recognised as reversible phosphorylation of serine, threonine and 
tyrosine residues to control nearly all aspects of life (Cohen, 2002). Phosphorylation 
plays a critical role in essentially all cellular processes through regulation of protein 
activity, sub-cellular localisation, expression levels and degradation, as well as 
protein-protein interactions. The phosphorylation status within a cell is highly 
dynamic, controlled by the action of kinases and phosphatases, and reflects the 
cell’s current physiological needs. It is unsurprising that aberrant phosphorylation 
has been associated with the onset and progression of many pathological 
conditions, e.g. various cancers (Hanahan and Weinberg, 2000), Parkinson’s 
(Greggio, 2012) and Alzheimer’s disease (Gong et al., 2006). Consequently, 
understanding phosphorylation at the molecular level of normal and diseased 
cellular states has become an area of intense research.  
It is estimated that ~30% of all mammalian proteins are phosphorylated at any one 
time, > 500 serine, threonine and tyrosine kinases comprise the human kinome, and 
that ~700,000 potential phosphorylation sites are available to any given kinase 
(Hunter, 1998; Manning et al., 2002; Ubersax and Ferrell, 2007). Phosphorylation 
can occur on serine, threonine, tyrosine, histidine, arginine, lysine, cysteine, 
glutamic acid, and aspartic acid residues, but by far the most prevalent sites are the 
hydroxyl groups of serine, threonine and tyrosine (Hunter, 1991). Out of all 
phosphorylation events, pS accounts for ~90%, pT ~10% and pY ~0.05% (Hunter 
and Sefton, 1980). Despite pY being the least abundant phosphorylation type, 
possibly explaining why it was discovered (fortuitously) relatively late (Eckhart et al., 
1979), it plays an essential role in receptor-mediated signal transduction, with its 
aromatic ring affording stronger binding with protein interaction partners compared 
to the aliphatic chains of pS and pT (Hunter, 1998). 
MS has revolutionised the characterisation of protein phosphorylation, as the large-
scale identification and quantitation of phosphopeptides is now feasible following 
recent advances in liquid chromatography, sample preparation techniques and MS 
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instrumentation. However, sample complexity and the low stoichiometry of 
phosphopeptides complicate the study of the phosphoproteome by MS (Rigbolt and 
Blagoev, 2012). Phosphopeptides have also been reported to suffer from lower 
ionisation efficiencies compared to unmodified peptides (Ishihama et al., 2007), but 
this is disputed (Steen et al., 2006). For effective MS analysis, these issues 
necessitate the use of enrichment strategies, e.g. strong cation exchange (SCX) 
(Beausoleil et al., 2004), TiO2 chromatography (Larsen et al., 2005; Pinkse et al., 
2004), immobilised metal affinity chromatography (IMAC) (Andersson and Porath, 
1986; Ficarro et al., 2002) and SCX followed by IMAC or TiO2 (Lemeer et al., 2008; 
Villen and Gygi, 2008) amongst others. Although pY-containing peptides may be 
enriched using these methods, its very low abundance necessitates the use of pull-
down strategies with pY-specific antibodies to achieve a high level of enrichment 
(Rush et al., 2005). 
The versatility of phosphoproteomic and quantitation strategies allows them to be 
applied in combination to a wide range of biological processes in various organisms. 
Quantitative phosphoproteomics, using SILAC or iTRAQ, has enabled the 
interrogation of downstream signalling from RTKs (Hammond et al., 2010; Morandell 
et al., 2008) and GPCRs (Christensen et al., 2010; Hoffert et al., 2012); as well as 
the characterisation of phosphoproteomic changes in EphB2- and ephrin-B1-
controlled cell sorting (Jorgensen et al., 2009), in Salmonella-infected cells (Rogers 
et al., 2011), and following stem cell differentiation (Rigbolt et al., 2011a). The 
successful application of quantitative phosphoproteomics to probe signalling events 
in different organisms, e.g. Saccharomyces cerevisiae (Saleem et al., 2010; 
Schreiber et al., 2012), Escherichia Coli (Macek et al., 2008) and Drosophila 
melanogaster (Chang et al., 2008), further demonstrates the wide scope of its utility. 
1.3.8A COLLISION-INDUCED DISSOCIATION OF PHOSPHORYLATED 
PEPTIDES 
 
Post-translational modification of residues on a peptide can redirect the preferred 
site of cleavage during CID. Phosphorylation of serine and threonine residues is the 
best known ‘MS/MS labile’ chemical modification, but other PTMs, e.g. 
glycosylation, sulfonation and nitrosylation, also fall into this category (Chicooree et 
al., 2014; Mikesh et al., 2006). Understanding the fragmentation behaviour of 
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phosphopeptides has enabled MS to become a valuable tool for recognising protein 
phosphorylation and pinpointing phosphorylation sites.  
 
Since the phosphate group of a phosphopeptide is relatively labile, it provides a low-
energy pathway that competes with backbone fragmentation in CID. Consequently, 
a MS/MS spectrum of a phosphopeptide typically contains a dominant neutral loss 
peak that is 98 (or occasionally 80 Da) lower than the precursor mass, 
corresponding to the loss of H3PO4 (or HPO3) (DeGnore and Qin, 1998; Liao et al., 
1994). Sometimes the neutral loss peak dominates to such an extent that other, 
sequence-informative ions are not observed. Fragmentation patterns of 
phosphoserine (pS) and -threonine (pT)-containing peptides differ in CID (Fig. 
1.17A). pS-containing peptides fragment in a simple, charge state-independent 
manner, by losing predominately H3PO4 to form dehydroalanine. pT-containing 
peptides display more complex, charge-dependent fragmentation behaviour, by 
predominantly losing H3PO4 to form dehydrobutyrine or losing HPO3 through 
dephosphorylation (DeGnore and Qin, 1998). Consequently, observing neutral loss 
of H3PO4 is a common method to recognise protein phosphorylation at serine and 
threonine residues. Neutral loss of H3PO4 can occur via two mechanisms: β-
elimination or charge-directed pathways (Fig. 1.17B) (Boersema et al., 2009). In β-
elimination, the phosphate group abstracts hydrogen from the α-carbon of the 
phosphorylated residue resulting in loss of the phosphate group (DeGnore and Qin, 
1998; Tholey et al., 1999). In charge-directed mechanisms, the phosphate group 
abstracts the mobile proton, leading to nucleophilic attack by neighbouring groups or 
E2-elimination reactions (Fig. 1.17B) (Boersema et al., 2009). Charge-remote and 
charge-directed mechanisms are likely to be in competition, with the charge-directed 
mechanism possibly the most abundant (Palumbo et al., 2008; Tholey et al., 1999).  
 
Generally, LITs will exhibit a higher level of neutral loss compared to collision cells, 
because the latter expose all ions to collision energy meaning they will automatically 
activate neutral loss fragments, whereas LITs usually activate the precursor ion 
only, which allows neutral loss fragments to remain intact. As a result, methods have 
been developed for LITs to obtain more sequence information from phosphorylated 
peptides by employing a second stage of activation, e.g. data-dependent neutral 
loss-triggered MS3 (Beausoleil et al., 2004) and multistage activation (MSA) 
(Schroeder et al., 2004). In MS3, a survey scan is performed to determine precursor 
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m/z values, followed by an MS/MS scan. If a dominant neutral loss peak is detected, 
a third step is triggered where the newly released neutral-loss precursor ion is 
further isolated and activated. As the neutral loss fragment no longer has a lower-
energy fragmentation pathway from the phosphate group available, more extensive 
backbone fragmentation can be achieved. However, any benefits provided by MS3 
come at the expense of speed. In MSA, also referred to as pseudo-MS3, a survey 
scan is performed before a precursor ion is isolated and activated at its m/z. This is 
followed by activation at m/z values where, in theory, different neutral loss fragments 
reside, while all other fragments remain trapped (Fig. 1.14C). MSA is likely to 
provide richer sequence information than MS3, because ions formed in the first 
activation event, which are discarded by MS3 and possibly not formed in subsequent 
activations, are included in the MSA spectrum. MSA can be viewed as generating a 
composite spectrum of the MS2 and MS3. Additionally, MSA has a speed advantage 
over MS3, as it doesn’t require refilling of the ion trap. Only a few studies have 
directly compared the utility of MS2, MS3 and MSA in large-scale phosphorylation 
analyses (Ulintz et al., 2009; Villen et al., 2008). But they differ in their conclusions 
regarding the benefit provided by additional activation steps, possibly because the 
studies used different neutral loss settings and MS setup. Villén et al. concluded that 
the extra time spent on additional activation events is not worthwhile; unlike Ulintz et 
al. who found MSA to outperform both MS2 and MS3 by identifying more 
phosphosites and that MSA spectra had the highest number of identifiable peaks 
and the most information content.  
 
Phosphotyrosine (pY)-containing peptides are generally stable under low-energy 
CID conditions, occasionally demonstrating neutral loss of HPO3. H3PO4 cannot be 
lost by pY, because the aromatic ring prevents E2-elimination or SN2-neighbouring 
group participation reactions and stabilises the C-O bond of pY’s C-O-P structure, 
causing fragmentation at the weaker O-P bond (Boersema et al., 2009; Tholey et al., 
1999). It is therefore challenging to detect pY in LITs. To address this issue, higher 
collision energies, e.g. one-tenth of precursor m/z, have been employed in collision 
cells and C-traps to improve the detection of pY by generating a diagnostic 
immonium ion at m/z 216.043 (Fig. 1.16A) (Olsen et al., 2007; Steen et al., 2001). 
Even if this immonium ion was generated in an LIT, it is likely it would be lost due to 
LMCO.  
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Fig. 1.17. Collision induced-dissociation of phosphopeptides. (A) Fragmentation of 
phosphoserine, -threonine and -tyrosine. During CID, the phosphomoiety is often lost in 
preference to peptide backbone fragmentation as a characteristic neutral loss. In contrast to 
phosphoserine, fragmentation of phosphothreonine and -tyrosine is complex. Phosphoserine 
predominately loses H3PO4; phosphothreonine typically loses H3PO4, but may also lose 
HPO3; phosphotyrosine infrequently exhibits neutral loss but more often generates an 
immonium ion at higher collision energies. (B) Examples of neutral loss fragmentation 
pathways. β-elimination, the phosphate group abstracts hydrogen from the phosphorylated 
residue’s α-carbon. Charge-directed pathway, protonation of the phosphate group leads to 
nucleophilic attack by the β-carbon’s carbonyl group. Red arrows indicate movement of 
electron pairs; red hydrogen is that abstracted by the leaving phosphoric acid. Based on 
Boersema et al., 2009. (C) Determining phosphosite localisation. Left, an unmodified 
hypothetical peptide; right, same peptide but with T4 phosphorylated. Orange and red ions 
are ‘site determining’. Orange, fragments with intact phosphate group attached (+80 Da from 
corresponding unmodified ion); red, fragments containing a dehydrobutyrine residue (-18 
Da).  
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1.3.8B    PHOSPHOSITE LOCALISATION 
 
Pinpointing a phosphosite can be even more demanding than identifying the peptide 
itself, especially when considering ~16% of amino acids in an average human 
protein are serine (8.6%), threonine (5.4%) or tyrosine (2.3%) (Echols et al., 2002). 
To confidently localise a phosphosite, ‘site determining’ ions must be present in the 
MS/MS spectrum. To demonstrate how phosphosites are localised, Fig. 1.17C 
shows theoretical spectra of a peptide in phosphorylated and non-phosphorylated 
forms. The peptide has three potential phosphorylation sites: T4, T8 and T9. 
Compared to the non-phosphorylated peptide, fragment ions with an intact 
phosphate group will be +80 Da, while dehydroalanine/ dehydrobutyrine residues 
are -18 Da. T8 and T9 are not phosphorylated, as the y6 ion and smaller y ions have 
identical m/z values as the unmodified peptide. T4 is likely to be phosphorylated as 
y8 and y7 ions are site determining, i.e. they are in +80 and -18 Da forms. 
Furthermore, b5 and b4 ions contain dehydrobutyrine residues, while b3 and b2 do 
not. For confident phosphosite localisation, fragment ions with an intact phosphate 
group are required, because loss of -18 Da can also correspond with the loss of 
water from the unmodified peptide (Boersema et al., 2009; Lehmann et al., 2007). 
When site-determining ions are lacking, phosphosite localisation could be 
prevented, especially if several possible phosphorylation sites exist on a peptide. 
Further complicating phosphosite localisation was the report of possible 
intramolecular transfer of phosphate between amino acids with a hydroxyl group 
during CID scrambling (Palumbo and Reid, 2008), but this has been disputed since 
(Aguiar et al., 2010).  
 
Due to the sheer number of MS/MS spectra generated by a single 
phosphoproteomics experiment, manual inspection to identify phosphosite(s) has 
become extremely difficult, if not impossible. Consequently, in the interests of 
throughput and objectivity, data analysis software packages have incorporated 
various strategies to identify protein phosphorylation and possible phosphosites. 
Because reviewing these different strategies in detail is beyond the scope of this 
thesis, the methods employed by Mascot and MaxQuant/ Andromeda are taken as 
examples. Most strategies for scoring localisation reliability fall into two main 
categories; first, those that assess the probability of site determining ions to be 
matched at random; second, those that calculate a difference score between the 
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possible site localisations following a database search (Chalkley and Clauser, 
2012). MaxQuant employs the former strategy with its PTM score (Olsen et al., 
2006), while Mascot uses the latter with its delta score (Savitski et al., 2011). For 
peak picking, both MaxQuant and Mascot use a similar method by splitting MS/MS 
spectra into 100 or 110 Th bins, respectively, with the most intense peaks within 
each bin used for searching. For phosphosite localisation, the PTM score considers 
the 4 highest peaks per bin and tests all combinations of serine, threonine and 
tyrosine phosphorylation; those with the highest scores are then reported. In the 
Mascot delta score, following a database search, the difference between the best 
and second best Mascot ion score are calculated for alternative phosphosites on the 
same peptide. Both of these strategies are used heavily, as well as several others, 
e.g. A-score, SLoMo and the SLIP score, but a consensus is yet to be reached on a 
standard strategy for determining phosphosite localisation (Chalkley and Clauser, 
2012).    
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1.4 OUTLINE AND OBJECTIVES OF THE THESIS 
 
With modern biology adopting an ever-increasing holistic approach to study the 
behaviour of complex signalling pathways, through the use of mathematical and 
computational modelling, it is important that accurate measurements of pathway 
component concentrations are made. Although Ras proteins have been extensively 
studied for over 30 years, it is remains unclear how many Ras molecules are 
present in a cell, as well as which isoform is most abundant. While several attempts 
have been made to measure cellular Ras abundance in the past few years, the 
accuracy of the developed techniques is disputable and the results from these 
studies conflict. The present thesis aims to develop a selected reaction monitoring 
(SRM)-based assay, combined with the protein standard absolute quantification 
(PSAQ) technique, to enable the accurate, precise and reliable quantification of H-, 
K(A)-, K(B)- and N-Ras isoforms at endogenous levels. The Ras quantification 
technique should also be designed to be easily utilised by most biological 
laboratories, with access to a mass spectrometry facility, by using procedures that 
are recognisable to such laboratories and/ or do not require specialist knowledge. 
The target cell lines in this thesis are a panel of isogenic SW48 colorectal cell lines 
that harbour a range of heterozygous K-Ras mutations, as well as H- and N-Ras 
mutants, with each mutant sequence expressed under its respective endogenous 
promoter. These cell lines can reveal if Ras mutations can affect isoform protein 
expression levels.  
 
Ras proto-oncogenes are commonly activated by mutations at codons 12, 13 and 
61, which occur in ~16% of human cancers and each result in a constitutively active 
Ras protein. However, clinical data indicates that codon 12 and 13 mutant K-Ras 
proteins are unequal in their signalling output, since colorectal cancer patients 
harbouring these mutations display different overall survival rates and 
responsiveness to anti-EGFR antibody therapy. By subjecting isogenic SW48 cells 
harbouring G12D, G12V and G13D K-Ras mutations, which represent 75% of 
colorectal cancer cases that harbour a K-Ras mutation, to proteomic and phospho-
proteomic analysis, using mass spectrometry-based techniques, this thesis aims to 
probe the differences in signalling output from the different K-Ras mutants. 
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2 – MATERIALS AND METHODS 
2.1 GENERAL SOLUTIONS AND BUFFERS 
 
All chemicals in this section and 2.2 were purchased from Sigma Aldrich (Poole, 
UK), unless stated otherwise.  
 
RADIOIMMUNOPRECIPITATION ASSAY (RIPA) LYSIS BUFFER: 
10 mM Tris HCl (pH 7.5), 150 mM NaCl, 0.1% [w/v] Triton X-100, 0.1% [w/v] SDS, 
1% [w/v] sodium deoxycholate, supplemented with 50 mM NaF, mammalian 
protease inhibitors (diluted 1:250; #P8340, Sigma Aldrich), PhosSTOP tablet (1 per 
10 mL; #04 906 845 001, Roche, West Sussex, UK), unless indicated otherwise. 
 
NP40 LYSIS BUFFER: 
25mM Tris HCl (pH 7.5), 0.5% [w/v] NP40, 100mM NaCl, supplemented with 50 mM 
NaF, mammalian protease inhibitors (diluted 1:250), PhosSTOP tablet (1 tablet per 
10 mL).  
 
TRANSFER BUFFER: 
25 mM Tris-HCl (pH 8.5), 190 mM glycine, 10% [v/v] methanol. 
 
10× TBS: 
200 mM Tris HCl (pH 7.6), 1.5 M NaCl.  
 
1× TBS-T: 
0.1% [w/v] Tween 20 (#EC-407, National Diagnostics, Hull, UK) in 1× TBS. 
 
BLOCKING SOLUTIONS: 
1× TBS-T supplemented with 5% [w/v] non-fat dry milk powder (Marvel, Premier 
foods, Hertfordshire, UK), 3% [w/v] Gelatin from cold water fish skin (#G7765, 
Sigma Aldrich) or 5% [w/v] BSA.  
 
DNA LOADING BUFFER: 
5% [w/v] glycerol, 0.1 mM EDTA, ~0.005% [w/v] bromophenol blue. 
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5× SAMPLE BUFFER: 
Tris HCl (pH 6.8), 15% [w/v] SDS, 50% [v/v] glycerol, 16% [v/v] beta-mercapto-
ethanol, with bromophenol blue as a dye. 
 
5× M9 MINIMAL MEDIA: 
120 mM Na2HPO4, 55 mM KH2PO4, 21.5 mM NaCl, 1 mM MgSO4.7H2O, 0.5 mM 
CaCl2, 48 mM NH4Cl, 2% [w/v] glucose, 0.5 mg/ mL of each hydrophilic amino acid, 
1 mg/ mL of each hydrophobic amino acid, not including arginine and lysine (pH 
7.4).  
 
2.2 SOLUTIONS AND BUFFERS FOR LC-MS/MS SAMPLE 
PREPARATION AND INSTRUMENTATION 
AMBIC: 
50 mM NH4HCO3 in HPLC-grade H2O (#23595328, VWR, Leicestershire, UK). 
 
REDUCTION BUFFER: 
10 mM dithiothreitol (DTT) in 50 mM Ambic.  
 
ALKYLATION BUFFER:  
55 mM iodoacetamide (IAA) in 50 mM Ambic.  
 
SDT BUFFER: 
100 mM Tris HCl (pH 7.6), 4% [w/v] SDS, 100 mM DTT. 
 
UREA DENATURING BUFFER: 
100 mM Tris HCl (pH 8.5), 8M Urea, 100 mM DTT. 
 
nanoHPLC BUFFER A: 
0.1% [v/v] formic acid in HPLC-grade H2O (VWR).  
 
nanoHPLC BUFFER B: 
0.1% [v/v] formic acid in HPLC-grade acetonitrile (ACN) (#20060320, VWR).  
 
SCX BUFFER A: 
1 mM NH4HCO2, 20% [v/v] ACN, 0.05% [v/v] TFA (pH 2.7). 
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SCX BUFFER B: 
200 mM NH4HCO2, 20% [v/v] ACN, 1.5% [v/v] TFA (pH 2.7). 
 
GEL FILTRATION BUFFER: 
40 mM Tris HCl (pH 7.4), 50 mM NaCl, 5 mM MgCl2.  
 
SAMPLE LOADING SOLUTION: 
0.1% [v/v] trifluoroacetic acid (TFA). 
 
2.3 MOLECULAR BIOLOGY 
2.3.1 REAGENTS 
 
The following items were from Invitrogen (Paisley, UK), SOC media (#15544-034), 
ultrapure agarose (#15510-019) and TOPO cloning kit (#450030), as well as 
subcloning efficiency DH5α (#18265-017), One Shot Mach1 (#C862003) and One 
Shot BL21 (DE3) (#C600003) chemically competent cells. Luria-Bertani (LB) broth 
and agar (LAB-168 and LAB-191, respectively) were purchased from LAB M Ltd. 
(Bury, UK). 100 mM dNTP mix was acquired from Agilent (#200415, Santa Clara, 
US) and nuclease free water from Sigma (#W4502). The DNA polymerase enzymes 
utilised were Taq polymerase (#BIO-21040, Bioline, London, UK) and KOD hot start 
(#71086, Merck Millipore, Billerica, MA, USA). From New England Biolabs 
(Hertfordshire, UK) were all restriction endonucleases, and Quick load 1kb and 100 
bp ladders (#NO648 and #NO467, respectively). National diagnostics provided 50× 
TAE buffer (#B9-0030). Gel extraction (#28706), Miniprep (#27106) and HiSpeed 
Maxiprep (#12663) kits were all from Qiagen (Crawley, UK).  
 
2.3.2 PLASMIDS  
 
pCR4-TOPO plasmid was from Invitrogen. pRSET-B-His-N-Ras and pRSET-B-K(B)-
Ras (human sequences) were kind gifts from Ignacio Rubio (Institute for Molecular 
Cell Biology, Friedrich-Schiller-Universität Jena, Germany). Wild-type, full-length 
human H- and K(A)-Ras sequences were subcloned into the pTrcHis A vector 
(Invitrogen) from plasmids described in (Laude and Prior, 2008; Prior et al., 2001), 
as detailed below. All DNA sequences were verified by DNA sequencing services 
(Dundee, UK). Maps of generated plasmids are provided in supplementary material. 
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Table 2.1. Primers used in this thesis. Primers utilised to amplify wild-type H- and K(A)-
Ras sequences, from those present in GFP-tagging vectors used in (Laude and Prior, 2008; 
Prior et al., 2001). Tm indicates melting temperature. F and R denote forward and reverse 
primers, respectively. Primers were custom ordered from Eurofins MWG operon.  
 
 
 
Table 2.2. PCR thermocycle programmes utilised in this thesis. Thermocycles were 
tailored to each polymerase used. KOD was utilised for amplification of Ras sequences for 
later subcloning, while Taq was employed in the bacterial colony PCR. A 3000 Techne 
thermocycler was used to perform each PCR reaction.  
 
2.3.3 POLYMERASE CHAIN REACTION (PCR) 
 
H- and K(A)-Ras wild-type human sequences from GFP-tagging vectors were 
targeted for subcloning into the pTrcHis A his-tagging vector. Primers described in 
Table 2.1 indicate those used to amplify these Ras sequences and designed to 
include BamH1/ Xho1 restriction sites. Primers were custom ordered from Eurofins 
MWG operon (Ebersberg, Germany). Typical PCR reaction volumes were 50 µL; 
reactions with KOD polymerase were performed in nuclease free water containing 
1× enzyme buffer, 0.8 mM dNTPs, 0.2 pM of forward and reverse primers, 1.5 mM 
MgSO4, 0.5 ng of DNA template (substituted with water in negative PCR control). 
Mixtures were made up in 0.65 mL Thermowell PCR tubes (#3745, Corning) and 
subject to thermal cycle programmes detailed in Table 2.2 using a Techne 3000 
(Bibby Scientific, Staffordshire, UK). Following the reaction, entire mixtures were 
subject to agarose gel electrophoresis. 
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2.3.4 AGAROSE GEL ELECTROPHORESIS 
 
Agarose gels were prepared by mixing ultrapure agarose with 1× TAE buffer (40mM 
Tris acetate, 1mM Na2EDTA) before heating in a microwave. Gels containing 
between 0.8-1% agarose were used in the present thesis. Ethidium bromide was 
added to a final concentration of 0.5 µg/mL to the gel, which was poured into mould 
and allowed to set. DNA samples were constituted in 1× DNA loading buffer to 
volumes of around 15 µL, before being separated in a horizontal midi tank 
(Invitrogen) at 100-150V for between 1-1.5 hrs. Bands were visualised using a UV 
dock and excised with a scalpel. DNA was extracted using a Qiagen gel extraction 
kit, as per manufacturer’s instructions.  
 
2.3.5 SUBCLONING AND BACTERIAL TRANSFORMATION 
 
PCR products from above steps were ligated into the pCR4-TOPO vector by mixing 
1.5 µL of PCR product (~50 ng), with 1µL salt solution (provided in the TOPO kit), 
2.5 µL water and 1 µL of the TOPO vector. The mixture was left for 15 mins at RT, 
before Mach1 cells were transformed with the ligated vector. The basic 
transformation procedure of each bacterial strain was as follows: 30 µL of cells were 
thawed on ice, before <100 ng of plasmid was added and mixed gently. The mixture 
was incubated on ice for 30 mins, then heat shocked at 42°C for 30 seconds and 
immediately placed back on ice for 2 minutes. Bacteria were then placed into 250 µL 
SOC media and allowed to recover at 37°C for 1 hr with shaking at 245 rpm. The 
mixture was plated out, in varying amounts, on LB agar plates supplemented with 
kanamycin or ampicillin as appropriate and incubated overnight at 37°C. Bacterial 
colony PCR was performed on 20 colonies of kanamycin-resistant Mach1 cells for 
each TOPO vector. Colonies were picked with a toothpick and dipped into the 
following solution: 1 µL 10× buffer (NH4), 0.4 µL MgCl2 solution (provided in the Taq 
polymerase kit), 0.8 mM dNTPs, 0.2 pM of forward and reverse primers, 0.05 µL 
Taq polymerase, making a final volume of 10 µL. The reaction mixture was subject 
to the thermocycle protocol stipulated in Table 2.2. This PCR step highlighted 
colonies containing the desired sequences. Three colonies of Mach1 cells 
transformed positive for the TOPO vector containing H- and K(A)-Ras sequences 
were picked again and grown up in LB broth overnight at 37°C with shaking at 245 
rpm. DNA from the ciltures was purified using a Qiagen Miniprep kit, as per 
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manufacturer’s instructions. Test digests were performed to further ensure insertion 
of each sequence into the TOPO vector. 3.5 µL of isolated DNA was mixed with 
200U (0.8 µL) of each BamH1 (#r0136, NEB) and Xho1 (#r0146, NEB) restriction 
enzymes, 2 µL of 10× BSA (provided by NEB), 2 µL of NEB buffer 3 and 10.9 µL 
water, making a final volume of 20 µL. Digests were performed at 37°C for 2 hours, 
before being heated at 65°C for 10 minutes to end the reaction. DH5α cells were 
transformed with the pCR4-TOPO vectors containing H- and K(A)-Ras sequences, 
as described previously, and a colony of each was grown in 50 mL LB broth 
supplemented with kanamycin overnight. The culture was subject to Maxiprep DNA 
purification and the isolated DNA was sequence verified. To subclone the Ras 
sequences into the pTrcHis A vector, pCR4-TOPO-H-Ras and -K(A)-Ras, as well as 
the pTrcHis A vector, were digested as described above. The Ras sequences and 
cut pTrcHis A vector were gel extracted and ligated using T4 ligase (#M0202, NEB), 
as per manufacturer’s instructions. DH5α cells were transformed with the ligated 
vectors and grown in 50 mL LB broth, as described above, and subject to Maxiprep 
purification. Insertion of the Ras sequences into the pTrcHis A vector was checked 
with test digestion, as detailed above. 
 
2.4 RECOMBINANT RAS PROTEIN PRODUCTION 
2.4.1 ISOTOPE-LABELLED H-, K(A)-, K(B)- AND N-RAS PROTEIN 
PRODUCTION 
 
Auxotrophic E.coli AT713 bacteria were procured from the Yale Coli Genetic Stock 
Center (New Haven, USA). This strain lacks ArgA and LysA biosynthetic genes 
(argA21, lysA22), making it suitable to generate isotope-labelled, full-length proteins. 
To make these bacteria chemically competent, they were grown on non-selective 
agar overnight at 37°C, before a single colony was picked and incubated in LB broth 
overnight at 37°C with shaking at 245 rpm. The culture was placed into 100 mL of 
fresh LB broth and incubated until an optical density (OD) of 0.4 was reached, as 
measured using a Multiskan Spectrum (Thermo Scientific, Rockford, IL, USA). 
Bacteria were pelleted by centrifugation at 2, 500 rpm for 10 min at 4°C, supernatant 
discarded and pellet resuspended in 50 mL of the following ice-cold, sterile filtered 
media: 80 mL LB broth, 10% [w/v] PEG, 10 mM MgCl2, 10 mM MgSO4 and 5 mL 
DMSO. Cells were chilled on ice for 10 mins before being aliquoted and stored at -
80°C. Chemical competency was checked by transforming the cells with pRSET-B-
K(B)-Ras and growing cells on LB agar supplemented with ampicillin. The 
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transformation procedure of the AT713 cells was the same as that stipulated in 
section 2.3.5, except 50 µL of cells were used.  
AT713 bacteria were transformed with pRSET-B-K(B)-RAS, pRSET-B-N-RAS, 
pTrcHis-A-H-Ras and pTrcHis-A-K(A)-Ras plasmids and grown in 5 mL LB broth for 
6 hours at 37°C with shaking at 245 rpm. 100 µL this culture was then transferred to 
100 mL of M9 minimal media, supplemented with L-lysine-U-13C6-15N2 (Lys8) and L-
arginine-U-13C6-15N4 (Arg10) both from Sigma (#608041 and #608033, respectively), 
and grown overnight under the same conditions as in the LB broth. 10 mL of culture 
was then spiked into 10× 100 mL fresh M9 minimal media, with heavy isotopes of 
arginine and lysine, and allowed to grow as before. When an OD of 0.6 was 
reached, isopropyl β-D-1-thiogalactopyranoside (IPTG, #I6758, Sigma) was added 
to a final concentration of 1 mM and the cells incubated for a further 3 hours. 
Bacteria were collected and pelleted by centrifugation at 4, 500 rpm, washed in ice-
cold PBS and pelleted once again. 
 
2.4.2 RAS PROTEIN PURIFICATION 
 
His-tagged Ras isoforms were subject to purification using a PrepEase his-tag 
purification kit (#78791 1 KT, USB now part of Affymetrix, Santa Clara, USA). Fresh 
bacterial AT713 cell pellets were resuspended in ice-cold 1× LEW buffer (supplied in 
kit), supplemented with bacterial protease inhibitors (diluted 1:500, #P8465, Sigma-
Aldrich). The mixture was then frozen at -80°C overnight and allowed to thaw on ice 
the following morning, before lysozyme (#L6876, Sigma-Aldrich) was added to a 
final concentration of 1 mg/ mL and incubated on ice for 30 mins with regular 
agitation. The culture was then sonicated 10 times for 20 seconds with 30-second 
intervals on ice, ahead of centrifugation at 40, 000 rpm for 30 mins at 4°C. The 
subsequent supernatant was subject to the remainder of the PrepEase his-tag 
purification kit, as per manufacturer’s instructions. Eluted Ras protein was 
concentrated using an Amicon Ultra 15-kDa MWCO filter (#UFC900, Millipore) 
through centrifugation at 4, 000 rpm until the total volume was reduced to ~1 mL. 
Ras elutions were then subject to gel filtration using an ÄKTA purifier and Superdex 
200 10/300 GL, both from GE Healthcare (Buckinghamshire, UK). Gel filtration 
buffer, stipulated in section 2.1, was passed through the column at 0.5 mL/ min and 
0.5 mL fractions were collected each minute. The purity of Ras isoforms was 
checked by subjecting ~1 µg of each protein to SDS-PAGE, using 4-12% [w/v] bis-
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tris NuPAGE gels (#NP0335BOX, Invitrogen), before colloidal blue staining 
(#LC6025, Invitrogen) and visualisation on an Odyssey system (LI-COR, NB, USA). 
Ras PSAQ standards were flash frozen in liquid nitrogen and stored at -80°C in 
LoBind tubes (#022431081, Eppendorf, Hamburg, Germany) that were pre-treated 
with 2% [w/v] BSA for 2 hours, before all BSA was removed and excess liquid 
allowed to evaporate in a tissue culture hood for 3 hours. All subsequent dilutions of 
stock protein standard was performed in gel filtration buffer supplemented with 2% 
[w/v] BSA. 
 
2.4.3 DETERMINATION OF ISOTOPE INCORPORATION IN THE RAS PSAQ 
STANDARDS 
 
500 ng of each isotope-labelled Ras protein was subject to SDS-PAGE and in-gel 
digestion with trypsin or elastase, before SRM-analysis on a 4000 QTRAP (AB 
SCIEX, Warrington, UK). The total wild-type Ras peptide, LVVVGAGGVGK, and 
pan-Ras peptide, FYTLVREI, were monitored in both light and heavy forms. The 
differences in signals between light and heavy was used as readout on the extent of 
isotope labelling. The materials and procedures involved in this analysis are 
described in depth in section 2.6.  
 
2.4.4 DETERMINATION OF ISOTOPE-LABELLED RAS PROTEIN 
CONCENTRATION 
 
Accurate measurement of the isotope-labelled, his-tagged Ras proteins is essential 
for the success of the PSAQ analysis. Isotopically light, his-tagged K(B)-Ras was 
generated from AT713 bacteria, as detailed above, but using LB broth instead of M9 
minimal media. The K(B)-Ras protein was purified with the PrepEase kit and gel 
filtrated using phosphate-buffered saline (PBS, #70011044, Invitrogen). The light 
K(B)-Ras protein was subject to a bicinchoninic acid (BCA) assay (#23225, 
Thermo), using the supplied BSA standards (#23208, Thermo), which, according to 
the manufacturer, is precisely formulated at 2 mg/mL and calibrated by direct 
comparison to purified BSA (Fraction V) from the National Institute of Standards and 
Technology (NIST). A second independent protein concentration measurement was 
made using an absorbance measurement at 280 nm on a Nanodrop 1000 (Thermo). 
PBS will not interfere with absorbance readings at this wavelength, making it a 
suitable buffer for such measurements. The molar extinction coefficient for the K(B)-
Ras protein was calculated as 13660 M-1 cm-1 using ProtParam (http://web. 
MATERIALS AND METHODS 
 78 
expasy.org/protparam/) and verified manually using the following equation (Gill and 
von Hippel, 1989; Pace et al., 1995):   
 𝜀   280 𝑀!!𝑐𝑚!! = #𝑇𝑟𝑝 5,500 +    #𝑇𝑦𝑟 1,490 + #𝑐𝑦𝑠𝑡𝑖𝑛𝑒 125  
 
Isotope-labelled Ras standards had their concentrations measured using a Bradford 
assay (Bio-Rad, Hertfordshire, UK), before they were mixed with 500 or 250 ng of 
the accurately quantified light K(B)-Ras at ratios between 1-2.5. The protein mixes 
were then subject to SDS-PAGE, in-gel digestion and subsequent SRM-analysis, 
detailed in section. The total wild-type Ras peptide, LVVVGAGGVGK, was 
monitored for both light and heavy versions enabling the accurate and precise 
quantification of the isotope-labelled Ras PSAQ standards. Detailed information on 
these procedures is provided in section 2.6. 
 
2.5 CELL LINES, GENERAL CELL CULTURE AND PROTEIN 
BIOCHEMISTRY  
2.5.1 CELL LINES, GENERAL CULTURE AND CELL LYSIS 
 
HeLa cells were from Graham Warren (Max F. Perutz Laboratories, Vienna, Austria) 
and grown in Dulbeccco’s Modified Eagles’ Medium (DMEM) with GlutaMAX 
(#10566, Invitrogen), supplemented with 10% [v/v] foetal bovine serum (FBS, 
#16000, Invitrogen), 100 U/ mL penicillin and 100 µg/ mL streptomycin (#15240, 
Invitrogen). Isogenic SW48 cell lines were from Horizon Discovery Group plc 
(Cambridge, UK): Parental (#HD PAR-006), heterozygous knock-in cells containing 
KRASG12D (#HD 103-011), KRASG12V (#HD 103-007), KRASG13D (#HD 103-002), 
KRASG12C (#HD 103-006), KRASG12S (#HD 103-013), KRASG12A (#HD 103-009), 
KRASG12R (#HD 103-010), HRAS12V (#HD 103-034), NRASG12V was generated in 
house by Dr. Simon Oliver and Prof. Ian Prior (University of Liverpool). Second, 
independent SW48 isogenic clones: KRASG12D, KRASG12V, KRASG13D share the 
same catalogue numbers as the first clones. All heterozygous knock-in cell lines 
were genetically matched to the Parental cell line. SW48 cells were grown in 
McCoy’s 5A medium with GlutaMAX (#36600, Invitrogen), supplemented with 10% 
[v/v] FBS and penicillin/ streptomycin as for DMEM. All cells were grown at 37°C 
with 5% [v/v] CO2 in a Binder cell incubator (Tuttlingen, Germany) and, unless 
stipulated otherwise, in 100 mm cell culture dishes (#430167, Corning). A confluent 
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monolayer (80% or higher) in a 100 mm dish was washed twice with 5 mL of ice-
cold PBS, before 200 µL of lysis buffer (RIPA or NP40) was added. Cells were 
rocked on ice for 15 minutes, before lysates were collected and cleared by 
centrifugation at 13, 000 rpm for 15 min at 4°C. Lysates were subject to a BCA 
assay (Thermo), as per manufacturer’s instructions. 100, 50 or 25 µg of lysate was 
constituted in 1× sample buffer, heated for 5 minutes at 95°C, allowed to cool and 
centrifuged briefly, before being subject to SDS-PAGE. RIPA was used for Ras 
abundance analysis, while NP40 lysis buffer was used for the remaining immunoblot 
experiments.  
 
2.5.2 SDS-PAGE AND IMMUNOBLOTTING 
 
Protein gels were either bought from Invitrogen (NuPAGE range) or were hand-
made using a Bio-RAD system with ingredients supplied by National Diagnostics: 4× 
ProtoGel resolving buffer (#EC-892), ProtoGel stacking buffer (#EC-893), ProtoGel 
(40% [v/v]) (#EC-891), N,N,N',N'-tetramethylethylene diamine (#EC-503). 
Ammonium persulphate was from Sigma (#A3678). Gels containing 10% [v/v] 
acrylamide were used to separate most lysates, while those containing 15% [v/v] 
acrylamide used for immunoblot analysis of cellular Ras abundance. Gels were run 
using Bio-RAD or NuPAGE-specific gel tanks at 50V for the first 15 mins, then 150V 
thereafter. Molecular weight markers were rainbow marker (#RPN800E, GE 
Healthcare) and pre-stained protein marker, broad range (#P7706, NEB). Proteins 
were transferred from gels to 0.22 or 0.45 µm nitrocellulose membranes using a 
GENIE blotter full submersion apparatus (Idea Scientific, MN, USA) at 0.9 amps for 
1 hr. For immunoblot analysis of Ras proteins, 0.22 µm pore size nitrocellulose 
membranes were used, whereas 0.45 µm was used for all other proteins. Following 
transfer, membranes were stained with Ponceau S solution (#P1710, Sigma) to 
visualise protein content and removed with washing in PBS. Membranes were 
blocked with Marvel milk, fish skin gelatin or BSA, before addition of primary 
antibody in blocking solution as appropriate (primary antibodies employed in this 
thesis are detailed in Table 2.3). Membranes were washed 3 times for 5 minutes 
using TBS-T, ahead of addition of infrared fluorescent secondary antibodies (LI-
COR) for 1 hr in blocking solution in the dark. Membranes were washed again, as 
before, then analysed using an Odyssey system (LI-COR). 
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Table 2.3. Primary antibodies employed in the present thesis. CST, Cell Signalling 
Technology, Leiden, The Netherlands; SC, Santa Cruz Biotechnology, Heidelberg, Germany; 
GeneTex, Hsinchu City, Taiwan; Sigma, Sigma-Aldrich; BD, BD Transduction Laboratories, 
Oxford, UK; Bethyl, Bethyl Laboratories Inc., TX, USA. 
 
Secondary antibodies employed were the IRDye range from LI-COR, specifically: 
donkey anti-mouse IRDye 800cw (#926-32212), donkey anti-mouse IRDye 680cw 
(#926-32222), donkey anti-rabbit IRDye 800cw (#926-32213), donkey anti-rabbit 
IRDye 680cw (#926-32223), donkey anti-sheep IRDye 800cw (#926-32214), donkey 
anti-rat IRDye 800cw (#926-32219). All were diluted 1:15, 000 in blocking buffer 
(BSA or Marvel) before use.  
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2.6 SRM ANALYSIS OF CELLULAR RAS ABUNDANCE  
2.6.1 DETECTION OF PROTEOTYPIC RAS PEPTIDES 
 
1 µg of isotope-labelled Ras protein isoforms were constituted in 1× sample buffer, 
before being subject to SDS-PAGE using NuPAGE NOVEX 10-well, 1.5 mm 4-12% 
bis-tris gels (#NP0335BOX, Invitrogen). Running of the gel was as described earlier. 
Gels were fixed with 50 mL of 10% acetic acid (#A6283, Sigma), 40% HPLC water, 
50% HPLC methanol (#20864, VWR) for 15 mins at RT, before staining with 
colloidal blue and excision of his-tagged Ras proteins with a scalpel. Gel pieces 
were diced into ~1 mm3 cubes, placed into LoBind tubes and destained using 50 
mM ambic, 50% ACN with heating and shaking at 37°C and 900 rpm using a 
Thermoshaker (Thermo). Once destained, gel pieces were reduced with reduction 
buffer for 30 mins at 37°C and 900 rpm, before the gel pieces were allowed to cool 
to RT and alkylated with alkylation buffer performed at RT in the dark for 30 mins. 
Gel pieces were then washed by dehydrating with 100% ACN and rehydrating with 
HPLC water two times. Gel pieces were dehydrated, ahead of addition of trypsin 
Gold (#V5280, Promega, Madison, WI, USA), LysC (#125-02543, Wako Chemicals, 
Richmond, VA, USA) or Elastase (#342682, Calbiochem, now part of Merck 
Millipore). Trypsin and LysC were used at a 1:25 protein-to-protein concentration (40 
ng), while elastase was used at a 1:133 ratio (7 ng). All proteases shared the same 
reaction buffer: 40 mM ambic, 9% [v/v] ACN. Each digest was performed overnight 
at 37°C. The following morning, supernatants were removed, placed into LoBind 
tubes and formic acid added to a final concentration of 0.1% to end the digestion. 
Gel pieces were dehydrated with ACN for 15 mins at RT with shaking at 900 rpm, 
then the supernatant added to the previous one. Peptides were spun down at 15, 
000 rpm for 10 mins, then transferred to fresh LoBind tubes, leaving behind 5 µL 
that may contain gel debris. Peptides were then dried for ~ 3 hrs in a vacuum 
concentrator at 60°C (RVC 2-25, Christ, Osterode am Harz, Germany). Peptides 
were resuspended in 0.1% TFA, placed into sample vials (#186000385c, Waters, 
Hertfordshire, UK) and subject to LC-MS/MS analysis.  
 
~100 ng of peptides were separated using a nanoAcquity UPLC system (Waters), 
with a C18, 1.7 µm particle size, 75 µm × 250 mm BEH130 column (#186003545, 
Waters) and C18, 5 µm particle size, 180 µm × 20 mm, Symmetry, 2G-V/M trap 
column (#186006527, Waters). Buffers used described in section 2.2. Peptides were 
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trapped for 1 min at 15 µL/ min flow rate in 0.1% [v/v] formic acid and 0.1% [v/v] 
ACN, before being separated on a 20 min, 3 to 62.5% CAN [v/v] linear gradient at a 
flow rate of 0.4 µL/ min. The column was kept at a constant 65°C. Eluting peptides 
were ionised by a nano-electrospray ionisation source (Proxeon, now part of 
Thermo) before MS analysis on an LTQ Orbitrap XL in data-dependent acquisition 
mode (DDA) (Thermo Fisher Scientific, Bremen, Germany). The Orbitrap acquired 
MS survey scans at 30, 000 resolution and m/z range of 300 to 2000. MS/MS of the 
top 5 multiply charged ions were acquired in the LTQ, after isolation and CID for 30 
ms at 35% energy. Dynamic exclusion was imposed with a rolling exclusion list for 
180 secs (n = 1). All spectra were acquired using Xcalibur software (version 2.0.7; 
Thermo Fisher Scientific). Acquired .RAW files were converted to the .mgf file format 
using msconvert (http://proteowizard.sourceforge.net/tools/msconvert.html) then 
subject to a Mascot MS/MS ion search (Matrix Sciences, London, UK) using the 
SwissProt human database with carbamidomethylation of cysteine set as a fixed 
modification, with 1 missed cleavage and peptide charge states of +2, +3 and +4. 
For elastase, no enzyme was selected. MS utilising the LTQ Orbitrap was performed 
at the University of Liverpool. 
 
~100 ng of peptides were separated using a nanoAcquity, as described above, and 
ionised using a nanospray II source (AB SCIEX) before MS analysis on a 4000 
QTRAP in information-dependent mode (IDA). An enhanced mass spectrometry 
(EMS) scan at an m/z range of 400 to 1200 at 4, 000 Da/ sec scan rate was 
performed, before an enhanced resolution (ER) scan at 200 Da/ sec of the top 5 
multiply charged ions that exceed 100, 000 counts per second (cps). The top 2 ions 
were then fragmented in the collision cell using CID with a rolling collision energy 
(CE), calculated using the equation: 
 𝐶𝐸   𝑒𝑉 = 𝑠𝑙𝑜𝑝𝑒  ×  𝑚/𝑧 + 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 
 
where slope and intercept are 0.058 and 4, respectively, for singularly charged ions, 
0.044 and 3 for +2 ions, and 0.044 and 2 for +3 ions. MS/MS spectra were obtained 
using an enhanced product ion (EPI) scan at 4000 Da/ sec using an m/z range of 
100 to 1100 Th. Dynamic fill time was employed to determine accumulation time for 
fragment ions. All spectra were acquired using Analyst (version 1.5, AB SCIEX). 
Acquired .wiff files were converted into the .mgf file format and searched as above. 
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MRM-initiated detection and sequencing (MIDAS) (Unwin et al., 2005) was 
performed with an initial user-defined MRM stage, before ions detected over a 10, 
000 cps intensity threshold were fragmented, as described above, followed by an 
EPI scan. Dynamic fill time was also utilised. Acquired MS/MS spectra were 
inspected manually. MS using the 4000 QTRAP was performed at the Paterson 
Institute for Cancer Research (now The Manchester Institute), University of 
Manchester, UK.  
 
2.6.2 SELECTION OF PROTEOTYPIC RAS PEPTIDES 
 
Ras proteotypic peptides were selected according to the criteria specified in section 
3.1.2. 
 
2.6.3 SELECTION OF TRANSITIONS 
 
Transitions were selected following the criteria set out in section 3.1.3. Table 3.1 
describes all transitions and 4000 QTRAP instrument settings utilised in the present 
thesis.  
 
2.6.4 COLLISION ENERGY OPTIMISATION 
 
Each peptide had a CE calculated using the equation described in section 2.6.1. 
~100 ng of peptides were separated using a nanoAcquity system using a gradient 
described in the next section. Peptides were then analysed using SRM on a 4000 
QTRAP with collision energies -4, -2, 0, +2 and +4 eV from the calculated CE value. 
Q3 values were adjusted by 0.1 Da for each different CE tested, as in (Sherwood et 
al., 2009). Optimal CE values were those that generated the greatest peak heights 
in 3 independent replicates.  
 
2.6.5 RETENTION TIME DETERMINATION 
 
IDA of 200 ng of Mass PREP E.coli digestion standard (#186003196, Waters) was 
performed to determine at what volume percentage of ACN peptides first and last 
eluted. A variety of different gradients were then used to separate ~100 ng of Ras 
peptides with SRM performed using calculated, non-optimised CE for each peptide. 
MATERIALS AND METHODS 
 84 
A 60-min 8-65% ACN in 0.1% [v/v] formic acid linear gradient was selected, 
following the criteria stipulated in section 3.1.4. Only differences from section 2.6.1 
were that trapping flow rate was 3 µL/ min for 10 mins and column temperature was 
60°C. Retention times were frequently assessed, since they change as the column 
and trap mature. The retention times detailed in Table 3.2 represent Ras peptide 
retention times on a fresh column and trap.  
 
2.6.6 VALIDATION OF INSTRUMENT PARAMETERS 
 
All optimised instrument settings were tested to ensure each Ras peptide generated 
a linear response between peptide abundance and measured intensity on the 4000 
QTRAP. Light H-, K(B)- and N-Ras proteins were produced in One Shot BL21 cells, 
following the protocols described above, gel filtrated in PBS and their concentration 
measured using a BCA assay. These proteins were also utilised in the immunoblot 
analysis of cellular Ras abundance. 250 ng of light Ras isoform protein was mixed 
with its counterpart isotope-labelled Ras PSAQ standard at ratios from 0.2 to 20. All 
dilutions were performed in gel filtration buffer supplemented with 2% [w/v] BSA. 
The protein mixtures were constituted in 1× sample buffer, before being subject to 
in-gel digest as in section 2.6.1. Dried peptides were resuspended in 25 µL 0.1% 
[v/v] TFA and 5 µL of sample was subject to SRM analysis as described in section 
2.6.10.  
 
2.6.7 CELL COUNTING AND LYSIS 
 
The SW48 cell lines, described in section 2.5.1, were grown to ~80% confluency 
before being washed with warm PBS, trypsinised and resuspended in 10 mL of 
PBS. 10 µL of cells was placed on either side of a Bright-Line haemocytometer 
(#Z359692, Sigma-Aldrich) and cells within 3 squares on either side were counted. 9 
mL of cells were spun down at 200 rcf for 5 min at RT, supernatant was checked to 
ensure no clumps of cells were floating and the PBS was carefully aspirated. 200 µL 
of ice-cold RIPA buffer (without PhosSTOP tablets and NaF) was added to the cell 
pellet and broken apart by briefly pipetting up and down. Cells were then incubated 
on ice for 20 mins, with regular slight agitation. Lysate volume was measured using 
a 100 µL Hamilton syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland). Cell 
counts and volume measurements are provided in the supplementary material, 
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which enable the number of cells used in the PSAQ assay to be determined. 
Lysates were spun at 13, 000 rpm for 15 mins at 4°C. Supernatant was taken, 
diluted 1:10 in RIPA buffer and subject to a BCA protein assay. Cleared lysates 
were flash frozen in liquid nitrogen and stored at -80°C until needed.  
 
2.6.8 SDS-PAGE AND IN-GEL DIGESTION OF PSAQ TARGET LYSATES 
 
100 µg of cell lysates were constituted in 1× sample buffer, along with isotope-
labelled PSAQ Ras standards (10 ng of K(B)-Ras, 5 ng of H- and N-Ras), before 
being subject to SDS-PAGE as described in section 2.6.1. Rainbow marker (GE 
Healthcare) was used as a protein marker. The gel was only fixed, not stained, to 
avoid excess colloidal blue blocking chromatography columns. A gel band spanning 
31-17 kDa was excised and diced, followed by in-gel digestion, as described in 
section 2.6.1, but using 400 ng of trypsin.  
 
2.6.9 SELECTED REACTION MONITORING AND DATA ANALYSIS 
 
~1 µg of peptides were separated using a nanoAcquity system using optimised CE 
values and chromatography gradients, as described in the previous sections. At the 
start of each run, an IDA scan was performed for the first and last 10 mins to obtain 
a basic assessment of spray performance. Between every 5 samples, or if a 
problem was observed in samples, an IDA scan of 100 ng of E.coli digest standard 
(Waters) was performed to determine chromatography performance. The acquired 
E.coli data were checked for consistent intensities and numbers of peptides 
identified in a Mascot MS/MS ion scan. If a fall in 40% intensity or 20% identified 
peptides was observed, the column and trap were exchanged, along with cleaning 
of the ion source. As mentioned in section 2.6.6, the retention times of each peptide 
will change with usage. In Table 2.4, example acquisition windows for each peptide 
are provided. These windows were altered as necessary to accommodate for shifts 
in retention time. Two independent acquisitions were required per sample, since H-
Ras specific, SYGIPYIETSAK, and N-Ras specific, SFADINLYR, eluted at very 
similar times. Data analysis was performed using Skyline (version 2.4) (MacLean et 
al., 2010).  
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Table 2.4. Acquisition time windows for proteotypic Ras peptides during the SRM-
based quantitative analysis. IDA was performed before and after SRM analysis to obtain a 
basic assessment of spray performance. A 60-min, 8-35% ACN linear gradient was used to 
separate Ras peptides, with total liquid chromatography run time at 105 mins, including 
regeneration and re-equilibration steps. IDA, information dependent acquisition. 
 
 
 
Table 2.5. Targeted precursor and fragment ion masses of Ras mutant-specific 
peptides. Peptide precursor and fragment ion masses were calculated using Skyline 
(version 2.4). Sample preparation and MIDAS settings are described in section 2.6.1 and 
2.6.11. MIDAS, MRM-initiated detection and sequencing.  
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To calculate copy numbers per cell, ng values of Ras abundance were converted 
into moles, before being divided by the number of cells that produced the 100 µg of 
lysate subject to SRM analysis. The subsequent molar amount was then multiplied 
by the Avogadro constant (6.0221413 × 1023). Results were visualised using JMP10 
(SAS, Cary, NC, USA).  
 
2.6.10 MIDAS DETECTION OF MUTANT-SPECIFIC RAS PEPTIDES 
 
Precursor and fragment ion masses of mutant Ras peptides, detailed in Table 2.5, 
were calculated using Skyline (version 2.4). Isogenic SW48 cells, harbouring the 
various K-Ras mutant proteins, were subject to sample preparation as described 
earlier. All lysates were subject to in-gel digestion with trypsin, except for the K-
RasG12R cell line where LysC was used. To ensure selectivity, only y ions were 
targeted in the MIDAS analysis. Targeted ions are described in Table 2.5. The 
MIDAS settings were as those described in section 2.6.1.  
 
2.6.11 DYNAMIC SILAC ANALYSIS OF RAS PROTEIN TURNOVER  
 
Parental SW48 cells, and those harbouring heterozygous KRASG12D, KRASG12V and 
KRASG13D mutations, were grown for 7 passages in SILAC DMEM (#LM010, Dundee 
cell products, Dundee, UK), containing either ‘light’ lysine (Lys0) and arginine (Arg0) 
(#L5501 and #A5506, respectively, Sigma) or ‘medium’ L-lysine-2H4 (Lys4) and L-
arginine-U-13C6 (Arg6) (#616192 and #643440, respectively, Sigma). All SILAC 
media also contained 200 mg/ ml proline (#P0380, Sigma) and 10% [v/v] dialysed 
FBS. Full FBS (Invitrogen) was dialysed using SnakeSkin 10 kDa MWCO dialysis 
tubing (#88245, Thermo) in 5 L of PBS over 24 hrs × 2 at 4°C, before sterile filtering 
(#431097, Corning). Labelling of cells was checked by subjecting 50 µg of lysate 
from each labelled cell line to in-gel digestion with trypsin, before SRM analysis on a 
4000 QTRAP monitoring for the total wild-type Ras peptide, LVVVGAGGVGK, and 
the K(B)-Ras specific peptide, QGVDDAFYTLVR.  
 
4 million cells were plated into 100 mm dishes and allowed to attach for 12 hrs. 
‘Medium’ cells were then washed with PBS and exposed to ‘heavy’ SILAC DMEM 
containing L-lysine-U-13C6-15N2 (Lys8) and L-arginine-U-13C6-15N4 (Arg10) for 0.5, 4, 
7, 11, 27 or 48-hour time points. All cells were trypsinised, spun down at 200 rcf and 
lysed as in section 2.6.8. 50 µg of ‘light’ cells was mixes with 50 µg of ‘medium/ 
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heavy’ cells and subject to SDS-PAGE and in-gel digestion as in section 2.6.9. 
Utilised transitions are detailed in Table 3.3. Data analysis was performed using 
Skyline (version 2.4). 50% turnover was determined to be the point where heavy 
and medium signals reached a ratio of 1. For further details see section 3.2.5. 
 
2.7 PROTEOMIC AND PHOSPHO-PROTEOMIC PROFILING OF 
ISOGENIC SW48 CELLS   
2.7.1 CELL CULTURE, SILAC MEDIA PREPARATION AND CELL LYSIS 
 
Parental SW48 cells, and those harbouring heterozygous KRASG12D, KRASG12V and 
KRASG13D mutations, were grown for 7 passages in SILAC McCoy’s 5A media 
(custom preparation, Dundee cell products), containing either ‘light’ lysine (Lys0) 
and arginine (Arg0), ‘medium’ L-lysine-2H4 (Lys4) and L-arginine-U-13C6 (Arg6) or 
‘heavy’ L-lysine-U-13C6-15N2 (Lys8) and L-arginine-U-13C6-15N4 (Arg10). Each media 
also contained 200 mg/ mL of proline and 10% [v/v] of self-dialysed 10 kDa MWCO 
FBS. At least three biological replicate data sets of each KRASMUTANT versus 
Parental SW48 were obtained (n = 4 for KRASG12D versus Parental). Figure 3.26 
provides an overview of the experimental setup utilised in this thesis. Incorporation 
of isotopes was checked by subjecting 25 µg of each cell line lysate to SDS-PAGE 
and in-gel tryptic digestion, before LC-MS/MS analysis on the LTQ Orbitrap XL in 
DDA mode, as described above. Acquired .RAW files were analysed using 
MaxQuant (version 1.0.13.13), followed by quantification of incorporation using an R 
script provided by Christian Kelstrup (Faculty of Health and Medical Sciences, 
University of Copenhagen, Denmark).  
 
For SILAC experiments, cells were grown to ~80% confluency in 245 cm2 square 
dishes (#431111, Corning), before being washed twice in ice-cold PBS and scraped 
into 10 mL of PBS per dish. Cells were combined where appropriate and spun down 
at 200 rcf for 15 min at 4°C. Supernatant was removed and cells were resuspended 
in ice-cold NP40 buffer, also supplemented with 40 mM β-Glycerol-Phosphate, 1 
mM EDTA and 1mM Na3VO4, in addition to the supplements described in section 
2.1. Cells were incubated on ice for 15 mins before being spun down again as 
above. The supernatant was taken and used as a crude cytosolic fraction. The pellet 
was resuspended in SDT buffer and treated as a crude nuclear fraction. Protein 
content was assessed using a BCA assay. 15 mg of each ‘light’, ‘medium’ and 
MATERIALS AND METHODS 
 89 
‘heavy’ cell lysates were then mixed (1:1:1 protein ratio).  
 
2.7.2 SAMPLE PREPARATION FOR PROTEOME ANALYSIS  
 
50 µg of the 45 mg 1:1:1 protein mix was constituted in 1× sample buffer, before 
being subject to SDS-PAGE and protein visualised through staining with colloidal 
blue. The gel was cut into 48 slices with a scalpel, according to protein content, and 
each slice diced, destained and in-gel tryptic digested as described earlier. Dried 
peptides were resuspended in 25 µL 0.1% [v/v] TFA and 5 µL was subject to LC-
MS/MS analysis on a LTQ Orbitrap XL in DDA mode, described further in section 
2.7.4. 
 
2.7.3 FILTER-AIDED SAMPLE PREPARATION, STRONG CATION EXCHANGE, 
TiO2-BASED PHOSPHOPEPTIDE ENRICHMENT 
 
For phosphopeptide isolation, filter-aided sample preparation (FASP) (Wisniewski et 
al., 2009) was utilised, before strong cation exchange (SCX) and TiO2-based 
phosphopeptide enrichment, based on (Olsen et al., 2006; Olsen and Macek, 2009). 
The 45 mg protein mix was precipitated by adding 100% TCA at a 1:5 ratio and 
incubating on ice overnight. The following morning, protein precipitates were 
pelleted by centrifugation at 1, 000 rpm and the supernatant discarded. Protein 
pellets were twice washed with ice-cold acetone for 5 mins. Pellets were then 
resuspended in urea denaturing buffer and sonicated for 10-20 times for 20 sec with 
30 sec intervals on ice when necessary. Amicon Ultra 30 kDa, 15 mL filters 
(#UFC903024, Millipore) were equilibrated by spinning 5 mL HPLC water through 
the filter at 4, 500 rpm. Resuspended protein was placed into 3 separate filters and 
spun down until the volume was reduced to 0.5 mL. 10 mL of fresh urea denaturing 
buffer was added to each filter and spun down again. To the concentrated 0.5 mL of 
protein, 3 mL of 55 mM IAA in urea denaturing buffer was added, followed by a 30 
min incubated at RT in the dark. The filters were then spun as above until the 
volume was again reduced to 0.5 mL, then a further 10 mL of urea buffer was added 
and spun once again. 10 mL of 55 mM ambic was added to each filter and spun 
down to 0.5 mL; this was repeated twice. 2 mL of ambic containing trypsin at a 
1:300 protein ratio was added to the filters and placed into a wet chamber (50 mL 
falcon with moist tissue at the bottom) and incubated overnight at 37°C. The 
following morning, filters were spun in fresh 50 mL falcon tubes until 0.2 mL was 
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remaining. 2 mL of ambic was added and spun down again; this was repeated twice. 
The ambic flow throughs were combined and acidified to a 1% final TFA 
concentration. Samples were desalted by applying them OASIS HLB cartridge 
(#186000117, Waters) and peptides eluted with 10 mL 90% ACN, 0.5 % formic acid, 
before drying in a vacuum concentrator at 60°C.  Dried peptides were resuspended 
in 2 mL of SCX buffer A and subject to strong cation exchange (SCX) using an 
ÄKTA system with attached S Resource column (#17-1178-01, GE Healthcare). 
Peptides were bound to the SCX column and eluted with increasing concentrations 
of SCX buffer B. A three step gradient was utilized at a flow rate of 1 mL/ min: (1) 
0% [v/v] B was applied to the column between for the first 17.5 mins following 
injection of peptides onto the column, (2) a 20 min, linear gradient from 0 to 50% 
[v/v] B, (3) 50 to 100% [v/v] B in 5 mins (Beausoleil et al., 2004; Hernandez-
Valladares et al., 2014; Olsen et al., 2006). 1 mL fractions were collected each 
minute and dried in a vacuum concentrator as above. Peptides were then subject to 
TiO2-based enrichment using stage tips, as described in (Dulla et al., 2010; 
Rappsilber et al., 2007; Sugiyama et al., 2007). Micro-columns were prepared by 
placing a small plug of C8-silica matrix (#12145002, Varian, Postfach, Germany) 
into 200 µL pipette tips (#S1111-1806, Starlab, Muri, Switzerland) and pushing them 
tight to the end. Peptides were dissolved in 30 µL 80% [v/v] ACN, 2% [v/v] TFA. 500 
mg of Titansphere 10 µm TiO2 beads (#5020-75010, GL Sciences, Eindhoven, The 
Netherlands) were resuspended in 5 mL of 80% [v/v] ACN, 0.2% [v/v] TFA. 50 µL of 
bead slurry was added to the micro-columns, followed by two washes of 50 µL 0.6% 
[v/v] suprapure NH4OH (#105428, Merck) with centrifugation at 3, 000 rpm for 5 
mins. This was repeated with 50 µL glycolic acid (GA) buffer (80 mg/ mL GA in 80% 
[v/v] ACN, 2% [v/v] TFA). GA was from Sigma (#G8284, Sigma). Peptides were 
applied to the columns and spun such that it took at least 5 mins for the liquid to 
pass through. Flow throughs were reapplied to the column and flicked vigorously to 
mix, before spinning down as before. TiO2 beads were then washed with 40 µL GA 
buffer, followed by 40 µL [v/v] 80% ACN, 0.2% [v/v] TFA and 40 µL 20% [v/v] ACN. 
Phosphopeptides were first eluted into LoBind tubes using 40 µL 0.6% suprapure 
NH4OH, followed by 40 µL 60% [v/v] ACN. The second elution involved 40 µL 1% 
[v/v] pyrrolidine (#83241, Fluka now part of Sigma-Aldrich), followed by 40 µL 60% 
[v/v] ACN. Both first and second elutions were dried using a vacuum concentrator as 
described earlier. Phosphopeptides were then resuspended in 0.5% [v/v] formic acid 
for MS analysis.  
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2.7.4 MASS SPECTROMETRY ANALYSIS, SPECTRAL MATCHING AND 
QUANTIFICATION 
 
Peptides were separated using a 60-min, 3-65% ACN in 0.1% formic acid gradient 
using a nanoAcquity and chromatography columns as described earlier. Proteome 
samples, described in section 2.7.2, were analysed using an LTQ Orbitrap XL in 
DDA mode, as described in section 2.6.1, but acquiring MS/MS on the top 6 multiply 
charged ions. Phosphopeptides were analysed using multistage activation 
multistage activation (MSA) (Schroeder et al., 2004), where the Orbitrap performed 
survey scans at 60,000 resolution, while the LTQ acquired MS/MS on the top 6 
multiply charged ions and activated neutral loss species at 98.0, 65.3 and 49.0 m/z 
below the precursor ion mass, each for 30 msec at 35% energy.  
 
Acquired RAW files were searched against the human IPI database (version 3.77), 
which contained 89,709 entries, using MaxQuant (version 1.2.2.5) and the 
Andromeda search engine (Cox and Mann, 2008; Cox et al., 2011). For the 
database search, the minimum peptide length was set to 6 residues and two missed 
cleavages were permitted. Cysteine carbamidomethylation was set as a fixed 
modification, while methionine oxidation and S/T/Y phosphorylation were set to 
variable. Deviations of 7 ppm and 0.5 Th were permitted for precursor and fragment 
ions, respectively. The false discovery rate was set to 0.1. MaxQuant then further 
statistically processed the data and performed quantification on SILAC triplet XICs. 
For quantification, only proteins with at least 3 peptides (one unique) were selected. 
Each biological replicate was analysed individually and all together in a single 
iteration of the pipeline.   
 
2.7.5 DATA ANALYSIS 
 
Data obtained from MaxQuant analyses were evaluated with Excel and MeV 
(version 4.8.1; www.tm4.org/mev). To compare the inter-experimental correlation 
between proteome and phosphoproteome analysis of each biological replicate, 
peptides/ phosphopeptides quantified in two or more replicates had their values 
log10 transformed, plotted on scatter plots and the R2 correlation(s) visualized as 
heatmaps. MeV was utilized to perform hierarchical clustering the R2 data. 
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Principle component analysis on covariances was performed with JMP10. Peptide 
data were included for analysis if ratios were available for every Par/ mutant 
condition. No imputation was performed. Peptides with missing ratios were excluded 
from the analysis. 
 
GProX was utilised to cluster values output by MaxQuant (Rigbolt et al., 2011b). 
SILAC ratios were subject to the fuzzy c-means algorithm for unsupervised 
clustering (Futschik and Carlisle, 2005). 6 clusters were selected, with the 
fuzzification value set to 2, regulation threshold of ± 0.58 and 200 iterations of the 
algorithm executed. Clustering was performed together with Dr. Dean Hammond 
(University of Liverpool). 
 
Gene Ontology (GO) analysis was performed using the DAVID functional annotation 
tool (version 6.7) (Huang da et al., 2009a), using the GOTERM BP FAT. IPI 
identifiers of shortlisted proteins and phosphopeptides were input as gene lists, with 
the background list comprised of all genes identified in the MS analysis as a whole. 
Threshold count was 2 and EASE score was set to 1. GO terms with a p-value ≤ 0.1 
were log10 transformed and visualised with JMP11 as heatmaps.  
 
Only class 1 phosphosites were considered in the phosphoproteome analysis. 
(localisation probability ≥ 0.75 and a score differential ≥ 5). For linear kinase motif 
analysis, sequence windows ± 6 residues adjacent to the phosphosite were 
extracted from MaxQuant output files, before being subject to MotifX analysis (Chou 
and Schwartz, 2011). Over-represented motifs were identified through comparison 
with the IPI human proteome (p-value 1 × 10-6, occurrence limit ≥ 1). Class 1 
phosphosites were also submitted to NetworKIN (version 2.0) to identify putative 
kinase regulators (Linding et al., 2008). Proteins were grouped by MotifX-identified 
motifs and percentage probability of being regulated by each indicated kinase, 
before being visualised as a heatmap using MeV. To demonstrate the overall 
regulation of sites associated with each motif (output), mutant/ Parental ratios from 
GProX clusters 5 and 6, as well as all phosphosites identified (long list), were 
normalised by assigned maximum increase and decrease in phosphorylation a 
value of 1 or -1, respectively. These predictions were performed with the aid of Prof. 
Ian Prior (University of Liverpool).
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3 – RESULTS 
 
3.1 DEVELOPMENT OF AN SRM-BASED RAS QUANTIFICATION 
TECHNIQUE COUPLED WITH PSAQ 
 
Due to its ability to detect and quantify thousands of peptides/ proteins from 
biological samples, shotgun proteomics has become a highly popular technique to 
study complex proteomes over the past decade. However, the shotgun approach is 
not optimal for the systematic quantification of proteins from complex matrices, as it 
is stochastic in nature and has limited sensitivity, plus only relative quantification of a 
sample’s most abundant components is commonly achieved (Gallien et al., 2011). 
Consequently, targeted proteomic approaches have emerged that precisely and 
quantitatively analyse chosen peptides from complex biological backgrounds. Such 
techniques are based on selected reaction monitoring (SRM), which was introduced 
in the late 1970s (Baty and Robinson, 1977; Zakett et al., 1978), and provide highly 
sensitive and selective quantitative proteomic assays (Anderson and Hunter, 2006). 
SRM-based approaches typically employ a triple quadrupole mass spectrometer 
(QqQ), where a precursor ion is selected in the first quadrupole, fragmented in the 
second and a particular fragment ion selected for detection by the third. The chosen 
precursor-fragment ion pair, known as a transition, can be altered every few 
milliseconds to enable the concurrent detection of multiple fragment ions from 
unlabelled and labelled precursor ions. Unlike the shotgun approach, targeted SRM-
based strategies require a minimum amount of information before they can begin: 
(1) target protein(s) must be known, (2) proteotypic peptides identified, (3) suitable 
transitions for each peptide selected, (4) instrument parameters optimised, (5) 
detection and quantification limits determined, (6) peptide abundance and signal 
response defined and (7) each transition validated (Gallien et al., 2011; Lange et al., 
2008). These parameters are defined during assay development, which can be a 
slow and iterative process. SRM-based techniques are compatible with a variety of 
stable isotope dilution strategies, e.g. AQUA, QconCAT and protein standard 
absolute quantification (PSAQ) (Barr et al., 1996; Beynon et al., 2005; Brun et al., 
2009; Dupuis et al., 2008; Gygi et al., 1999a). Out of these options, PSAQ enables 
the most accurate protein quantification, since the stable-isotope labelled, full-length 
protein standard is added at the beginning of the workflow, meaning it will be subject 
to the same systematic errors and losses as its endogenous counterpart. 
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Fig. 3.1. Workflow of the developed SRM-based quantification technique, coupled 
with protein standard absolute quantification, for measurement of cellular Ras 
abundance. 
 
Furthermore, because the amino acid sequence of the labelled standard and 
endogenous protein are identical, digestion of both proteins will be equal. This isn’t 
the case for AQUA and QconCAT strategies since they assume complete digestion 
and recovery of the endogenous material (Gallien et al., 2011; Lowenthal et al., 
2014). This chapter describes the development of an SRM-based proteomic 
technique, coupled with the PSAQ strategy, for the accurate quantification of cellular 
Ras abundance (Fig. 3.1). Three human Ras proto-oncogenes encode for four major 
Ras isoforms: H-, K(A)-, K(B)- and N-Ras. These isoforms are 21 kDa proteins, 
188/9 amino acids in length and share complete sequence homology from residues 
1-85 and 90% homology from residues 85-165, with the major differences located in 
the C-terminal hypervariable region (HVR), where there is less than 15% sequence 
similarity (Karnoub and Weinberg, 2008; Omerovic et al., 2007). The described 
SRM-based strategy (and PSAQ standards) can distinguish between H-, K(A)-, 
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K(B)- and N-Ras isoforms and was designed to be utilised in biological laboratories 
with access to a mass spectrometry facility, since the workflow comprises of 
methods that are highly familiar to such laboratories or do not require specialist 
knowledge, e.g. the fractionation of the target lysate is performed using SDS-PAGE 
and the subsequent in-gel digest step involves simple reduction and alkylation 
reactions before digestion with well-known and easily obtainable proteases.  
 
3.1.1 IDENTIFICATION OF PROTEOTYPIC RAS PEPTIDES 
 
To establish an SRM-based assay it is necessary to identify peptides that uniquely 
identify the protein(s) of interest and reliably generate a good MS response. To 
identify such peptides, known as proteotypic peptides (Mallick et al., 2007), from 
Ras GTPases is a significant challenge, as the four major isoforms are small 
proteins that are 85% identical, meaning that a limited number of peptides may be 
generated by proteolysis and those generated may be shared between all or some 
isoforms. As a result, four proteases, trypsin, LysC, elastase and GluC, were 
evaluated for their ability to generate proteotypic peptides that distinguish between 
each Ras isoform and also provide total Ras information.  
 
3.1.1A  TRYPSIN-GENERATED RAS PEPTIDES  
 
Most large-scale proteomic projects utilise trypsin to digest proteins into analysable 
peptide populations. Trypsin is an aggressive protease, stable under a wide range of 
conditions and displays high cleavage specificity at arginine and lysine residues 
(Olsen et al., 2004). Since tryptic peptides contain a C-terminal basic residue, they 
are typically multiply charged and therefore highly suitable for fragmentation under 
low-energy CID conditions (Paizs and Suhai, 2005). In silico tryptic digestion of Ras 
isoforms was performed and predicted peptides ≥ 7 ≤ 30 residues in length were 
searched for in PeptideAtlas (Desiere et al., 2006). Many of the predicted Ras tryptic 
peptides were contained in the PeptideAtlas MS/MS spectral repository, including 
LVVVGAGGVK, a peptide that contains positions 12 and 13, and others that would 
describe each Ras isoform. However, to discover if these peptides were detectable 
in our hands, 1 µg of his-tagged H-, K(A)-, K(B)- and N-Ras was subject to SDS-
PAGE, reduction with dithiothreitol (DTT) and alkylation with iodoacetamide (IAA), 
before in-gel digestion with trypsin. ~200 ng of peptides were separated by 
nanoscale C18 RP-HPLC on a nanoAcquity UPLC (Waters) and analysed on an 
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LTQ Orbitrap XL (Thermo Scientific) using unbiased, data-dependent acquisition of 
the top 5 most abundant peptides (Fig. 3.2). For all RAW files acquired, each was 
subject to a Mascot MS/MS ion search (Matrix Science). The detected tryptic Ras 
peptides, not considering those with missed cleavages, were on average 12.3 ± 4.2 
residues long and would describe total wild-type Ras at positions 12 and 13, total K-
Ras, and uniquely identify H-Ras, K(A)-Ras, K(B)-Ras and N-Ras. Plus, some 
detected peptides were shared between two isoforms. To ensure specificity to Ras, 
all detected peptides, and those described below, were subject to Protein BLAST 
analysis (Basic Local Alignment Search Tool, National Library of Medicine), using 
the blastp algorithm and non-redundant protein sequences database (Gish and 
States, 1993). 
 
3.1.1B  LYS-C-GENERATED RAS PEPTIDES  
 
LysC is a protease that cleaves specifically at the C-terminal side of lysine residues 
(Wada and Kadoya, 2003). In silico LysC digest generated a peptide set that was 
poorly represented in the PeptideAtlas repository. Ras proteins were in-gel digested 
with LysC and ~200 ng of the subsequent peptides were analysed as described 
above (Fig 3.3). On average, a LysC peptide was 13.8 ± 5.0 residues in length and 
those detected could differentiate between H-, K- and N-Ras, but not K(A)- and 
K(B)-Ras. Furthermore, several of the detected peptides contain mid-chain arginine 
residues. 
 
3.1.1C   ELASTASE-GENERATED RAS PEPTIDES 
 
Elastase is a much less specific protease than trypsin or LysC, with a preference to 
cleave at the C-terminal side of small neutral amino acids (Rietschel et al., 2009). As 
a result, it is difficult to predict which Ras peptides will be generated using this 
enzyme. Ras proteins were digested with elastase before fractionation and analysis 
as described for trypsin (Fig. 3.4). Many overlapping peptides were observed, yet 
those detected would enable the differentiation of each Ras isoform and also 
provide total Ras information. One elastase peptide of interest is FYTLVREI, a pan-
Ras peptide, located towards the C-terminal end of Ras, that does not contain 
residues that are commonly mutated in human cancer (Prior et al., 2012).    
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Fig. 3.2. Trypsin-generated Ras peptides. 1 µg of each his-tagged Ras isoform was 
subject to in-gel digestion with trypsin, before ~200 ng of peptides was analysed by LC-
MS/MS on an LTQ Orbitrap XL using data-dependent acquisition of the top 5 most abundant 
peptides. All peptides were detected in 3 independent runs. Dashed lines indicate sites of 
missed cleavages. Underlined residues are those commonly mutated in human cancer: G12, 
G13 and Q61. 
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Fig. 3.3. LysC-generated Ras peptides. 1 µg of his-tagged Ras proteins was subject to in-
gel digestion with LysC. ~200 ng of peptides were analysed by LC-MS/MS on an LTQ 
Orbitrap XL using data-dependent acquisition of the top 5 most abundant peptides. All 
peptides were detected in 3 independent runs. Underlined residues are those commonly 
mutated in human cancer: G12 and G13. 
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Fig. 3.4. Elastase-generated Ras peptides. ~200 ng of elastase in-gel digested Ras 
peptides were subject to LC-MS/MS analysis with an LTQ Orbitrap XL using data-dependent 
acquisition of the top 5 most abundant peptides. Grey regions contain overlapping peptides 
with different specifies for Ras isoforms. All peptides were detected in 3 independent runs. 
Dashed lines indicate sites of observed cleavages. 
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Fig. 3.5. GluC in silico digest of Ras isoforms. H-, K(A)-, K(B)- and N-Ras sequences 
were in silico digested with GluC and peptides ≥ 7 ≤ 30 residues in length were collated.  
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3.1.1D  GLU-C-GENERATED RAS PEPTIDES (IN SILICO DIGEST)  
 
The GluC enzyme (Staphylococcus aureus Protease V8) specifically cleaves at the 
C-terminal side of glutamic acid residues, but also cleaves at aspartic acid residues 
at a 200-300 times slower rate (Birktoft and Breddam, 1994; Drapeau et al., 1972). 
In silico GluC digest was performed (Fig. 3.5) and predicted peptides ≥ 7 ≤ 30 
residues in length were input into PeptideAtlas where several were matched to 
spectra, including DSYRKQVVIDGE, a pan-Ras peptide, and DAFTYLVRE, 
TSAKTRQGVDDAFYTLVRE and DAFYTLVRE, which are unique for K(A)-, K(B)- 
and N-Ras, respectively. However, no H-Ras GluC peptide was present in the 
PeptideAtlas database and many of those present have two or more highly basic 
mid-chain residues.   
 
3.1.2 PROTEOTYPIC PEPTIDE SELECTION 
 
In a typical SRM-based approach, it is common that only a few representative 
peptides are used to determine the presence and quantity of a protein in a biological 
sample (Lange et al., 2008). Consequently, the careful selection of peptides is an 
essential step in the development of any SRM-based assay. The following criteria 
was used to determine which peptides were most suitable to measure cellular Ras 
abundance: (1) the peptide must be unique to Ras, (2) preference will be given to 
those observed previously, i.e. the peptide is present in a repository, (3) the peptide 
should not have many chemically modifiable residues, e.g. methionine, glutamine or 
asparagine, (4) the peptide must not be longer than 22 amino acids, (5) the peptide 
must not be from the HVR of Ras, (6) where possible, other sites of post-
translational modification ought to be avoided, (7) peptides generated due to missed 
cleavages must be excluded and (8) peptides with multiple mid-chain basic residues 
should be discounted. An optimal setup is where a single digestion with one 
protease provides the abundances of each Ras isoform and also that of total Ras. 
However, none of the tested proteases delivers on this scenario. Yet, from those 
tested, trypsin generated the largest number of peptides that satisfy the 
aforementioned criteria and provided the most information regarding Ras 
abundance from a single digestion (Fig. 3.6).  
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Fig. 3.6. Utility of proteotypic Ras peptides generated using different proteases to 
describe various aspects of cellular Ras abundance. Green, at least one peptide 
detected that satisfies criteria stipulated in section 1.2; amber, detected or predicted 
peptide(s) do not match all criteria; red, peptide not available or those detected/ predicted fail 
to match most criteria. Total Ras, all Ras isoforms; wt Ras (12/13), wild-type Ras at positions 
12 and 13; wt Ras (61), wild-type Ras at position 61; Total K, both K-Ras isoforms. All 
proteases were tested experimentally, except for GluC. 
 
Trypsin was therefore chosen as the primary protease to obtain information on Ras 
isoform abundance and total wild-type Ras at positions 12 and 13. Since the two 
tryptic peptides that describe total Ras are 25 and 26 amino acids long and contain 
several chemically modifiable residues, they are unsuitable for SRM analysis and 
were discounted. To complement the trypsin digest, a separate digest with elastase 
can be performed and the FYTLVREI peptide monitored to obtain total Ras 
information. Since the LTQ Orbitrap XL is not the instrument platform that was 
utilised for the SRM assay, it was necessary to detect the candidate proteotypic 
peptides using a triple quadrupole mass spectrometer. 1 µg of his-tagged Ras 
isoforms were in-gel digested with trypsin and, in a separate digest, K(B)-Ras was 
also digested with elastase, subsequently ~200 ng of peptides were subject to LC-
MS/MS analysis using information dependent acquisition (IDA) of the top 2 most 
abundant peptides on a 4000 QTRAP (AB SCIEX). Acquired .wiff files were subject 
to a Mascot MS/MS ion search. All candidate peptides were detected using this 
method, except for the elastase peptide FYTLVREI, the K(A)- and K(B)-Ras tryptic 
peptides VEDAFYTLVR and QGVDDAFYTLVR. MRM-initiated detection and 
sequencing (MIDAS) (Unwin et al., 2005; Unwin et al., 2009) was employed to 
detect these peptides instead, since it is more sensitive than IDA (Fig. 3.7).  
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Fig. 3.7. MIDAS detection of proteotypic Ras peptides. MRM-initiated detection and 
sequencing (MIDAS) (Unwin et al., 2005; Unwin et al., 2009) was performed to detect the 
indicated peptides on the 4000 QTRAP (AB SCIEX) triple quadrupole mass spectrometer, 
after they failed to be identified during an initial information dependent acquisition (IDA) scan. 
Precursor and fragment ion settings are indicated. Graphs show the total ion current and 
insets display the captured MS/MS spectra. 
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Fig. 3.8. Selected proteotypic Ras peptides. All peptides are tryptic, bar FYTLVREI that is 
elastase-derived. The candidate peptides describe total Ras, wild-type Ras at positions 
12/13, total K-Ras, H-Ras, N-Ras, differentiate between the two K-Ras splice variants and 
provide redundancy through peptides that are shared between two isoforms. Underlined 
residues are positions 12 and 13, which are commonly mutated in human cancer. 
 
However, a clear MS/MS spectrum for the total K-Ras peptide DSEDVPMVLVGNK 
was unattainable when using MIDAS or IDA, meaning this peptide had to be 
discounted. The selected proteotypic peptide set is shown in Fig. 3.8. 
 
3.1.3  SELECTION OF TRANSITIONS 
 
Peptide quantification using an SRM-based assay requires the selection of specific 
m/z settings for the first and third quadrupole. This combination of m/z values will 
select for a particular precursor/ product ion pair, known as a transition. It is optimal 
to select between 3 to 5 transitions per peptide, such that a large proportion of the 
peptide’s ion current is measured during the analysis, e.g. 5 transitions will typically 
account for >70% of the peptide’s total ion current (Lange et al., 2008). To obtain the 
highest sensitivity, it is important to select transitions that correspond to the most 
intense fragment ions of each precursor, as the intensities of individual fragment 
ions derived from the same precursor can differ substantially. Based on the acquired 
MS/MS spectra and following optimisation (see section 1.4), transitions were 
selected for all candidate Ras peptides that correspond to endogenous/ unlabelled 
(K0 R0) and isotope-labelled (K8 R10) versions (Table 3.1), as the generated 
isotope-labelled, full-length Ras protein standards are labelled in this manner 
(described in section 1.6). 
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Table. 3.1. Transitions and optimised 4000 QTRAP (AB SCIEX) instrument settings for 
proteotypic Ras peptides. Transitions were chosen for endogenous/ unlabelled (K0 R0) 
and isotope-labelled (K8 R10), Ras peptides. K0, isotopically light lysine; R0, isotopically 
light arginine; K8, 13C6 15N2 L-lysine (+8 Da); R10, 13C6 15N4 L-arginine (+10 Da). eV, electron 
volt. Underlined residues indicate the presence of carbamidomethylation.  
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3.1.4 OPTIMISATION OF INSTRUMENT PARAMETERS 
 
The sensitivity of SRM-based assays is dependent upon proper tuning of instrument 
parameters. One critical parameter parameter is collision energy (CE), which 
determines the speed at which ions travel through the q2 collision cell. Default CE 
values for each peptide were calculated using a generalised equation for doubly 
charged peptides. CEs ± 2 and ± 4 electron volts (eV) from the default values were 
tested on all transitions by altering the Q3 m/z by 0.01 Da for each CE examined 
(Sherwood et al., 2009). ~100 ng of Ras peptides (in-gel digested) were separated 
on a nanoAcquity UPLC (Waters) as described earlier, then subject to analysis on 
the 4000 QTRAP in SRM mode with 100 msec dwell times for each CE (Fig. 3.9). 
Over 70% of transitions experienced increases in areas under the curve and peak 
heights following optimisation, e.g. y9 and y8 ions of LVVVGAGGVGK (Fig. 3.9A), 
and y8 ion of SYGIPYIETSAK (Fig. 3.9B). Others, like the a2 and y7 ions of 
LVVVGAGGVGK, however, gained little benefit from the optimisation. As to be 
expected, the larger Ras peptides required higher collision energies to achieve 
maximum generation of fragment ions (Fig. 3.9C). All optimised CEs are detailed in 
Table 3.1. 
 
To enable a robust scheduled SRM assay, a chromatographic gradient was 
optimised that sufficiently separated the Ras peptides whilst not inducing excessive 
peak broadening. A 60-minute, 8-35% acetonitrile gradient was selected to separate 
the Ras peptides using RP-HPLC with a 25 cm × 75 µm (1.7 µm particle size) 
column and nanoAcquity UPLC system (Waters). This gradient did not cause 
excessive peak broadening, as most peptides elute over 30 seconds, and nearly all 
retention times were unique (Table 3.2), with the exception of N- and H-Ras specific 
peptides, SFADINLYR and SYGIPYIETSAK, respectively, which almost co-elute.  
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Fig. 3.9. Collision energy optimisation. (A) Example collision energy optimisations for 
LVVVGAGGVGK, a total wild-type Ras peptide, and (B) SYGIPYEITSAK, a H-Ras-specific 
peptide. ~100 ng of Ras peptides were subject to RP-HPLC before analysis on a 4000 
QTRAP (AB SCIEX) in SRM mode. Each transition (see Table 3.1) was exposed to ± 2 and 
± 4 electron volts from the default value, calculated using a generalised equation for doubly 
charged ions. (C) Overview of optimal collision energies for the proteotypic Ras peptides. 
Presented data representative of 3 replicates.    
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Table 3.2. Determination of retention times for proteotypic Ras peptides. ~100 ng of 
Ras peptides (in-gel digested) were subject to reversed-phase HPLC using a 60-minute, 8-
35% acetonitrile gradient on a 25 cm × 75 µm column and nanoAcquity UPLC system 
(Waters). Peak intensity indicates elution time at which signal intensity was greatest; peak 
width, time from which the peak reached and returned to 5% maximum intensity. All peptides 
are tryptic, unless indicated. Data presented as mean ± SD (n = 3).   
 
Dwell times for each transition were chosen to ensure maximum sensitivity whilst 
obtaining a minimum of 8 data points per transition during the elution of each 
peptide, a requirement for accurate quantification (Lange et al., 2008). The 
LVVVGAGGVGK peptide generates the strongest signal and therefore 100 msec 
dwell times per transition were chosen. For all other peptides, a 200 msec dwell time 
for each transition was selected, since this limits cycle time to 2 seconds, when 5 
light and heavy transitions are monitored, and will therefore obtain ~15 data points 
for each transition for a peptide that elutes over 30 seconds. Yet, it is very likely that 
the observed intensities of the Ras peptides will reduce when analysed in the 
presence of a complex biological background due to ion suppression. Consequently, 
the 200 msec dwell times should allow for a drop in signal and still maintain a 
minimum of 8 data points for each transition. 
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3.1.5 VALIDATION OF TRANSITIONS  
 
Although SRM analyses are highly selective due to the two consecutive mass 
filtering stages, a particular transition may not be specific in the presence of a 
complex biological background. Since no MS/MS spectra are acquired during an 
SRM assay, interfering signals can be easily mistaken as being derived from the 
target peptide. Several validation steps for each transition were therefore performed. 
All chosen transitions were based on observed fragment ions from MS/MS spectra 
obtained using pure Ras protein digests on the 4000 QTRAP in IDA or MIDAS 
modes. This ensures that all selected transitions are genuine. Further validation 
steps are performed on the acquired SRM data itself, which are detailed in the 
following chapter. Briefly, heavy isotope-labelled peptides (with 15N and 13C 
incorporated) exactly co-elute with their endogenous counterparts. This enables the 
clear identification of the target peptides from any non-specific signals. Additionally, 
the signal intensity ratios of the transitions should be identical between the light and 
heavy peptides. Any change in these ratios would indicate interference with one or 
more transitions.  
 
Interference between transitions was also probed. Since unlabelled and isotope-
labelled versions of the same peptide have identical b-ion series, there is the 
possibility that cross talk may occur if the collision cell is insufficiently cleared 
between transitions when b ions are targeted (Fig. 3.10A). ~100 ng of Ras peptides 
were subject to SRM analysis where LVVVGAGGVGK and VEDAFYTLVR peptides 
were monitored and a b-ion was selected for transmission (true transition). 
Immediately after this transition, another was acquired that selects for the same b 
ion in Q3 but a non-existent precursor in Q1 (false transition) (Fig. 3.10B). There 
was no detectable level of cross talk in the false transition, which therefore permits 
the use of b ions in the SRM assay. 
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Fig. 3.10. Cross talk between transitions targeting b ions on the 4000 QTRAP. (A) 
Although unlabelled and isotope-labelled peptides have different precursor and y ion 
masses, their b ion series are identical. (B) Determination of no cross talk between 
transitions. ~100 ng of Ras peptides were subject to SRM analysis on the 4000 QTRAP 
monitoring for LVVVGAGGVGK and VEDAFYTLVR in Q1 and a b-ion in Q3 (true transition). 
This was immediately followed by a transition that selects for the same Q3 mass, but a Q1 
mass that selects for a non-existent precursor (false transition).  
 
Furthermore, to determine that the SDS-PAGE fractionation technique, selected 
transitions and optimised instrument settings in combination are compatible with 
generating a linear relationship between Ras peptide abundance and MS response 
on the QqQ, 250 ng of unlabelled Ras protein isoforms were mixed with isotope-
labelled Ras protein at ratios from 0.2 - 20, before being subject to SDS-PAGE and 
in-gel digestion. Generation of isotope-labelled, full-length Ras protein standards is 
detailed in the next section. 50 ng of light Ras peptides, and between 10 ng and 1 
µg of isotope-labelled peptides, were injected onto a RP-HPLC column, using the 
optimised gradient described previously, before SRM analysis using the transitions 
and settings stipulated in Table 3.1. All tested Ras peptides demonstrated a linear 
response between peptide abundance and signal intensity, with R2 values between 
0.999 and 0.978 and slopes all close to 1 (Fig. 3.11).  
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Fig. 3.11. Linearity between Ras peptide abundance and MS response. Isotopically 
light, full-length Ras isoforms were mixed with isotope-labelled Ras proteins at ratios from 
0.2 to 20, before being subject to in-gel digestion. 50 ng of light Ras peptides, and between 
10 ng and 1 µg of heavy Ras peptides, were injected onto a RP-HPLC column and subject to 
SRM analysis on a 4000 QTRAP using the transitions and settings stipulated in Table 3.1. 
 
At 10 and 25 ng, only 2 clear transitions were detected for the K-Ras total peptide, 
SFEDIHHYR, and H-Ras specific peptide, SFEDIHQR. Both of these peptides were 
detected in doubly and triply charged states, plus several of their fragment ions were 
either singularly or doubly charged. Also, if the y4 ion of the K(B)-Ras specific 
peptide, QGVDDAFYTLVR, is monitored along with the 4 selected transitions, R2 is 
maintained at 0.999 but the slope increases to 1.374. As a result, the y4 transition 
does not behave in the same way as the other selected transitions and therefore 
cannot be utilised in the SRM assay. 
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3.1.6 PRODUCTION OF PSAQ RAS STANDARDS 
 
Since the PSAQ strategy requires the generation of full-length, isotope-labelled 
protein standards and the selected proteotypic Ras peptide set contain either a C-
terminal arginine or lysine residue (mid-chain arginine for the selected elastase 
peptide), full-length, his-tagged Ras protein isoforms were produced labelled with 
13C6 15N2 L-lysine (+8 Da) and 13C6 15N4 L-arginine (+10 Da). To express these 
proteins, auxotrophic AT713 E.coli (Yale Coli Genetic Stock Center, New Haven) 
were used. These bacteria are deficient for ArgA and LysA biosynthetic genes 
(argA21, lysA22), making them suitable for generating protein uniformly labelled with 
arginine and lysine isotopes. 
 
Wild-type H- and K(A)-Ras sequences were cloned into the pTrcHis A vector 
(Invitrogen), while pRSET vectors (Invitrogen) containing his-tagged, wild-type K(B)- 
and N-Ras sequences were kindly provided by Ignacio Rubio (Institute of Molecular 
Cell Biology, University of Jena). AT713 E.coli were transformed with these 
plasmids and grown in M9 minimal media, supplemented with heavy arginine and 
lysine (Fig. 3.12). The his-tagged Ras isoforms were initially purified using a USB 
PrepEase his-tagged protein purification kit (Affymetrix), before being subject to gel 
filtration using a Superdex 200 10/300 GL and ÄKTA protein purification system 
(both GE Healthcare). The Ras PSAQ standards were not contaminated with any 
other protein and over 99% isotopically labelled (Fig. 3.13). Concentrations of the 
Ras PSAQ standards were determined by generating an isotopically light K(B)-Ras 
protein, whose concentration was measured using two independent methods: 
absorbance measurement at 280 nm using a NanoDrop 1000 and a bicinchoninic 
assay (both Thermo). The two methods gave results that were only 9% different. A 
known amount of the light K(B)-Ras protein was mixed with volumes of the Ras 
PSAQ standard, before in-gel digestion and SRM analysis of light and heavy 
versions of the shared LVVVGAGGVGK peptide on the 4000 QTRAP. Comparison 
of the intensities of the respective isotope signals enabled accurate measurement of 
the PSAQ standards (Fig. 3.14).  
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Fig. 3.12. Production of isotope-labelled (K8, R10) H-, K(A)-, K(B)- and N-Ras protein 
isoforms. (A) Expression and initial purification of isotope-labelled Ras proteins. 
Auxotrophic AT713 E.coli were transformed with plasmids containing his-tagged, wild-type 
Ras isoform sequences and grown in isotopic M9 minimal media, containing heavy arginine 
and lysine, for 3 hours following induction with isopropyl β-D-1-thiogalactopyranoside. 
Bacteria were pelleted by centrifugation and his-tagged proteins purified using a PrepEase 
purification kit (Affymetrix). (B) Further purification of his-tagged Ras isoforms using gel 
filtration. The first elution of each protein was further purified using size exclusion 
chromatography with a Superdex 200 GL (GE healthcare). UV traces and colloidal blue 
staining of 25 µL of the indicated fractions are shown. (C) Final purity of the his-tagged Ras 
protein standards. Fractions C7-C9 were combined for all Ras isoforms, bar N-Ras where 
only the C7 fraction was collected. The band at 34 kDa in H- and K(A)-Ras gels represents a 
bacterial protein contaminant, which was removed via the gel filtration. 
RESULTS – AN SRM-BASED RAS QUANTIFICATION TECHNIQUE 
 114 
 
 
Fig. 3.13. Extent of isotope labelling of the full-length, PSAQ Ras isoform standards. 
Each his-tagged, isotope-labelled (K8 R10) Ras protein standard was subject to separate in-
gel digestions with trypsin and elastase, before analysis of light and heavy versions of 
LVVVGAGGVGK and FYTLVREI peptides using a 4000 QTRAP (AB SCIEX) in SRM mode. 
The standards were > 99% labelled on lysine residues, whilst no light version of the arginine 
containing peptide was detected.   
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Fig. 3.14. Concentration of the isotope-labelled (K8 R10), Ras PSAQ standards. (A) 
Colloidal blue staining of 1µg and (B) total light labelling of full-length, his-tagged K(B)-Ras. 
(C) Concentration of the light His-K(B)-Ras protein. Two independent methods were utilised: 
absorbance at 280 nm (A280) and bicinchoninic assay (BCA). Performed in triplicate. Mass 
of the his-tag (17% of total protein) was deducted. (D) Concentration of heavy-labelled H-, 
K(A)-, K(B)- and N-Ras proteins. A known amount of the accurately quantified light His-K(B)-
Ras (250 or 500 ng) was mixed with volumes of isotope-labelled (K8 R10) PSAQ Ras 
standards and subject to in-gel tryptic digestion, before RP-HPLC and SRM analysis on a 
4000 QTRAP, monitoring for light and heavy forms of the LVVVGAGGVGK peptide 
(transitions described in Table 3.1). Comparing the relative intensities of the different isotope 
signals enabled accurate measurement of the Ras PSAQ standards.  
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3.1.7 DISCUSSION 
 
Since the four major Ras isoforms are 85% identical and only 188/9 residues in 
length, they present a significant challenge to be targeted by SRM-based 
proteomics. As a result, four proteases (trypsin, LysC, GluC and elastase) were 
evaluated for their ability to generate proteotypic Ras peptides that distinguish the 
Ras isoforms. Candidate peptides were selected based on their amino acid 
sequence, likely charge state(s), presence of chemically modifiable residues and 
known Ras PTMs. From the proteases tested, trypsin generated the largest number 
of proteotypic peptides that were amenable to SRM analysis and defined the most 
aspects of cellular Ras abundance. Trypsin differentiates the four major isoforms, 
describes wild-type Ras at positions 12/ 13 and provides redundancy with peptides 
shared between isoforms. Yet, a tryptic peptide that defines total Ras levels was 
lacking, as the Ras identical region (residues 1-85) contains only 6 arginine and 
lysine residues. Consequently, an elastase-derived peptide FYTLVREI (residues 
156-163) may be utilised to obtain total Ras information, but would require a 
separate digestion.  
 
Tryptic peptides are commonly observed as doubly charged ions, with one proton 
sequestered by their C-terminal basic residue whilst the other, following excitation, 
can migrate to energetically less favourable sites along the peptide backbone to 
cause dissociation (Paizs and Suhai, 2005). As the majority of selected tryptic Ras 
peptides do not contain a highly basic amino acid other than at their C-terminus, 
they are likely to reside in a single charge state. Yet, two tryptic Ras peptides 
contain mid-chain histidine residues: SFEDIHHYR (K-Ras) and SFEDIHQYR (H-
Ras). These were detected as doubly and triply charged precursor ions that 
fragment into a mix of singly and doubly charged product ions. This is not ideal for 
SRM, as the mid-chain histidine residues may sequester the additional proton, 
making the peptide less amenable to fragmentation by CID. Moreover, the signal 
from these peptides is spread across multiple charge states. Both of these factors 
will reduce the sensitivity of the SRM assay, possibly explaining why these peptides 
were inadequately detected from in-gel digests of 10 and 25 ng of pure Ras protein. 
Overall, this potentially jeopardises the detection of these peptides at endogenous 
levels. However, trypsin provides alternative H- and K-Ras peptides that can be 
utilised if these peptides are not detectable in a target lysate.  
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The presence of proline residues in peptides can be advantageous in terms of 
sensitivity for SRM, as peptides preferentially fragment N-terminally of these 
residues and generate an intense y-ion signal (Schwartz and Bursey, 1992). Two 
selected tryptic Ras peptides contain proline residues, the H-Ras specific peptide 
SYGIPYIETSAK and the shared H- and N-Ras peptide, SYGIPFIETSAK. Both 
generated a dominant y8 ion signal, exemplified by the H-Ras peptide, where only 
two other fragment ions, b2 and b3, were viable choices for transitions. y7 and y6 
product ions were initially chosen, but following CE optimisation, their intensities 
remained ~100-fold less than that for the y8 ion. As a result, this peptide is 
quantified using only 3 transitions. 
 
Peptides that contain methionine, asparagine and glutamine can be chemically 
modified and therefore present problems for SRM-based strategies. When modified, 
these residues experience a change in mass. Methionine can undergo oxidation, 
generating methionine sulfoxide or sulfone, causing a mass increase of 15.99 or 
31.99 Da, respectively (Ghesquiere and Gevaert, 2014). Asparagine and glutamine 
residues can undergo deamidation and be converted into isoaspartate/ aspartate 
and glutamate, respectively (Geiger and Clarke, 1987; Lange et al., 2008; 
Piszkiewicz et al., 1970). This modification causes an increase in mass of almost 1 
Da, but occurs at a much lower rate for glutamine residues. Such mass changes are 
important, because Q1 will eject modified peptides if not specifically selected for in 
SRM. Chemical modifications, like different charge states, will also act to spread a 
peptide’s signal and reduce the sensitivity of the assay. Tryptic peptides with 
methionine residues were therefore discounted: DSEDVPMVLVGNK (K-Ras) and 
DSDDVPMVLVGNK (H- and N-Ras). As tryptophan can also be oxidised, peptides 
containing this residue would also be discounted, but interestingly Ras does not 
contain this residue. Since Ras is a small protein, it was not possible to avoid 
peptides that contain asparagine or glutamine: TGEGFLCVFAINNTK (H and K), 
QGVEDAFYTLVR (H and N) and QGVDDAFYTLVR (K(B)-Ras). Although these 
peptides are prone to chemical modification, the use of the PSAQ strategy ought to 
compensate for acquired modifications, since the heavy standard is added at the 
earliest possible point in the workflow, both the isotope-labelled and endogenous 
proteins should be equally affected by such modifications.  
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Fig. 3.15. Post-translational modifications of Ras. Known modifications of H-Ras (top) 
and K(B)-Ras (bottom). Based on (Ahearn et al., 2012). 
 
The only point of variation would be if there are differences between the 
endogenous protein isolated from cells and the isotope-labelled standards, but this 
is largely unavoidable. Yet, non-acidic buffers were used during the purification of 
isotope-labelled standards and cell lysis to limit the extent of deamidation.  
 
Ras PTMs must also be considered when selecting peptides for quantification, as 
modified peptides must be specifically selected if they are to be detected using 
SRM. While K(B)-Ras requires farnesylation to associate with the plasma 
membrane, the remaining isoforms require further palmitoylation to achieve 
membrane binding (Ahearn et al., 2012; Prior and Hancock, 2012). These lipid 
modifications occur in the HVR of Ras and therefore any peptide in this region was 
discounted. However, Ras proteins can also be modified on residues outside of this 
region (Fig. 3.15). From the selected peptides (Fig. 3.8), ubiquitylation of K147 will 
affect SYGIPYIETSAK (H-Ras) and SYGIPFIETSAK (K- and N-Ras) (Jura et al., 
2006; Sasaki et al., 2011). However, the detected levels of ubiquitylated H-Ras were 
between 1-2% of total H-Ras, meaning this peptide should be capable of reporting 
accurate H-Ras levels despite being modified. Yet, the extent of K- and N-Ras 
ubiquitylation at K147 is unclear, but the use of this peptide can be validated if 
individual values for cellular K- and N-Ras match its results. 
 
LysC, GluC and elastase were not chosen as the primary protease to acquire 
information on cellular Ras abundance. LysC and GluC generated peptides with 
multiple mid-chain highly basic residues, meaning the fragmentation of these 
peptides may be limited and, as described earlier, their signals will be diluted. 
Furthermore, LysC generated longer peptides compared to trypsin and most tended 
to contain chemically modifiable residues. Elastase generated the most peptides 
compared to the other enzymes tested, but many were overlapping. When peptides 
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overlap, their signal is shared and the possibility of detecting them in a target lysate 
is reduced. Consequently, these proteases were only considered to complement the 
tryptic digest. Elastase digestion consistently generated the pan-Ras peptide 
FYTLVREI, while GluC generated the pan-Ras peptide DSYRKQVVIDGE. Neither of 
these peptides is affected by common Ras mutations and therefore suitable to 
define total cellular Ras. These proteases can therefore be utilised to obtain total 
Ras information in a separate digest alongside trypsin.  
 
Once the Ras proteotypic peptides were chosen, suitable transitions for each 
peptide were selected. To ensure that each transition was genuine, only fragment 
ions observed in MS/MS spectra obtained using the 4000 QTRAP were considered. 
y-ions were given preference over b- and a-ions, since y-ions contain more of the 
peptide they will have a more unique mass. Where possible, a minimum of three y-
ions was selected per peptide, supplemented with up to two a- or b-ions. Transitions 
were optimised with respect to CE in order to increase the intensity of each fragment 
ion and improve assay sensitivity. Following optimisation, unlabelled and isotope-
labelled proteins were mixed at various ratios and subject to in-gel digestion and 
SRM analysis with the optimised instrument settings. All tested peptides 
demonstrated a linear relationship between Ras peptide abundance and signal 
intensity. However, the K(B)-Ras peptide, QGVDDAFYTLVR, demonstrated an 
interesting phenomenon, where the inclusion of a y4 ion caused the slope of the MS 
response to increase. This indicates that, at higher abundances the isotope-labelled 
y4 ion is more intense than its unlabelled counterpart. This is puzzling, but ultimately 
means the y4 ion cannot be employed in the SRM assay. Along with optimised 
instrument parameters, a 60-minute RP-HPLC linear gradient was designed. All 
peptides displayed unique retention times, bar, SFADINLYR and SYGIPFIETSAK, 
which nearly co-elute. This unfortunately necessitates the use of two independent 
LC runs to monitor both of these peptides when using the 4000 QTRAP, but this 
shouldn’t be necessary, faster and more sensitive on newer QqQ instruments. The 
developed assay was readily capable of detecting all Ras isoforms at 10 ng levels 
and is compatible with samples derived from human, mouse, rat, chicken and 
guinea pig tissues. In the next chapter, the SRM Ras quantification technique was 
applied to quantitate Ras isoform abundance in isogenic SW48 colorectal cancer 
cell lines, harbouring a variety of K-Ras codon mutations, as well as H-Ras and N- 
RasG12V mutations.  
RESULTS – QUANTIFICATION OF CELLULAR RAS ABUNDANCE 
 120 
3.2 QUANTIFICATION OF CELLULAR RAS ABUNDANCE 
 
Ras GTPases are small, predominately plasma membrane-localised proteins, which 
sit near the top of signalling pathways regulating cell proliferation, differentiation and 
apoptosis (Prior and Hancock, 2012). All human cells harbour three Ras proto-
oncogenes, that encode for four major protein isoforms: H-, K(A)-, K(B)- and N-Ras 
(Fiorucci and Hall, 1988; Furth et al., 1987), and are amongst the most frequently 
mutated in human cancer, with an average mutation incidence rate of 16% (Prior et 
al., 2012). Although Ras isoforms share the same effector- and nucleotide-binding 
regions, and are overall 85% identical, they are not functionally redundant 
(Castellano and Santos, 2011). Despite being studied for over 30 years, a complete 
understanding of Ras function and dysfunction, particularly in human cancer, is yet 
to be realised. Moreover, it is still uncertain how many Ras molecules are present in 
a cell. This is a critical parameter, especially when cell signalling research is nearing 
the end of identifying/ characterising individual proteins, but shifting from a 
reductionist approach to a more holistic one to understand how proteins work 
together to form complex molecular networks and circuits using mathematical and 
physicochemical modelling (Aldridge et al., 2006; Bordbar et al., 2014).  
 
Several studies have attempted to quantify cellular Ras abundance in recent years; 
however, their findings are conflicting. Omerovic et al. utilised an immunoblotting 
strategy to show that K-Ras is relatively the most abundant isoform in several 
commonly used cell lines (Omerovic et al., 2008). In contrast, Lampson et al. 
suggest that K-Ras is the minor isoform, due to ribosomal stalling on rare codons 
within in the KRAS gene to cause poor K-Ras protein expression; plus, they 
demonstrated that H-Ras was ~20-fold better expressed than K-Ras when 
identically tagged cDNA was transfected into cells (Lampson et al., 2013). SRM-
based proteomics has also been applied to the question of cellular Ras abundance. 
Wang et al. performed immunoprecipitation of Ras proteins, before tryptic digestion 
and addition of AQUA reference peptides, ahead of SRM analysis (Wang et al., 
2011). The Wang study found that, on average, there are over 1 million Ras 
molecules per cell, with K-Ras the most abundant isoform. Confusingly, Ruppen-
Canas et al. employed the same technique as the Wang study, but detected ~100-
fold less Ras in their samples (Ruppen-Canas et al., 2012). Using a different 
approach, Halvey et al. subjected samples to SDS-PAGE and in-gel digestion, 
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before addition of Ras-specific AQUA peptides and SRM analysis (Halvey et al., 
2012). They found a ~10-fold less Ras in their samples compared the Wang study, 
but could not convert this into molecules per cell. Global, label-free proteomic 
studies also provide a number for Ras molecules per cell. Schwanhausser et al. and 
Nagaraj et al. both employed the intensity based absolute quantification (iBAQ) 
technique to measure the abundances of thousands of proteins in mouse NIH3T3 
and HeLa cells, respectively (Nagaraj et al., 2011; Schwanhausser et al., 2011). The 
Nagaraj study quantified 173,933 K-Ras molecules per HeLa cell, while the 
Schwanhausser study calculated 22,089 H-Ras, 41,089 K-Ras and 378,351 N-Ras 
molecules per NIH3T3 mouse cell. Overall, there have been a wide range of 
numbers reported for Ras molecules per cell and disagreement over which isoform 
is most abundant. Here we measure the cellular Ras abundance in a panel of 
isogenic SW48 colorectal cell lines, harbouring a variety of Ras mutations, utilising 
the SRM-based Ras quantification strategy and PSAQ standards described in the 
previous chapter. In addition, we investigate the turnover of wild-type and mutant 
Ras molecules utilising the SW48 isogenic cell line panel, coupled with dynamic 
SILAC.  
3.2.1 IMMUNOBLOT ANALYSIS OF RAS ISOFORM ABUNDANCE 
 
Firstly, we assessed the utility of immunoblotting to quantify cellular Ras abundance, 
since this is a well-established technique to identify specific proteins and determine 
their expression levels in tissues or cells in culture. 100 to 10 ng of his-tagged H-, 
K(B)- and N-Ras, along with 25, 50 and 100 µg of HeLa cell lysate, was subject to 
immunoblotting with H-, K-, N- and Pan-Ras antibodies (Fig 3.16A). Densitometry 
analysis of the his-tagged Ras proteins provides a standard curve from which Ras 
isoform abundance in the HeLa lysates can be calculated (Fig. 3.16B). Unlike the K- 
and pan-Ras antibodies, which displayed largely linear responses between his-
tagged Ras abundance and densitometry signal in all replicates, the H-Ras antibody 
failed to exhibit a linear response, while the N-Ras antibody achieved such a 
response only once. When Ras abundance in HeLa cells was calculated, the 
variability between biological replicates was high, e.g. in 50 µg lysate, H-Ras was 
calculated as 15.39 ± 8.32 ng, K-Ras 8.20 ± 9.88 ng and N-Ras 10.88 ± 8.31 ng 
(Fig. 3.2C). 
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Fig. 3.16. Immunoblot analysis of cellular Ras abundance. (A) Immunoblots estimating 
cellular Ras abundance in HeLa cells. 100 to 10 ng of his-tagged Ras isoforms (1:1:1 mix of 
H-, K(B)- and N-Ras for pan-Ras) and 25, 50 and 100 µg of HeLa lysate were immunoblotted 
with isoform-specific and pan-Ras antibodies. (B) Response between his-tagged Ras protein 
abundance and densitometry signal. Black curves correspond to the immunoblots in A. (C) 
Calculated Ras isoform abundance in HeLa cell lysate. Bars represent mean ± SD of 3 
biological replicates.  
 
Furthermore, the amount of total Ras calculated using the pan-Ras antibody did not 
match the individual isoforms summed together, e.g. for 50 µg lysate, the pan-Ras 
antibody signal indicates that total Ras is 80.59 ± 55.39 ng whereas the summed 
total is 34.47 ng. Moreover, the quantity of Ras does not double when the amount of 
HeLa lysate is doubled, from 25 to 50 µg lysate, calculated H-Ras increased 1.2-
fold, K-Ras 1.18-fold and N-Ras 3-fold (Fig. 3.16C).  
 
Although immunoblotting generates results with high variability, it does indicate that 
K-Ras may be the least abundant isoform in HeLa cells, while H- and N-Ras are 
expressed at similar levels. Nevertheless, this strategy cannot be used to accurately 
and robustly measure the abundance of Ras isoforms in cell lines or other biological 
samples.  
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3.2.2 DETECTION OF PROTEOTYPIC RAS PEPTIDES IN ISOGENIC SW48 
COLORECTAL CELL LINES 
 
The present thesis targeted an isogenic panel of SW48 colorectal cell lines, 
harbouring a range of Ras mutations, for the measurement of cellular Ras 
abundance. The isogenic cell lines were generated through targeted homologous 
recombination, which exchanges an endogenous Ras allele for a mutant Ras 
sequence. In addition to the K-Ras wild-type control cell line (known as the Parental/ 
wt cell line), the K-Ras mutations present in the isogenic panel represent those 
observed in over 75% of colon tumours (G12D, G12V and G13D), plus others that 
are less prevalent (G12C, G12S, G12A and G12R) (Prior et al., 2012; Vaughn et al., 
2011). Also included were H-RasG12V and N-RasG12V mutations, which are rare 
occurrences in colon cancer (< 3%). All mutant cell lines were heterozygous for their 
respective Ras mutations.  
 
To discover if the selected proteotypic Ras peptides were detectable at endogenous 
levels in the isogenic SW48 cell line panel, 100 µg of SW48 Parental, K-RasG12D, 
K-RasG12V and K-RasG13D cell lysates were subject to SDS-PAGE. The Ras 
containing band was excised, before reduction and alkylation with DTT and IAA, 
respectively. The sample was then in-gel digested with trypsin (and elastase in a 
separate digestion), ahead of peptide extraction, chromatographic separation and 
SRM analysis on the 4000 QTRAP (AB SCIEX), using the settings described in the 
previous chapter. All peptides were detectable at endogenous levels, bar the K(A)-
Ras-specific peptide and the elastase pan-Ras peptide. Despite increasing dwell 
times for each transition to 400 msec, neither peptide could be detected using the 
4000 QTRAP and were therefore excluded from the analysis. The detectable 
proteotypic Ras peptides are detailed in Fig. 3.17. 
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Fig. 3.17. Proteotypic Ras peptides used for quantification of cellular Ras abundance 
in the isogenic SW48 colorectal cell line panel. Top, the proteotypic, tryptic peptides 
detected and used for Ras quantification in the SW48 cell line panel. K(A)-Ras was 
undetectable at endogenous levels in the SW48 cells and was therefore excluded. Bottom, 
Locations of the proteotypic peptides overlaid on the crystal structures of H-, K(B)- and N-
Ras. H-Ras structure from (Milburn et al., 1990), Protein Data Bank (PDB) code: 4q21; K(B)-
Ras, PDB code: 3gft; N-Ras, PDB code: 3con, residues 61-71 not visualised. For Ras 
quantification, 10 ng of isotope-labelled (K8 R10) K(B)-Ras and 5 ng of H- and N-Ras 
proteins were spiked into 100 µg of cell lysate, before being processed as described in Fig. 
3.1.  
 
3.2.3 CELLULAR RAS ABUNDANCE IN ISOGENIC SW48 COLORECTAL CELL 
LINES 
 
To quantify cellular Ras abundance in the SW48 isogenic panel, cells were grown to 
~80% confluency in 10 cm dishes, detached through trypsinisation and resuspended 
in 10 mL phosphate-buffered saline (PBS), before being counted with a 
haemocytometer. 6 independent squares on the haemocytometer were counted and 
only cell counts with < 20% CV were considered for analysis. 9 mL of cells was 
collected and centrifuged at 200 rcf for 5 min, followed by aspiration of excess PBS. 
Cell lysis was performed with 200 µL RIPA buffer, supplemented with protease 
inhibitors, for 20 mins on ice with regular, slight agitation. Cell lysate volume was 
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measured using a Hamilton syringe, ahead of centrifugation at 13,000 rpm in a 
bench-top centrifuge for 15 min at 4°C. The cleared lysate was subject to a BCA 
protein assay, then flash frozen and stored at -80°C until needed. 10 ng of isotope-
labelled K(B)-Ras and 5 ng of labelled H- and N-Ras were spiked into 100 µg of 
each cell lysate, before being subject to SDS-PAGE. A gel band spanning 31-17 
kDa was excised and reduced and alkylated, as described above. In-gel tryptic 
digest was performed overnight and extracted peptides were resuspended 0.1% 
trifluoroacetic acid (TFA) after drying in a Speed Vac at 60°C. ~1 µg of peptides was 
separated using RP-HPLC on a NanoAcquity UPLC system before SRM analysis on 
the 4000 QTRAP triple quadrupole mass spectrometer. Acquired .wiff files were 
analysed using Skyline (version 2.4). 
 
To ensure that each transition is valid, it was checked that the endogenous and 
heavy versions of each peptide co-eluted exactly; plus, the order of transitions, with 
respect to intensity, remained almost identical between endogenous and heavy 
peptides (Fig. 3.18A). When unlabelled and labelled transitions were integrated, the 
signal intensity for both versions was within a factor of 3 for all peptides tested (Fig. 
3.18B). Together, these observations demonstrate that every transition monitored is 
genuine and the ratio between light and heavy peptides enables highly accurate 
quantification. To assess technical reproducibility, 5 independent acquisitions of a 
single sample were performed, with each peptide showing a variance of ≥ 7.1%.    
 
In the Parental SW48 cell line, per 100 µg lysate, 10.93 ± 0.90 ng of total wild-type 
Ras was quantified, along with 2.68 ± 0.30 ng H-Ras, 6.00 ± 0.66 K(B)-Ras and 
3.38 ± 0.1 ng N-Ras (Fig. 3.19A). Summing the individual isoforms together gives 
12.07 ± 0.99 ng, which is 110.4% of the total amount measured by the wild-type Ras 
peptide. Since the cells were counted and the cell lysate volume measured, it is 
possible to calculate accurately the number of Ras molecules per cell. In the 
Parental cell line there is 286,987 ± 33,098 total Ras molecules, with 70,242 ± 6,646 
H-Ras, 156,460 ± 18,429 K(B)-Ras and 88,975 ± 3,071 N-Ras molecules. Summing 
the isoforms together gives 315,676 ± 26,216, which is 110.0% of that calculated 
using the wild-type peptide (Fig. 3.19A). In the K-RasG12D cell line, 343,782 ± 
77,329 wild-type Ras, 116,151 ± 28,943 H-Ras, 297,533 ± 64,544 K(B)-Ras and 
155,853 ± 30,385 N-Ras molecules per cell were quantified. Compared to Parental, 
this represents a 1.65-fold increase in H-Ras, 1.90-fold in K(B)-Ras and 1.75-fold in 
N-Ras protein copy numbers.  
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Fig. 3.18. Selected reaction monitoring of proteotypic Ras peptides in SW48 isogenic 
cell lines. (A) Individual transitions of endogenous (K0 R0) and heavy (K8 R10) peptides 
describing total wild-type, H-, K(B)- and N-Ras abundance in the Parental (homozygous 
KRASWT) SW48 cell line. (B) Integrated transitions (normalised to heavy signal) of the 
proteotypic Ras peptides in Parental (PAR) and heterozygous KRAS G12D knock-in 
(KRASG12D) SW48 cells. Presented data representative of 3 biological replicates. 
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Fig. 3.19. Cellular Ras abundance in SW48 isogenic cell lines. (A) Quantify of Ras 
isoforms in the isogenic colorectal cell lines. Top, ng of Ras per 100 µg of lysate. Bottom, 
Number of Ras molecules per cell. All mutant cell lines are heterozygous knock-ins. (B) 
Agreement between Ras quantification using peptides shared between isoforms, 
TGEGFLCVFAINNTK (H and K), SYGIPFIETSAK (K and N) and LVVVGAGGVGK (all wild-
type isoforms), with summing the respective isoforms together. n ≥ 20 for H+K and N+K, n = 
3 for Pan as only applicable to the wild-type Ras SW48 cell line. Bars represent mean ± SD. 
(C) Percentage contribution of isoforms to the cellular Ras complement in the wild-type Ras 
SW48 cell line. (D) Number of mutant Ras molecules per cell. Percentages indicate the 
proportion of the respective isoform that is mutated. Unless stipulated, bars represent mean 
± SD of 3 biological replicates. Analysis performed using Skyline (version 2.4). 
 
 
 
 
 
 
 
 
RESULTS – QUANTIFICATION OF CELLULAR RAS ABUNDANCE 
 128 
By adding the individual isoforms together this gives 569,537 ± 115,223 total Ras 
molecules per K-RasG12D expressing SW48 cell. Subtracting the calculated wild-
type, approximately 197,066 ± 61,152 mutant K-RasG12D molecules could be 
present per cell, meaning ~ 57% of the K-Ras complement is mutated in the K-
RasG12D cell line (Fig. 3.19D). The K-RasG13D cell line showed a similar increase 
in H-, K(B)- and N-Ras numbers as the K-RasG12D cell line, yet had large variance, 
most likely due to difficulties in counting this cell line. Interestingly, the K-RasG12V 
cell line had similar Ras levels compared to Parental. Cells harbouring H- and N-
RasG12V also demonstrated slight change from the wild-type cell line. The peptides 
shared between isoforms can be utilised to validate the numbers reported by the 
peptides unique to isoforms. TGEGFLCVFAINNTK, shared between H- and K-Ras, 
accounts for 89.83 ± 13.46% of the Ras abundance calculated by H- and K(B)-Ras-
specific peptides. While, SYGIPFIETSAK, shared between K- and N-Ras, explains 
95.88 ± 10.4% of K(B)- and N-Ras levels (Fig. 3.19B). Although QGVEDAFYTLVR, 
shared between H- and N-Ras, was monitored, it was unreliably detected during the 
assay and therefore could not be used. Using the wild-type Parental cell line, the 
contribution of each isoform to the cellular Ras complement can be calculated: H-
Ras 24.70 ± 3.80%, K(B)-Ras 54.97 ± 0.52% and N-Ras 31.10 ± 2.84% (Fig. 
3.19C).  
 
3.2.4 DETECTION OF MUTANT-SPECIFIC RAS PEPTIDES 
 
Since the isogenic SW48 colorectal cell line panel express a range of K-Ras mutant 
proteins, it was tested if mutant-specific peptides could be identified. A G12V-
specific mutant peptide, LVVVGAVGVGK, and a G12D/G13D peptide, 
LVVVGADGVGK, have been detected previously (Ruppen-Canas et al., 2012; 
Wang et al., 2011). However, the G12D/G13D peptide could not differentiate 
between codon 12 or 13 aspartate substitutions; plus, peptides unique to other Ras 
mutants have not yet been discovered. 100 µg of lysate from each SW48 isogenic 
cell line, harbouring G12D, G12V, G13D, G12A, G12C, G12S and G12R 
heterozygous K-Ras mutations, was subject to SDS-PAGE and in-gel tryptic 
digestion as described earlier (LysC digestion for G12R). ~1 µg of peptides was 
fractionated by RP-HPLC, ionised and subject to MIDAS on a 4000 QTRAP, 
monitoring for y9, y8 and y7 fragment ions of each mutant peptide.  
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Fig. 3.20. MIDAS detection and MS/MS spectra of mutant-specific Ras peptides. 
Isogenic SW48 colorectal cell lines, harbouring G12D, G12V, G13D, G12A, G12C and G12S 
heterozygous K-Ras mutations, were targeted for their respective mutant peptides using 
tryptic digestion and MIDAS. 100 µg of cell lysate was subject to SDS-PAGE and the region 
containing endogenous Ras excised, before in-gel tryptic digestion. ~200 ng of peptides 
were fractionated by RP-HPLC and y9, y8 and y7 ions of each mutant peptide targeted using 
MIDAS with 200 msec dwell times on a 4000 QTRAP (AB SCIEX). Mutant Ras precursor 
and product ions were predicted using Skyline (version 2.4). The G12R-specific peptide 
could not be detected in either doubly or triply charged states. The cysteine residue of the 
G12C-specific peptide was subject to carbamidomethylation. 
 
 
Mutant-specific peptides for all mutant proteins were detected, bar the G12R-
specific peptide (Fig. 3.20). Moreover, the MS/MS spectrum of the G12D-specific 
peptide contains a diagnostic y4 ion that differentiates it from the G13D-specific 
peptide. The G12V-specific peptide was barely detectable with MIDAS, exemplified 
by its ~10-fold less intensity; plus, it could not be reliably detected using SRM. 
Detection of these peptides verifies, at the proteomic level, that each cell line 
expressed its respective K-Ras mutant protein, yet the G12R-specific peptide was 
undetectable in the K-RasG12R cell line, most likely due to issues associated with 
the presence of a mid-chain arginine.  
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3.2.5 TURNOVER ANALYSIS OF RAS WILD-TYPE AND MUTANT PROTEINS 
 
It is unclear if there are differences between wild-type and mutant Ras protein 
turnover, synthesis and degradation rates. Consequently, SW48 isogenic cell lines 
harbouring G12V H-, K- and N-Ras mutations, along with G12D and G13D K-Ras 
mutations, were subject to dynamic SILAC analysis (Fig. 3.21A). To assess 
turnover, synthesis and degradation rates of the Ras proteins, SW48 cells were 
grown in ‘light’ (K0 R0) or ‘medium’ (K4 R6) media, with the latter pulse labelled with 
‘heavy’ media for various time points. The ‘light’ and ‘medium/ heavy’ cells were 
then mixed at a 1:1 protein ratio and subject to SRM analysis (Fig. 3.21B) (Boisvert 
et al., 2012). The targeted peptides and selected transitions are detailed in Table 
3.3.  
 
To ensure the ‘light’ and ‘medium’ cells were appropriately labelled, 50 µg of lysate 
from each cell line labelled with these isotopes were subject to SDS-PAGE and the 
Ras-containing band excised and in-gel digested with trypsin. By targeting the total-
wild type and K(B)-Ras specific peptides with SRM, labelling of arginine and lysine 
residues was determined (Fig. 3.22). The ‘light’ cells had no trace of medium 
isotopes, while ‘medium’ cells were >99% labelled on lysine residues and >95% 
labelled on arginine. 50 µg of ‘light’ and ‘medium/ heavy’ cell lysates were mixed and 
solubilised with sample buffer, prior to SDS-PAGE and in-gel tryptic digest of the 
Ras-containing gel region. Extracted peptides were subject to the same separation 
and MS analysis as described earlier. Example SRM traces from the dynamic 
SILAC experiment are provided in Fig. 3.23.  Although ‘light’, ‘medium’ and ‘heavy’ 
signals of each peptide were reliably detected, the ratios between medium/ light and 
heavy/ light were highly variable. This meant that, unfortunately, Ras isoform 
synthesis and degradation rates could not be calculated. However, reliable heavy/ 
medium ratios were acquired, enabling measurement of Ras isoform turnover (Fig. 
3.24). In the Parental cell line, 50% of total wild-type Ras turned over in 15.22 ± 0.91 
hours, H-Ras 22.82 ± 2.49, K(B)-Ras 17.49 ± 2.80 and N-Ras 17.46 ± 2.03 hours. 
The cell lines harbouring K-Ras mutations exhibited slightly increased turnover 
times for all isoforms. Interestingly, the G13D mutant peptide exhibited a 50% 
turnover rate of 22.51 ± 1.23 hours, more than a 5-hour increase compared to the 
wild-type K-Ras in the Parental cell line. The G12D mutant peptide had a lower 50% 
turnover rate of 17.10 ± 3.29 hours. 
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Fig. 3.21. Dynamic SILAC analysis of Ras isoform turnover. (A) The SW48 isogenic 
colorectal cell lines subject to turnover analysis. All mutant cells are heterozygous knock-ins. 
(B) Method employed to determine turnover, synthesis and degradation of Ras isoforms. 
‘Medium’ cells (K4 R6) were exposed to ‘heavy’ media (K8 R10) for the indicated time 
periods, before lysis and mixed 1:1 with ‘light’ cell lysate (K0 R0). Sample processing is 
described in Fig. 3.1, but no cell counting was performed. Targeted peptides and transitions 
employed in the selected reaction monitoring analysis are detailed in Table 3.3.  
 
 
 
 
 
Table 3.3. Targeted peptides and transitions used for Ras turnover analysis. 
Transitions selected for unlabelled Ras (K0 R0), ‘medium’ labelled Ras (K4 R6) and ‘heavy’ 
Ras (K8 R10). K0, isotopically light lysine; R0, isotopically light arginine; K4, 4,4,5,5-D4 L-
lysine (+4 Da); K6, 13C6 L-arginine (+6 Da); K8, 13C6 15N2 L-lysine (+8 Da); R10, 13C6 15N4 L-
arginine (+10 Da). For schematic of the turnover analysis, see Fig. 3.21. 
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Fig. 3.22. Incorporation of isotope labels into ‘light’ and ‘medium’ cells for the Ras 
turnover analysis. ‘Light’ cells (K0 R0) had no detectable ‘medium’ isotope signals, while 
the ‘medium’ cells (K4 R6) were > 99% labelled on lysine residues and >95% on arginine 
residues.  
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Fig. 3.23. Dynamic SILAC analysis of Ras isoform turnover using selected reaction 
monitoring. Cells were labelled with ‘light’ (K0 R0) or ‘medium’ (K4 R6) isotopes, before the 
‘medium’ cells were pulsed labelled with ‘heavy’ (K8 R10) media for various time points. 
Equal protein amounts of ‘light’ and ‘medium/ heavy’ cell lysates were mixed, before sample 
processing as described in Fig. 3.1. (A) Individual transitions for wild-type and G12D mutant 
peptides corresponding to ‘light’ (K0 R0), ‘medium’ (K4 R6) and ‘heavy’ (K8 R10) conditions. 
(B) Example integrated transitions. Taken from ‘medium’-labelled SW48 cells, harbouring 
heterozygous K-RasG12D mutation, pulse labelled with ‘heavy’ media for 11 hrs.  
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Fig. 3.24. Turnover of Ras isoforms in isogenic SW48 cell lines harbouring various K-
Ras mutations. Cells were labelled with ‘medium’ (K4 R6) media before pulse labelling with 
‘heavy’ (K8 R10) media for various time points. (A) Turnover of Ras isoforms and mutant 
proteins. Left, heavy/ medium ratio (H/M) over the course of the dynamic SILAC experiment 
in SW48 cells harbouring wild-type Ras (Par). Right, turnover of mutant peptides (G12D and 
G13D) in cells harbouring these mutations, compared to wild-type K-Ras and total wild-type 
from the Par cell line. (B) 50% turnover of Ras isoforms. 50% turnover was defined as the 
time point when ‘medium’ and ‘heavy’ signals reached a ratio of 1. n = 3 for Parental cell line; 
n = 2 for cell lines harbouring K-Ras mutations. Bars indicate mean ± SD.  
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Fig. 3.25. Immunoblot characterisation of colorectal SW48 isogenic cell lines 
harbouring G12V, G12D and G13D K-Ras mutations. Cells were grown in McCoy’s 5A 
media supplemented with 10% FBS and starved overnight in media with no FBS where 
indicated (16 hr starve). Cell lysis was performed with RIPA buffer, before 50 µg of SW48 
cell lysate was subject to SDS-PAGE and immunoblotting against the indicated proteins. (A) 
Abundance of H-, K- and N-Ras in the isogenic cell line panel. (B) Similar activation of AKT 
and ERK by the different codon Ras mutants, but not MEK.  
 
3.2.6 IMMUNOBLOT CHARACTERISATION OF THE SW48 ISOGENIC CELL 
LINE PANEL 
 
Isogenic SW48 colorectal cell lines harbouring G12V, G12D and G13D K-Ras 
mutations were subject to characterisation through immunoblotting. Although 
immunoblotting was shown to be unreliable when measuring the exact abundance 
of cellular Ras, it was used to gauge the relative abundance of the Ras isoforms in 
the SW48 cell line panel (Fig. 3.25A). A slight increase in H-Ras expression is 
visible from Parental in each of the K-Ras mutant cell lines, while little change is 
observed in N-Ras abundance. However, there is a clear increase in K-Ras 
expression in the G12D and G13D K-Ras mutant cell lines. Probing immunoblots for 
components of canonical Ras signalling pathways revealed a drop in Akt activation 
in K-Ras mutant cells, while activation of ERK remained constant in all cell lines 
(Fig. 3.25B). Yet, G12D and G13D mutant K-Ras potently activated MEK. 
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3.2.7 DISCUSSION 
 
In an initial attempt to quantify cellular Ras abundance, the well-established 
technique of immunoblotting was utilised. However, inconsistent results were 
obtained between biological replicates and linear responses between protein 
abundance and densitometry signal were difficult to obtain, possibly because of 
issues during transfer or that the antibody cannot discriminate between changes in 
protein abundance at low protein levels. Consequently, an SRM-based Ras 
quantification technique was established (as detailed in chapter 1). Although 
previous attempts have been made to measure cellular Ras abundance with SRM-
based techniques, the described methods have disputable accuracy. Wang et al. 
quantified over 1 million Ras molecules per SW480 cell, by immunoprecipitating Ras 
proteins from a target lysate, before tryptic digestion and spike in of AQUA peptide 
standards (Wang et al., 2011). Since their pull-down strategy captured ~25% of Ras 
protein from samples, and some Ras remained attached to the beads following 
elution, a correction factor had to be applied to the acquired data. The establishment 
of this correction factor is confusing, as it was performed by spiking isotopically light 
Ras protein at different concentrations into an unlabelled cell lysate, which 
inexplicably already had its Ras abundance measured. Moreover, no useful 
information is given regarding how the cells were counted in the study. Furthermore, 
quantification was enabled by AQUA, which assumes complete digestion of the 
endogenous material. Ruppen-Canas et al. employed the same technique as the 
Wang study to measure Ras abundance in various tumour samples, but quantified 
Ras at ~100-fold lower levels (Ruppen-Canas et al., 2012). Consequently, two 
independent laboratories have utilised the same technique, but obtained two very 
different results despite analysing similar samples. Halvey et al. adopted a different 
strategy by subjecting a target lysate to SDS-PAGE before in-gel tryptic digestion, 
extraction of peptides and spike in of AQUA peptide standards (Halvey et al., 2012). 
This approach does not account for different efficiencies and fluctuations in peptide 
recovery from gel pieces, nor does it account for incomplete digestion of the 
endogenous material. Global, label-free approaches employing the intensity based 
absolute quantification (iBAQ) algorithm also provide an insight into cellular Ras 
abundance. Schwanhausser et al. and Nagaraj et al. measured the abundance of 
thousands of proteins in NIH3T3 and HeLa cell, respectively (Nagaraj et al., 2011; 
Schwanhausser et al., 2011). Although the iBAQ technique enables the 
quantification of thousands of proteins, it can only provide approximate protein copy 
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numbers. This is because the number of theoretically observable peptides, a 
parameter used by the algorithm to quantify total protein copy numbers, is predicted 
computationally and may not be correct for many proteins. In addition, each peptide 
has its own unique MS response, meaning that most peptides, even from the same 
protein or present at the same concentration, will be detected at different intensities 
by the mass spectrometer. Consequently, peptide physicochemical properties can 
undermine the accuracy of the iBAQ technique, if only one or two peptides have 
been detected for a protein. The iBAQ approach is most useful to describe the 
abundance of protein groups as a whole (personal correspondence, Matthias 
Selbach, Max Delbrück Center for Molecular Medicine, Germany). Here Ras 
abundance was measured using the PSAQ strategy, which obviates the need for a 
correction factor and resolves problems associated with incomplete digestion and 
fluctuations/ differences in peptide recovery from gel pieces; plus, all measured 
endogenous Ras peptides are compared to a chemically identical, isotope-labelled 
counterpart. Consequently, the presented data represents the most accurate 
measurement of cellular Ras isoform abundance to date.  
 
In the Parental SW48 cell line, 10.93 ng of total Ras per 100 µg of lysate was 
quantified, which is somewhat different to the Halvey study that quantified 1-7 ng of 
total Ras in 100 µg lysate in all their samples, while the Wang study detected over 
25 ng of Ras per 100 µg sample in their cell lines, with the SW480 cell line 
containing more than 100 ng of Ras. However, it is unclear how Wang and 
colleagues calculated that there are over 1 million wild-type Ras molecules per 
SW480 cell. Wang et al. report that an SW480 cell has 155% more wild-type Ras 
than the Parental SW48 cell lines quantified in this thesis, but obtained 4 mg of 
protein from the lysis of 5.6 million SW480 cells, whereas the present thesis 
obtained ~1 mg of protein from ~10 million SW48 cells. Such a protein yield reported 
by the Wang study is a very impressive one, but since they do not stipulate how 
their cells were counted, an element of doubt remains over its accuracy and over 
their quantification technique in general.   
 
The present thesis calculates that there are 287,000 Ras molecules per Parental 
SW48 cell and assuming a cell’s diameter is ~20 µm (diameter determined using an 
electron microscope grid, performed by Prof. Ian Prior) and that ~50% of Ras protein 
is associated with the plasma membrane (Laude and Prior, 2008), it can be 
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calculated that per µm2 of plasma membrane there are approximately 114 bound 
Ras molecules. As the volume of a Parental SW48 cell is ~2 pL (measured using a 
ScepterTM cell counter, Millipore) the cellular molarity of Ras is 253 mM. The cellular 
Ras complement was also determined, with K(B)-Ras the most abundant isoform 
(55%), followed by N-Ras (31%) then H-Ras (25%). Since these final values are 
subject to the summed technical and biological variability of 4 independent peptide 
measurements from 3 biological replicates, it is not unexpected or concerning that 
they do not add up to 100% exactly (actually add up to 111%). K(A)-Ras was 
undetectable in the SW48 cell line, which could be due to a little to no mRNA 
expression for this minor K-Ras isoform (Plowman et al., 2006).  
 
Compared to the Parental cell line, cells harbouring G12D and G13D K-Ras 
mutations express increased levels of H- and N-Ras, and nearly double the amount 
of K(B)-Ras, which was also observed using immunoblotting. This is interesting 
since G12D and G13D are first and third most common K-Ras mutation in CRC, 
respectively (Vaughn et al., 2011). By summing the individual isoforms together, the 
K-RasG12D mutant cell line contains 1.8-fold more Ras compared to Parental, with 
as many as 197,000 mutant Ras proteins per cell, meaning around 57% of the K-
Ras protein expressed is mutant. G12A and G12R K-Ras mutations also show an 
increase in K-Ras protein expression, but not at the same levels as G12D and 
G13D. In contrast, the second most common K-Ras mutation in CRC, G12V, 
exhibited slight change in Ras isoform abundance compared to Parental, indicating 
little K-RasG12V protein expression. Yet the mutant protein is present in these cells, 
since a G12V-specific mutant peptide was detected using MIDAS, with 31,000 
mutant K-RasG12V proteins per cell, accounting for 20% of K-Ras complement. 
Similarly, neither H- nor N-RasG12V mutations induced significant change to Ras 
isoform expression compared to Parental. These data suggest that mutant Ras 
protein expression is associated with its transforming activity. Early Ras research 
showed that different H-Ras mutations exhibited a range of transforming activities, 
with G12V usually having the greatest potency (Der et al., 1986; Seeburg et al., 
1984; Sloan et al., 1990). K-RasG12V reduced activation of the PI3K pathway to a 
similar extent as G12D and G13D mutations, despite having 15-fold lower 
expression, but could not activate MEK like these mutations. This, it could be that 
Ras mutations exert their different biological effects, not only through slight 
structural differences or differently impaired GTPase activities, but also through 
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differential protein expression. Furthermore, since a Ras mutation induces stress on 
the cell, a K-RasG12V mutation could be such a prolific oncogenic signalling 
molecule that the cell cannot tolerate its increased expression and actively limits its 
cellular abundance. While G12D and G13D mutations could be less transforming 
than G12V, as eluded to previously (Cespedes et al., 2006), enabling the cell to 
tolerate the presence of hundreds of thousands of these mutant molecules.  
 
Each cell line harbouring a heterozygous Ras mutation expressed similar levels of 
wild-type Ras protein as Parental. This could indicate that the mutant Ras protein is 
simply added on top of the usual cellular Ras complement in the SW48 cell line 
panel. It also shows that despite a range of Ras mutations being present, the cell 
maintains a minimum level of wild-type Ras. Mutant and wild-type Ras have been 
shown to interact with each other, with mutant Ras proteins able to activate 
endothelial nitric oxide synthase or SOS which in turn activates wild-type Ras (Jeng 
et al., 2012; Lim et al., 2008); plus, wild-type H- and N-Ras can help promote K-Ras-
driven tumourigenesis (Bentley et al., 2013; Grabocka et al., 2014; Young et al., 
2013). Yet, wild-type Ras proteins have also been reported to act as tumour 
suppressors, with wild-type H-Ras alleles deleted in some mouse cancers (Bremner 
and Balmain, 1990; Keller et al., 2007b; To et al., 2013). Thus, the cellular wild-type-
to-mutant Ras protein ratio is likely to be context dependent. In CRC, as the 
colorectal SW48 isogenic panel maintained a minimum amount of wild-type Ras, 
with increases in wild-type H- and N-Ras in G12D and G13D K-Ras mutant cell 
lines, wild-type Ras isoforms may contribute to colorectal carcinogenesis in the 
presence of certain K-Ras mutations.  
 
To determine if Ras isoforms exhibit different turn over rates in the presence of 
different K-Ras mutations, isogenic SW48 cells harbouring wild-type (Parental), or 
those harbouring G12D, G12V and G13D K-Ras mutations, were subject to dynamic 
SILAC analysis. The initial aim was to determine synthesis, degradation and 
turnover rates, but as the light-to-medium and light-to-heavy ratios were erratic in 
most analyses, it prevented synthesis and degradation calculations from being 
performed. The reason for inconsistent ratios is unclear, as all cells were seeded in 
the same manner and treated with the same media, although containing different 
isotope labels. However, the medium-to-heavy ratio was reliable throughout the 
analyses, which provided an insight into how the Ras protein isoforms turnover. In 
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the Parental cell line, H-Ras had the longest 50% turnover rate, with K(B)- and N-
Ras showing similar times. This shows for the first time that Ras isoforms do not 
share the same turnover rate or half-life. The measured 50% turnovers at a glance 
seem to be shorter than the expected 20 hour half-life of Ras (Ulsh and Shih, 1984), 
since the calculations have not considered cell growth. Interestingly, the turnover 
rates of the Ras isoforms increase in the presence of a K-Ras mutation, but the 
variability also increases. However, the G13D-mutant peptide displayed a 5-hour 
longer turnover rate compared to the wild-type K(B)-Ras peptide in Parental cells. 
Although this observation needs to be verified, it provides the first indication that 
certain mutant Ras proteins may turnover differently within the cell. This could also 
provide a mechanism through which mutant Ras proteins can increase their 
expression levels.  
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3.3 PROTEOMIC AND PHOSPHO-PROTEOMIC PROFILING OF 
ISOGENIC COLORECTAL CELLS HARBOURING DISTINCT 
ACTIVATING K-RAS MUTATIONS 
 
Mammalian cells express three isoforms of the highly homologous p21 Ras family of 
monomeric GTPases: H-, K- and N-Ras. These proteins act as molecular switches 
and timers, which are predominantly localised to the plasma membrane where they 
are activated by cell surface receptors, e.g. epidermal growth factor receptor 
(EGFR), to regulate cell proliferation, survival and apoptosis (Karnoub and 
Weinberg, 2008). Mutation of Ras at conserved codons 12, 13 or 61 results in 
constitutive activation of the molecule, through impaired intrinsic GTPase activity 
and resistance to GTPase activating protein (GAP) activity (Prior et al., 2012). 
Although each codon mutation is activating, the position of the mutation has 
functional and clinical relevance.  
 
Colorectal cancer (CRC) is the third most common cancer worldwide, with an overall 
5-year survival rate of 11% for patients with metastatic disease (Siegel et al., 2012). 
Over a third of CRC tumours harbour a K-Ras mutation (Prior et al., 2012), while the 
majority of these mutations affect codon 12 (78%), a significant fraction are at codon 
13 (22%) (Vaughn et al., 2011). Early Ras research indicated that different amino 
acid substitutions at codons 12, 13 and 61 exhibited a range of transforming 
activities (Der et al., 1986; Seeburg et al., 1984; Sloan et al., 1990). More recent 
work has shown that K-RasG12D and G13D mutations induce different soft tissue 
sarcoma types and metabolic phenotypes (Guerrero et al., 2002; Vizan et al., 2005), 
though K-RasG12D more potently transforms cells and makes them more resistant 
to apoptosis (Guerrero et al., 2000). Yet, CRC patients harbouring K-RasG13D 
mutant tumours tend to display a worst overall survival rate than patients with other 
K-Ras mutations (Bazan et al., 2002; Modest et al., 2011; Samowitz et al., 2000; 
Tejpar et al., 2012). Furthermore, CRC patients with codon 12 and 13 K-Ras 
mutations display differential responsiveness to anti-EGFR therapy (De Roock et al., 
2010; Tejpar et al., 2012). Together, these data suggest that different activating K-
Ras mutations are unequal in their signalling outputs. The mechanisms through 
which this occurs are unclear, but it may be attributable to the slight structural 
differences between the mutant Ras proteins (Franken et al., 1993; Muraoka et al., 
2012), the differentially impaired GTPase activity of the Ras mutants (John et al., 
1988; Trahey and McCormick, 1987) or the shift in equilibrium of the GTP-bound 
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Ras conformational states (Geyer et al., 1996; Spoerner et al., 2001; Ye et al., 
2005). 
 
Previous studies have applied various ‘omic’ approaches to identify mutant K-Ras 
specific signatures (Guha et al., 2008; Singh et al., 2012; Sudhir et al., 2011; Sweet-
Cordero et al., 2005; Tchernitsa et al., 2004; Vartanian et al., 2013). However, some 
of these studies utilise different cell lines to compare oncogenic Ras signalling, 
which, due to the variability in genetic background, makes direct attribution of the 
result to the presence of oncogenic Ras difficult. One strategy to overcome this is 
use of isogenic cell lines. To date, almost all isogenic models either stably over-
express oncogenic Ras, following random insertion of the mutant gene into the 
genome of an isogenic cell line, or genetically ablate a wild-type or mutant allele.  
 
Here we utilise isogenic SW48 colorectal cell lines, in which targeted homologous 
recombination has exchanged (knocked-in) an endogenous K-Ras allele for a 
mutant K-Ras sequence. Since the mutant K-Ras gene is under control of the 
endogenous K-Ras promoter, this isogenic model enables mutant K-Ras protein to 
be expressed at physiologically relevant levels. The G12D, G12V and G13D K-Ras 
mutations present in the isogenic panel are the three most observed K-Ras 
mutations in CRC, representing over 75% of all CRC cases that harbour a K-Ras 
mutation (Prior et al., 2012; Vaughn et al., 2011). These isogenic cell lines were 
subject to quantitative proteomic and phospho-proteomic MS-based analyses, to 
determine signalling signatures associated with each K-Ras mutation.  
 
3.3.1 K-RAS MUTATION-SPECIFIC NETWORK RESPONSES 
 
Isogenic SW48 colorectal cell lines harbouring homozygous wild-type K-Ras or 
heterozygous G12D, G12V or G13D K-Ras mutations were used to investigate the 
effects of different amino-acid substitution (G12D vs. G12V) or codon mutation 
(G12D vs. G13D). Stable isotope labelling of amino acids in cell culture (SILAC) 
(Ong et al., 2002) was employed in a triplex conformation to selectively label each of 
the isogenic cell lines, such that a minimum of 3 biological replicates comparing 
each mutant cell line with the Parental control cell line was performed (Fig. 3.26). 
Following SILAC labelling, cell lysates were mixed at a 1:1:1 protein ratio before 
being subject to SDS-PAGE or TiO2-based phospho-peptide enrichment strategies.  
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Fig. 3.26. Experimental workflow employed to profile isogenic SW48 colorectal cell 
lines, harbouring distinct activating K-Ras mutations, at proteomic and phospho-
proteomic levels. The isogenic SW48 cell lines were subject to targeted homologous 
recombination of an endogenous K-Ras allele to knock-in a wild-type (Parental) or a mutant 
sequence encoding for K-Ras G12V, G12D or G13D. The configuration is such that at least 
n = 3 for each mutant cell line versus control (n = 4 for K-RasG12D vs. Parental). FASP, 
filter-aided sample preparation (Wisniewski et al., 2009); SCX, strong-cation exchange. 
Experiments performed in collaboration with Dr. Dean Hammond (University of Liverpool). 
 
RESULTS – K-RAS MUTANT-SPECIFIC SIGNALLING SIGNATURES 
 144 
Gel slices and phosphopeptide-enriched fractions were subject to LC-MS/MS 
analysis using an LTQ Orbitrap XL (Thermo Fisher), in data-dependent acquisition 
mode sequencing the top 6 most abundant proteins. Phosphopeptide fractions were 
subject to multistage activation, activating 49.0, 69.3 and 98 Th from the precursor 
ion mass. Quantification and spectral matching was performed with MaxQuant and 
the Andromeda search engine (Cox and Mann, 2008; Cox et al., 2011). To enable 
consistent and predictable cell growth, the isogenic SW48 cells were grown in 
McCoy’s 5A SILAC media. Due to the presence of bacto-peptone, labelling arginine 
residues was 69.43 ± 0.54% and lysine 89.12 ± 0.13%. Yet, this labelling 
discrepancy is accounted for during the ‘first search’ performed by MaxQuant 
(personal correspondence, Jürgen Cox, Max-Planck-Institut für Biochemie, 
Martinsried, Germany).  
 
Across all experiments, responses were measured from 2,359 unique proteins in the 
proteome data and 3,971 unique phosphopeptides from TiO2 enrichments. 65% of 
proteins and 35% of phosphopeptides were identified at least twice across biological 
replicates (Fig. 3.27A). 3,727 phosphosites could be assigned to a specific amino 
acid (localisation probability ≥ 0.75, score differential > 5; class 1 phosphosite), 
which comprised of 3,030 pSer, 632 pThr and 65 pTyr sites mapped to 1,288 
proteins.  
 
To determine reproducibility between biological replicates and inter-mutation 
response variability, cross-correlation analysis between all experiments was 
performed (Fig. 3.28A). Hierarchical clustering indicates good experimental 
reproducibility between biological replicates, which have at least a 5-fold higher 
coefficient of determination (R2) than between any other inter-isogenic cell type 
correlations. These consistent responses enabled observation of K-Ras mutation-
specific signatures. The cross-correlation analyses, along with principle component 
analysis (Fig. 3.28B), indicates that, whilst proteome and phospho-proteome outputs 
are similar between G12V and G12D K-Ras, there is divergence between codon 12 
and 13 mutations. The major difference between G12V and G12D mutations seem 
to be the extremity of their responses (Fig. 3.27C and D; Fig. 3.28B). In contrast, 
G13D mutant cells show prevalent protein and phosphopeptide up-regulation, 
compared to the codon 12 mutations (Fig. 3.27B and C).  
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Fig. 3.27. Overview of acquired SILAC data sets. (A) Overlap of identified proteins and 
phosphopeptides between biological replicates. 65% of proteins and 35% of 
phosphopeptides were observed in more than 1 experiment. (B) Overlap and co-
responsiveness between proteome and phosphoproteome data sets. (C) Responsive 
subsets within each K-Ras mutant cell line. Percentages indicate the proportion of proteins/ 
phospho sites significantly changed compared to the total proteome or phospho-proteome. 
(D) Range of regulated protein and phospho site values. Proteins and phospho sites were 
considered significantly changed/ regulated according to ≥ 1.5-fold change from Parental. 
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Fig. 3.28. K-Ras mutation-specific proteome and phospho-proteome network 
responses. (A) Cross-correlation analyses between each experiment performed. A 
consistent correlation between biological replicates is apparent, while cells harbouring codon 
12 mutations share greater correlation compared to cells with K-RasG13D, most evident in 
the phospho-proteome. Values for peptide/ phospho-peptides shared between each 
experiment were used in the analysis. Pearson correlation (r) indicates linkage strength 
between experiments. (B) Principle component analysis on covariances of individual 
experiments (top) and following combination of the data (bottom). Codon 12 mutations 
exhibit similar projections at both proteome and phospho-proteome levels, unlike K-
RasG13D.   
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3.3.2 DIFFERENTIAL RESPONSES BETWEEN CODON 12 AND 13 MUTANT    
K-RAS  
 
Utilising the GProX proteome analysis software (Rigbolt et al., 2011b), proteins and 
phosphopeptides were clustered according to their mutation-specific responses 
versus Parental (Fig. 3.29 and Fig. 3.30). Six clusters were generated for each data 
set, with clusters 5 and 6 being of particular interest since they represent codon 12 
versus codon 13-specific responses. In the proteome data set, 115 proteins were 
isolated in clusters 5 and 6. Gene Ontology (GO) analysis (performed using the 
DAVID functional annotation tool 6.7) revealed that mitochondrial proteins involved 
in oxidative phosphorylation were enriched in cluster 5 (Huang da et al., 2009a; 
Huang da et al., 2009b; Iwata et al., 1998), i.e. proteins up-regulated by codon 12 
mutant K-Ras, but not K-RasG13D (Fig. 3.29B). In cluster 6, proteins involved in 
carbohydrate biosynthesis and cellular homeostasis were enriched.     
 
In the phospho-proteome data set, 274 phosphopeptides from 198 proteins were 
contained in clusters 5 and 6 (Fig. 3.30A). 56 phosphopeptides from these clusters 
are associated with 27 cell adhesion or cytoskeleton proteins, with microtubule-
associated protein 1B (MAP1B) and tight-junction protein ZO-2 (TJP2) represented 
by multiple phosphopeptides (Fig. 3.30B and C). Other notable proteins with 
phosphosites present in clusters 5 and 6 include the HGF-receptor MET T995 and 
Caveolin-1 S37, which both exhibit a >10-fold increased phosphorylation status 
compared to codon 13, along with BRAF S729 that exhibits enhanced 
phosphorylation in codon 13 mutant cells versus codon 12.  
 
To examine complete patterns of phosphopeptide responses, proteins represented 
by multiple phosphopeptides (≥ 3 in entire data set) from clusters 5 and 6 were 
curated and compared with available proteome data (Fig. 3.31). Comparison of 
protein abundance with phosphopeptide signal enables determination if a 
phosphosite displays increased phosphorylation or that a change protein expression 
is responsible for the observed alteration in signal. Changes in protein abundance 
tended to be a minor influence on phosphopeptide ratios, but interestingly protein 
abundance and phosphorylation typically trended in the same direction.  
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Fig. 3.29. Proteins displaying differential codon 12 and 13 mutant K-Ras responses. 
(A) Clustering of proteins based on response to the different K-Ras mutations. Mutant/ Par 
ratios were subject to clustering with the Fuzzy c means algorithm using GProX. Clusters 5 
and 6 contain proteins that are likely to be signatures of codon 12 and 13-specific signalling 
in colorectal cancer. (B) Gene Ontology (GO) analysis of each cluster performed using the 
DAVID functional annotation tool 6.7. (C) Scatterplot of clusters 5 and 6 with proteins 
involved in the cytochrome bc1 complex (cyt. bc1) highlighted. GProX cluster analysis 
performed with the help of Dr. Dean Hammond (University of Liverpool).  
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Fig. 3.30. Phosphopeptides displaying differential codon 12 and 13 mutant K-Ras 
responses. (A) Clustering of phosphopeptides based on response to G12V, G12D and 
G13D K-Ras mutations. Mutant/ Par ratios were subject to clustering with the Fuzzy c means 
algorithm using GProX. Clusters 5 and 6 contain proteins that are probable signatures of 
codon 12 and 13-specific signalling in colorectal cancer. (B) Gene Ontology (GO) analysis of 
each cluster performed using the DAVID functional annotation tool 6.7. (C) Scatterplot of 
clusters 5 and 6. Cytoskeletal and adhesion proteins are highlighted. GProX cluster analysis 
performed with the help of Dr. Dean Hammond (University of Liverpool).  
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Fig. 3.31. Relationship between phosphopeptide response and proteome changes. 
Proteins represented by phosphopeptides from clusters 5 and 6 (see Fig. 3.30) that had ≥ 3 
phosphopeptides identified in the entire dataset were curated, along with their respective 
protein abundance values.  
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Fig. 3.32. Predicted kinase regulators of phosphosites associated with differential 
codon 12 and 13 mutant K-Ras responses. MotifX analysis identified over-represented 
linear phosphorylation motifs from those present in the entire phospho-proteome data set 
(long list) and phospho-proteome GProX clusters 5 and 6 (Chou and Schwartz, 2011; 
Schwartz and Gygi, 2005). NetworKIN was then utilised to identify candidate kinases 
(Linding et al., 2008). Output column indicates average responses of sites associated with 
each motif. n indicates the total number of over-represented motifs identified by MotifX and 
used in the output column. Figure generated with the aid of Prof. Ian Prior (University of 
Liverpool).  
 
Given the central role of protein kinases in regulating Ras responses, their 
contribution to the dataset was examined. 38 kinases in total were identified, with 35 
kinase phosphopeptides from 96 responsive (≥ 1.5-fold change compared to 
parental) to the presence of an oncogenic K-Ras mutation. Notable kinases 
identified include EGFR, MET, MAP2K2 (MEK2) and ERK2. The identified 
phosphosite of ERK2, T185, becomes phosphorylated during activation and was 
down-regulated in G13D versus codon 12 cell lines. To predict which kinases may 
be modulating the responses observed in phosphoproteome clusters 5 and 6, MotifX 
was utilised to identify over-represented phosphorylation motifs (Chou and 
Schwartz, 2011; Schwartz and Gygi, 2005), before NetworKIN analysis predicted 
the candidate kinases through integration of consensus substrate motifs and 
contextual modelling (Linding et al., 2008) (Fig. 3.32). Kinases involved in the 
regulation of the cell cycle and promotion of proliferation, e.g. cyclin-dependent, 
MAP and MOK kinases, were identified as potential kinases targeting members of 
clusters 5 and 6.    
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3.3.3 DCLK1 IS EXCLUSIVELY UPREGULATED IN SW48 ISOGENIC CELLS 
HARBOURING CODON 12 K-RAS MUTATIONS  
 
Within the proteome dataset, doublecortin-like kinase-1 (DCLK1) and A-kinase 
anchor protein 12 (AKAP12) were prime examples of proteins responsive to K-
RasG12D, showing ≥ 8-fold up-regulation versus Parental. Immunoblotting 
confirmed the distinctive expression pattern of these proteins (Fig. 3.33A), which 
was recapitulated in a second independent clone of each isogenic SW48 cell line 
(Fig. 3.34).  Up-regulation of MET and Caveolin 1 was also confirmed in codon 12 
mutant K-Ras cells (Fig. 3.33A). The observation of codon 12-specific DCLK1 up-
regulation is notable, since recent data suggests that this protein is a colon cancer 
tumour stem cell marker (Nakanishi et al., 2013). Together, these observations led 
us to examine the extent of the codon 12-specific phenomenon, by analysing a 
wider panel of SW48 cell lines that harbour other K-Ras mutations not tested in the 
proteomic analysis. Interestingly, DCLK1 expression was significantly increased in 
all cells harbouring a codon 12 K-Ras mutation, while K-RasG13D and N-RasG12V 
had expression levels equivalent to Parental (Fig. 3.33B and C). The molecular 
weight markers and detected peptides/ phosphopeptides suggest that isoforms 3 
and 4 of DCLK1 are the up-regulated proteins (Fig 3.33B and D), which contain an 
active kinase but lack the doublecortin-like domains enabling microtubule binding 
(Burgess and Reiner, 2001). MET exhibited the same expression pattern as DCLK1, 
possibly indicating a shared mechanism promoting up-regulation, while TJP2/ ZO-2 
was shown to be preferentially up-regulated in the codon 12 mutant cell line only.  
 
3.3.4 DISCUSSION 
 
By applying large-scale quantitative proteomics to the SW48 isogenic cell line panel, 
an unprecedented insight into differential signals emanating from oncogenic G12D, 
G12V and G13D K-Ras mutants has been achieved, in a colorectal cancer setting. 
Our first and possibly most prominent observation is that K-Ras mutants have 
distinct signalling outputs. Since codon 12 mutants share greater overlap than 
codon 13 mutations on both proteome and phosphoproteome levels, it could be the 
positioning of the mutation has greater influence on the outputs of oncogenic K-Ras, 
rather than the type of amino acid substitution. This observation is important, as 
almost all Ras studies and Ras-related clinical trials assume that activating Ras 
mutations activate downstream signalling networks to the same extent. 
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Fig. 3.33. DCLK1 is exclusively upregulated in cells harbouring codon 12 K-Ras 
mutations. (A) Immunoblot verification of selected hits from the MS-based SILAC analysis. 
(B) Immunoblot analysis of a wider panel of isogenic SW48 cell lines, harbouring K-Ras 
mutations not tested in the proteomic analysis, demonstrates that DCLK1 and MET are 
upregulated in the presence of a codon 12 K-Ras mutation, whereas ZO-2 is upregulated 
specifically by a codon 13 mutation. n ≥ 3 for each panel. (C) Densitometry analysis DCLK1 
expression across the entire SW48 cell line panel, including cells harbouring an N-RasG12V 
mutation. Bars represent mean ± SD. Signal normalised to G12D response. (D) Location of 
detected peptides and phosphopeptides along human DCLK1 isoforms. Part A includes 
immunoblots performed by Dr. Dean Hammond (University of Liverpool). ZO-2 and MET 
blots supplied by Dr. Emma Rusilowicz (University of Liverpool). 
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Fig. 3.34. Recapitulation of results in a second, independent SW48 clone. Both sets of 
independent clones demonstrate equivalent up-regulation of selected proteins. Immunoblots 
performed by Dr. Dean Hammond (University of Liverpool).  
 
To understand the mechanisms that differentiate codon 12 and 13 mutant K-Ras 
signalling, 274 phosphopeptides and 115 proteins were identified that responded 
differently to the presence of the different codon mutations. Amongst these, 
AKAP12, a cell adhesion protein that orchestrates interactions between kinases 
(Akakura and Gelman, 2012; Malbon et al., 2004), and caveolin 1, an essential 
component of membrane caveolae that can modulate Ras signalling (Kranenburg et 
al., 2001; Parton and del Pozo, 2013), were specifically up-regulated in codon 12 
mutant cells versus codon 13, with up-regulation of caveolin previously associated 
with oncogenic K-Ras (Roy et al., 2013). As these proteins are both potential tumour 
suppressors (Su et al., 2010), with AKAP12 commonly lost in CRC (Liu et al., 2011), 
it seems somewhat paradoxical that these proteins are up-regulated in the presence 
of oncogenic Ras. Yet, these responses could be the cell’s attempt to dampen the 
distinct, aberrant signalling emanating from codon 12 mutant K-Ras. The HGF-
receptor c-MET was similarly responsive to codon 12 mutations, but its up-
regulation was also consistently observed in a wider panel cell lines harbouring 
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other codon 12 mutations. The up-regulation of MET has a well-established role in 
Ras-mediated carcinogenesis (Furge et al., 2001; Webb et al., 1998) and despite 
being upstream of Ras it could still be affected by oncogenic Ras signalling, since 
interplay between Ras pathway activation and growth factor receptors has been 
demonstrated by the inhibition of BRAF leading to the activation of EGFR via loss of 
negative feedback (Prahallad et al., 2012). In contrast, aldehyde dehydrogenase 
ALDH3A1 and TJP2 ZO-2 were selectively up-regulated in codon 13 mutant cell 
lines. ALDH3A1 is involved in the oxidation of a range of endogenous aldehydes 
and was originally designated as the tumour ALDH, due to its increased expression 
in a variety of cancers, and may contribute to drug resistance (Parajuli et al., 2014). 
TJP2 ZO-2 is a member of the membrane-associated guanylate kinase (MAGUK) 
family, which have a role as a scaffolding protein, as well as in the organisation of 
tight junctions and adherens junctions. 
 
The most amplified protein in our dataset was DCLK1, which was most responsive 
to K-RasG12D but also consistently up-regulated in cells expressing codon 12 
mutant K-Ras. DCLK2 has been previously identified as a synthetically lethal 
component in a genome-wide RNAi screen of colorectal DLD1 cells (Luo et al., 
2009). Although the function of DCLK1 is poorly understood, consultation of the 
Cancer Cell Line Encyclopaedia, which contains data from over 1,000 cell lines 
(Barretina et al., 2012), revealed co-responsiveness with MAP1B, a major 
cytoskeletal protein and prominent phosphosite responder in codon 12 mutant cells 
(Lee et al., 2008), suggesting functional interaction between these oncogenic K-Ras 
responsive proteins. DCLK1 has an emerging role in colorectal carcinogenesis, as it 
has recently been identified as a CRC tumour stem cell-specific marker (Nakanishi 
et al., 2013), where ablation of DCLK1 positive tumour stem cells caused regression 
of polyps without damage to surrounding normal tissue. Plus, DCLK1 is frequently 
over-expressed in CRC and associated with a poorer prognosis/ overall survival 
(Gagliardi et al., 2012). Moreover, siRNA knockdown or inhibition of DCLK1 reduces 
colorectal and pancreatic proliferation (Weygant et al., 2014). As of yet, there has 
been no connection between DCLK1 expression and K-Ras mutational status, yet 
this association is likely to be highly context dependent since no significant 
correlation was identified in the Cancer Cell Line Encyclopaedia. Considering the 
size of DCLK1 isoform identified on immunoblots and the peptides/ phospho-
peptides detected, the DCLK1 isoforms observed are the short isoforms 3 and 4. 
RESULTS – K-RAS MUTANT-SPECIFIC SIGNALLING SIGNATURES 
 156 
These proteins lack the doublecortin domains necessary for microtubule binding and 
have a reported role in modulating memory and cognitive abilities (Francis et al., 
1999; Le Hellard et al., 2009). Yet, it could be possible that DCLK1 isoform 1 or 2 is 
being converted into the shorter isoforms, through cleavage by calpain (Burgess and 
Reiner, 2001), but cleavage would have to be extremely rapid and incessant to 
prevent the observation of the longer DCLK1 isoforms. The pattern of expression of 
DCLK1, AKAP12 and MET were recapitulated in a second, independent clone, 
indicating that the observed results are not due to clonal selection, but represent 
responses attributable to oncogenic K-Ras signalling. 
 
The data presented in this thesis provides the first unbiased, global screen of 
signals emanating from different oncogenic K-Ras mutations. The use of isogenic 
cell lines enables identification of specific signalling signatures without the 
confounding effects of differences in genetic background. One key observation of 
this study is that each Ras mutation induces a unique signalling response, meaning 
the precise Ras mutational status should be considered in experimental designs and 
interpretation of results when studying oncogenic Ras function. Several recent 
studies identified synthetically lethal genes when depleted/ inhibited in cell lines 
harbouring various K-Ras mutations (Barbie et al., 2009; Luo et al., 2009; Sarthy et 
al., 2007; Scholl et al., 2009; Singh et al., 2012; Steckel et al., 2012). Each study 
used different cell types that harboured a variety of K-Ras mutations and found 
inconsistent responses between cell lines. Not only are these inconsistent 
responses likely to arise due to differences in genetic backgrounds between cell 
lines, but the present data here also suggest they arise due to differential signalling 
from the different K-Ras mutations.  
 
In summary, several key proteins with known functions related to colorectal 
carcinogenesis were shown to be differentially responsive to codon 12 or 13 K-Ras 
mutations. Amongst these is the colon cancer stem cell marker DCLK1. Most 
strikingly, we found that the three most abundant K-Ras mutations observed in 
colorectal cancer: G12D, G12V and G13D, generate distinct signalling signatures at 
both the proteome and phosphoproteome levels, showing that K-Ras mutations are 
not equal in their signalling outputs.  
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4 – OUTLOOK AND CONCLUSION 
 
Up to now there has been uncertainty regarding the number of Ras molecules per 
cell and which isoform is the most abundant. Previous attempts to measure cellular 
Ras abundance utilise either an immunoprecipitation or SDS-PAGE step prior to 
addition of AQUA peptides (Halvey et al., 2012; Ruppen-Canas et al., 2012; Wang 
et al., 2011). Consequently, these methods are vulnerable to inaccuracies and 
variations, exemplified by the Wang and Ruppen-Canas studies obtaining ~100-fold 
different results despite employing the same Ras quantification technique. The 
SRM-based Ras quantification method and PSAQ standards developed in the 
present thesis has enabled the most accurate measurement of cellular Ras isoform 
abundance to date. The described Ras quantification technique is also easily 
implementable in most biological laboratories, since SDS-PAGE is a very familiar 
fractionation technique to these laboratories and the in-gel digest steps do not 
require specialist knowledge. The developed technique reliably detected H-, K(B)- 
and N-Ras at endogenous levels, as well as other peptides shared between 
isoforms to verify the isoform-specific quantification. Furthermore, the PSAQ 
technique accounts for variations in peptide recovery from gel pieces and 
incomplete digestion. Despite not being detected at endogenous levels using the 
4000 QTRAP, the described K(A)-Ras-specific and elastase-derived total Ras 
peptides could be utilised in future studies employing newer and more sensitive 
instrumentation. As a result, the Ras quantification technique detailed in this thesis 
enables quantification of almost all aspects of cellular Ras abundance.  
 
Over 250,000 Ras molecules were measured in a Parental SW48 cell, with K-Ras 
the most abundant isoform, meaning per µm2 of plasma membrane ~114 Ras 
proteins are bound. Intriguingly, we measured a varying amount of Ras between 
isogenic SW48 cell lines harbouring a range of heterozygous Ras mutations. SW48 
cells harbouring G12D and G13D K-Ras mutations, the first and third most common 
K-Ras mutations in CRC (Prior et al., 2012; Vaughn et al., 2011), contained almost 
double the amount of Ras compared to the Parental, with around 200,000 mutant K-
Ras proteins expressed. In contrast, cells harbouring K-RasG12V, the second most 
common mutation in CRC, and those with H- and N-RasG12V, exhibited little 
difference for the Parental cell line, with ~30,000 copies of mutant protein. These 
differing amounts of Ras could be attributable to the differing transforming activities 
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of each Ras mutant. The G12V mutation could have such strong transforming 
activity that the cell is unable to tolerate many copies of Ras afflicted with this 
mutation, irrespective of which isoform is mutated. An insight into the possible 
additional potency of the G12V mutation came from immunoblot analyses of 
phospho-AKT, which showed, despite being expressed at lower levels than K-
RasG12D and G13D, K-RasG12V was able to reduce the activation of the PI3K 
pathway to equivalent levels. Thus, the cell may be able to tolerate a certain amount 
of oncogenic Ras signalling up to a certain threshold before it limits expression of 
the mutant protein. The G12V Ras mutation may reach this threshold sooner than 
other mutations, possibly explaining why it is expressed at 6-fold lower levels 
compared to G12D and G13D K-Ras mutations. The range of abundances observed 
for other K-Ras mutations present in the isogenic panel could also reflect their 
respective transforming potentials. Since K-RasG12D is the most common Ras 
mutation in CRC, it could be that a large proportion of colon tumours prefer the least 
transforming Ras mutation during colorectal carcinogenesis, to limit the stress 
imposed on the cell from the aberrant signals emanating from the mutant Ras 
protein. 
 
Large-scale proteomic and phospho-proteomic profiling of isogenic SW48 cell lines 
revealed that G12V, G12D and G13D K-Ras mutations revealed each activated a 
distinct signalling network. Yet, the codon 12 mutations (G12V and G12D K-Ras) 
exhibited the greatest degree of signalling overlap, suggesting that, although each 
mutation signals uniquely, the position of the mutation has a greater effect on 
signalling than an amino acid substitution. Several proteins relevant to colorectal 
carcinogenesis were found to be sensitive to certain Ras mutations. Of note is 
DCLK1, a marker of colon tumour stem cells and tumour-initiating cells in the 
pancreas (Bailey et al., 2014; Nakanishi et al., 2013), which was consistently up-
regulated in SW48 cells harbouring codon 12 mutant K-Ras. This up-regulation 
seems unique to K-Ras, since N-RasG12V did not amplify DCLK1 expression. 
Although early Ras work revealed that different Ras mutations have a range of 
transforming activities (Der et al., 1986; Seeburg et al., 1984; Sloan et al., 1990), 
several recent studies do not take this into account (Barbie et al., 2009; Scholl et al., 
2009; Steckel et al., 2012). The data presented in this thesis re-enforces this early 
Ras research, by showing that different Ras mutations induce a unique signalling 
response and selective up-regulation of different proteins. 
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6 – SUPPLEMENTARY MATERIAL 
6.1 PROTEOTYPIC RAS PEPTIDE MS/MS SPECTRA 
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Fig. 6.1. MS/MS spectra of the Ras-specific proteotypic peptides identified in the 
present thesis. All spectra were acquired on using a 4000 QTRAP using isotope-labelled 
Ras peptides (Lys8, Arg10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUPPLEMENTARY MATERIAL 
 188 
 
SUPPLEMENTARY MATERIAL 
 189 
6.3 PLASMID MAPS 
 
Name of construct: pCR4-TOPO-H-Ras wild-type 
Origin of vector: pCR4-TOPO kit 
Origin of insert: PCR of GFP-H-Ras. 
Vector size: 3956 bp 
Insert size: 570 bp 
ORF starts: 303 – 872 bp 
Constructed by: Craig Mageean (Univ. Liverpool) 
Resistance: Kanamycin/ ampicillin 
Date: 06.05.11 
Maxiprep conc: 0.22 ug/ uL 
Comments: Fully sequenced H-Ras wild-type ORF with no mutations. Contains ATG 
and stop codon with added BamH1 and Xho1 restriction sites to cut out the entire 
sequence. 
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Alignment of Ras sequence from pCR4-TOPO-H-Ras with H-Ras ORF (taken from 
Uniprot #P0112): 
 
 
pCR4-TOPO-H-RasG12      CCATGACGGAATATAAGCTGGTGGTGGTGGGCGCCGGCGGTGTGGGCAAGAGTGCGCTGA 360 
H-Ras_ORF               --ATGACGGAATATAAGCTGGTGGTGGTGGGCGCCGGCGGTGTGGGCAAGAGTGCGCTGA 58 
                          ********************************************************** 
 
pCR4-TOPO-H-RasG12      CCATCCAGCTGATCCAGAACCATTTTGTGGACGAATACGACCCCACTATAGAGGATTCCT 420 
H-Ras_ORF               CCATCCAGCTGATCCAGAACCACTTTGTGGACGAATACGACCCCACTATAGAGGATTCCT 118 
                        ********************** ************************************* 
 
pCR4-TOPO-H-RasG12      ACCGGAAGCAGGTGGTCATTGATGGGGAGACGTGCCTGTTGGACATCCTGGATACCGCCG 480 
H-Ras_ORF               ACCGGAAGCAGGTGGTCATTGATGGGGAGACGTGCCTGTTGGACATCCTGGATACCGCCG 178 
                        ************************************************************ 
 
pCR4-TOPO-H-RasG12      GCCAGGAGGAGTACAGCGCCATGCGGGACCAGTACATGCGCACCGGGGAGGGCTTCCTGT 540 
H-Ras_ORF               GCCAGGAGGAGTACAGCGCCATGCGGGACCAGTACATGCGCACCGGGGAGGGCTTCCTGT 238 
                        ************************************************************ 
 
pCR4-TOPO-H-RasG12      GTGTGTTTGCCATCAACAACACCAAGTCTTTTGAGGACATCCACCAGTACAGGGAGCAGA 600 
H-Ras_ORF               GTGTGTTTGCCATCAACAACACCAAGTCTTTTGAGGACATCCACCAGTACAGGGAGCAGA 298 
                        ************************************************************ 
 
pCR4-TOPO-H-RasG12      TCAAACGGGTGAAGGACTCGGATGACGTGCCCATGGTGCTGGTGGGGAACAAGTGTGACC 660 
H-Ras_ORF               TCAAACGGGTGAAGGACTCGGATGACGTGCCCATGGTGCTGGTGGGGAACAAGTGTGACC 358 
                        ************************************************************ 
 
pCR4-TOPO-H-RasG12      TGGCTGCACGCACTGTGGAATCTCGGCAGGCTCAGGACCTCGCCCGAAGCTACGGCATCC 720 
H-Ras_ORF               TGGCTGCACGCACTGTGGAATCTCGGCAGGCTCAGGACCTCGCCCGAAGCTACGGCATCC 418 
                        ************************************************************ 
 
pCR4-TOPO-H-RasG12      CCTACATCGAGACCTCGGCCAAGACCCGGCAGGGAGTGGAGGATGCCTTCTACACGTTGG 780 
H-Ras_ORF               CCTACATCGAGACCTCGGCCAAGACCCGGCAGGGAGTGGAGGATGCCTTCTACACGTTGG 478 
                        ************************************************************ 
 
pCR4-TOPO-H-RasG12      TGCGTGAGATCCGGCAGCACAAGCTGCGGAAGCTGAACCCTCCTGATGAGAGTGGCCCCG 840 
H-Ras_ORF               TGCGTGAGATCCGGCAGCACAAGCTGCGGAAGCTGAACCCTCCTGATGAGAGTGGCCCCG 538 
                        ************************************************************ 
 
pCR4-TOPO-H-RasG12      GCTGCATGAGCTGCAAGTGTGTGCTCTCCTGACTCGAGACAAGGGCGAATTCGCGGCCGC 900 
H-Ras_ORF               GCTGCATGAGCTGCAAGTGTGTGCTCTCC------------------------------- 567 
                        *****************************                                
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Name of construct: pCR4-TOPO-K(A)-Ras wild-type 
Origin of vector: pCR4-TOPO kit 
Origin of insert: PCR of GFP-K(A)-Ras  
Vector size: 3956 bp 
Insert size: 585 bp 
ORF starts: 295 – 880 bp 
Constructed by: Craig Mageean (Univ. Liverpool) 
Resistance: Kanamycin/ ampicillin 
Date: 12.04.11 
Maxiprep conc: 0.14 ug/ uL  
Comments: Fully sequenced K(A)-Ras wild-type ORF with no mutations. Contains 
ATG and stop codon with added BamH1 and Xho1 restriction sites to cut out the 
entire sequence. 
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Alignment of Ras sequence from pCR4-TOPO-K(A)-Ras with K(A)-Ras ORF (taken 
from Uniprot #P0116). 
 
 
pCR4-TOPO-K_A_-RasG12      GGATCCATGACTGAATATAAACTTGTGGTAGTTGGAGCTGGTGGCGTAGG 100 
K_A_-Ras_ORF               ------ATGACTGAATATAAACTTGTGGTAGTTGGAGCTGGTGGCGTAGG 44 
                                 ******************************************** 
 
pCR4-TOPO-K_A_-RasG12      CAAGAGTGCCTTGACGATACAGCTAATTCAGAATCATTTTGTGGACGAAT 150 
K_A_-Ras_ORF               CAAGAGTGCCTTGACGATACAGCTAATTCAGAATCATTTTGTGGACGAAT 94 
                           ************************************************** 
 
pCR4-TOPO-K_A_-RasG12      ATGATCCAACAATAGAGGATTCCTACAGGAAGCAAGTAGTAATTGATGGA 200 
K_A_-Ras_ORF               ATGATCCAACAATAGAGGATTCCTACAGGAAGCAAGTAGTAATTGATGGA 144 
                           ************************************************** 
 
pCR4-TOPO-K_A_-RasG12      GAAACCTGTCTCTTGGATATTCTCGACACAGCAGGTCAAGAGGAGTACAG 250 
K_A_-Ras_ORF               GAAACCTGTCTCTTGGATATTCTCGACACAGCAGGTCAAGAGGAGTACAG 194 
                           ************************************************** 
 
pCR4-TOPO-K_A_-RasG12      TGCAATGAGGGACCAGTACATGAGGACTGGGGAGGGCTTTCTTTGTGTAT 300 
K_A_-Ras_ORF               TGCAATGAGGGACCAGTACATGAGGACTGGGGAGGGCTTTCTTTGTGTAT 244 
                           ************************************************** 
 
pCR4-TOPO-K_A_-RasG12      TTGCCATAAATAATACTAAATCATTTGAAGATATTCACCATTATAGAGAA 350 
K_A_-Ras_ORF               TTGCCATAAATAATACTAAATCATTTGAAGATATTCACCATTATAGAGAA 294 
                           ************************************************** 
 
pCR4-TOPO-K_A_-RasG12      CAAATTAAAAGAGTTAAGGACTCTGAAGATGTACCTATGGTCCTAGTAGG 400 
K_A_-Ras_ORF               CAAATTAAAAGAGTTAAGGACTCTGAAGATGTACCTATGGTCCTAGTAGG 344 
                           ************************************************** 
 
pCR4-TOPO-K_A_-RasG12      AAATAAATGTGATTTGCCTTCTAGAACAGTAGACACAAAACAGGCTCAGG 450 
K_A_-Ras_ORF               AAATAAATGTGATTTGCCTTCTAGAACAGTAGACACAAAACAGGCTCAGG 394 
                           ************************************************** 
 
pCR4-TOPO-K_A_-RasG12      ACTTAGCAAGAAGTTATGGAATTCCTTTTATTGAAACATCAGCAAAGACA 500 
K_A_-Ras_ORF               ACTTAGCAAGAAGTTATGGAATTCCTTTTATTGAAACATCAGCAAAGACA 444 
                           ************************************************** 
 
pCR4-TOPO-K_A_-RasG12      AGACAGAGAGTGGAGGATGCTTTTTATACATTGGTGAGAGAGATCCGACA 550 
K_A_-Ras_ORF               AGACAGAGAGTGGAGGATGCTTTTTATACATTGGTGAGGGAGATCCGACA 494 
                           ************************************** *********** 
 
pCR4-TOPO-K_A_-RasG12      ATACAGATTGAAAAAAATCAGCAAAGAAGAAAAGACTCCTGGCTGTGTGA 600 
K_A_-Ras_ORF               ATACAGATTGAAAAAAATCAGCAAAGAAGAAAAGACTCCTGGCTGTGTGA 544 
                           ************************************************** 
 
pCR4-TOPO-K_A_-RasG12      AAATTAAAAAATGCATTATAATGTAACTCGAGCCAAGGGCGAATTCGTTT 650 
K_A_-Ras_ORF               AAATTAAAAAATGCATTATAATGTAA------------------------ 570 
                           **************************                         
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Name of construct: ptrchisA-H-Ras wild-type 
Origin of insert: Sequence cut from pCR4-TOPO-H-Ras with BamH1 and Xho1 
Vector size: 4414 bp 
Insert size: 570 bp 
ORF starts: 515 – 1089 bp 
Constructed by: Craig Mageean (Univ. Liverpool) 
Resistance: Ampicillin 
Date: 18.05.11 
Maxiprep conc: 41.1 ng/ uL  
Comments: Contains ATG and stop codon with added BamH1 and Xho1 restriction 
sites to cut out the entire sequence. Exact same sequence as PCR4-TOPO-H-Ras 
wild-type. 
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Name of construct: ptrchisA-K(A)-Ras wild-type 
Origin of insert: Sequence cut from pCR4-TOPO-H-Ras with BamH1 and Xho1 
Vector size: 4414 bp 
Insert size: 585 bp 
ORF starts: 413 – 1090 bp 
Constructed by: Craig Mageean (Univ. Liverpool) 
Resistance: Ampicillin 
Date: 18.05.11 
Maxiprep conc: 38 ng/ uL  
Comments: Contains ATG and stop codon with added BamH1 and Xho1 restriction 
sites to cut out the entire sequence. Exact same sequence as PCR4-TOPO-K(A)-
Ras wild-type. 
 
 
 
 
 
 
 
 
 
 
 
 
